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Enzymes are proteins that catalyze the chemistry of life.  Biochemical and structural 
characterization of an enzyme and the interactions it makes with ligands facilitates our 
understanding of the processes that make life possible and enables us to devise 
methods to modulate the enzyme's activity for the benefit of human health.  In this 
work, biochemical and structural studies are presented that aim to expand our 
understanding of several classes of enzymes.  In the first part, analyses of two 
enzymes that have been shown to have a role in lifespan extension in some organisms 
are presented.  The Sir2 enzyme from the malaria-causing parasite Plasmodium 
falciparum is shown to be an NAD+-dependent deacetylase and an acetyllysine-
dependent and acetyllysine-independent NAD+ glycohydrolase.  In addition, several 
examples of the Sir2 modulating enzyme, nicotinamidase, are characterized both 
structurally and biochemically.  These works provided additional insights into and 
valuable tools for the study of Sir2-dependent lifespan extension.  In the second part, 
several studies of enzymes that are responsible for purine degradation in the 
opportunistic human pathogen, Klebsiella pneumoniae, are presented.  Using a 
combination of structural and biochemical methods, we characterize the enzymes 
responsible for ureidoglycine aminotransfer, 2-oxo-4-hydroxy-4-carboxy-5-
 ureidoimidazoline (OHCU) decarboxylase and allantoin racemase.  The examination 
of the aminotransferase from K. pneumoniae reveals a novel pathway from 
ureidoglycine to oxalurate and provides structural evidence for this enzyme's 
specificity for ureidoglycine.  We characterize the first reported inhibitor of OHCU 
decarboxylase and demonstrate structurally and biochemically how this molecule 
causes a conformational change, disrupting the organization of the active site.  The 
structures of allantoin racemase, the first for this class of enzyme, shed new light on 
ligand binding and the mechanism of the racemization reaction.  Together, these 
studies elucidate a great deal of the unique complexity that is present in this important 
pathway.  
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CHAPTER 1 
INTRODUCTION TO SECTION I 
 Research on aging and age-related diseases has led to several exciting 
breakthroughs in the recent past.  One such discovery is the relationship between 
calorie restriction and lifespan as modulated by the enzymes called Sirtuins (1).  The 
Sirtuins are a class of protein modifying, NAD+-dependent enzymes that are present in 
all three domains of life.  These proteins consume NAD+ in the process of 
deacetylation and/or ADP-ribosyltransfer of their target (2, 3). Sirtuins have been 
shown to play a role in several biological processes, including lifespan regulation, 
stress response, DNA silencing, transcriptional regulation and metabolic control (4, 5).  
While Sirtuins have highly-conserved active sites, distinct enzymes can catalyze 
deacetylation (2, 3) , ADP-ribosyltransfer to protein nucleophiles (6-8) or both.     
The NAD+ dependent deacetylase activity of Sirtuins can be modulated in vivo 
by controlling the level of the known Sir2 inhibitor, nicotinamide (9-11).  The 
presence of this molecule is controlled, in part, by the enzyme nicotinamidase (PncA), 
which hydrolyzes nicotinamide into nicotinic acid.  In this way, this enzyme has a 
direct impact on Sir2 activity and its concomitant roles in cellular pathways.  In 
addition to its ability to modulate Sirtuins, PncA activity is required for activation of 
the front-line tuberculosis prodrug, pyrazinamide.  PncA encoded by M. tuberculosis 
hydrolyzes pyrazinamide to form pyrazinoic acid, the active form of the drug (12).  
Despite the effectiveness of this drug, pyrazinamide resistant strains of M. 
tuberculosis, encoding changes in the PncA gene, have emerged (13).  These genes 
have been mapped to catalytic residues as well as to residues predominantly structural 
in nature (14, 15).    
The following three chapters contain studies on the Sir2 enzyme from 
Plasmodium falciparum (PfSir2), the organism responsible for the most prevalent 
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 form of malaria, and the nicotinamidase enzyme from several different human 
pathogens including Streptococcus pneumoniae (SpNic), Borrelia burgdorferri, and 
Plasmodium falciparum.  Chapter 2 details a functional and mechanistic analysis of 
PfSir2, revealing several novel features of this enzyme.  In this report, we reveal that 
PfSir2 not only catalyzes NAD+ dependent deacetylation, but can also function as an 
NAD+ glycohydrolase in both an acetyllysine-dependent and -independent manner 
(Figure 1.1). 
 
 
Figure 1.1 Chemistry catalyzed by Plasmodium falciparum Sir2. 
 
The final two chapters of this section outline biochemical and structural studies 
of nicotinamidases, respectively.  In Chapter 3, the steady-state kinetics and 
mechanism of PncA are examined through biochemical analyses of this enzyme from 
several organisms.  In addition, several novel nicotinamidase inhibitors are identified 
and characterized in this work.  Chapter 4 is an extension of the research detailed in 
Chapter 3 and deals with the structural characterization of SpNic by x-ray 
crystallography.  In this study, structures of SpNic in complex with several ligands 
reveal important active site features and provide insights into the nicotinamidase 
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 reaction mechanism.  The trapped intermediates in the SpNic-ligand structures provide 
evidence for several putative intermediates along the reaction pathway (Figure 1.2). 
 
   
 
 
Figure 1.2.  Structures of substrate and trapped intermediates in the Streptococcus 
pneumoniae nicotinamidase. 
 
 The studies covered in Chapters 2 through 4 identify novel functionality, 
characterize the steady-state kinetics, examine ligand binding and provide new 
insights into the reaction mechanism for two important enzymes, Sir2 and PncA.  This 
work expands our understanding of these enzymes, provides the basis for further 
investigation of their function and provides additional tools to aid in the search for 
small molecule modulators of their activity. 
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CHAPTER 2 
PLASMODIUM FALCIPARUM SIR2 IS AN NAD+-DEPENDENT DEACETYLASE 
AND AN ACETYLLYSINE-DEPENDENT AND ACETYLLYSINE-
INDEPENDENT NAD+ GLYCOHYDROLASE  
2.1 Abstract 
Sirtuins are NAD+-dependent enzymes that deacetylate a variety of cellular 
proteins and in some cases catalyze protein ADP-ribosyltransfer.  The catalytic 
mechanism of deacetylation is proposed to involve an ADPR-peptidylimidate, 
whereas the mechanism of ADP-ribosyltransfer to proteins is undetermined.  Herein 
we characterize a Plasmodium falciparum sirtuin that catalyzes deacetylation of 
histone peptide sequences.  Interestingly, the enzyme can also hydrolyze NAD+.  Two 
mechanisms of hydrolysis were identified and characterized.  One is independent of 
acetyllysine substrate and produces α-stereochemistry as established by reaction of 
methanol which forms α-1-O-methyl-ADPR.   This reaction is insensitive to 
nicotinamide inhibition. The second solvolytic mechanism is dependent on acetylated 
peptide and is proposed to involve the imidate to generate β-stereochemistry.   
Stereochemistry was established by isolation of β-1-O-methyl-ADPR when methanol 
was added as a co-solvent.  This solvolytic reaction was inhibited by nicotinamide, 
suggesting that nicotinamide and solvent compete for the imidate. These findings 
establish new reactions of wildtype sirtuins and suggest possible mechanisms for 
ADP-ribosylation to proteins.  These findings also illustrate the potential utility of 
nicotinamide as a probe for mechanisms of sirtuin catalyzed ADP-ribosyltransfer. 
2.2 Introduction 
The sirtuins are protein-modifying enzymes broadly found in all phyla of life 
that utilize NAD+ as a substrate to effect protein modification via deacetylation and/or 
ADP-ribosyltransfer (1, 2). Sirtuins have been shown to participate in a variety of 
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biological processes, including lifespan regulation, stress response, DNA silencing, 
transcriptional regulation and metabolic control (3, 4).  Sirtuins have phylogenetically 
highly-conserved active sites, although distinct enzymes catalyze deacetylation (1, 2) , 
ADP-ribosyltransfer to protein nucleophiles (5-7) or both (7). The mechanism for the 
deacetylation reaction catalyzed by sirtuins is consistent with an imidate mechanism 
(8) and is supported by a wealth of data (9-16). The protein ADP-ribosyltransfer 
mechanisms are undetermined and products of ADPR-transfer have been largely 
uncharacterized (5, 6, 17).   Sauve and Schramm argued that sirtuin chemistry could 
be understood by recognizing that ADP-ribosyltransfer is central to their catalytic 
function (9).  This mechanistic proposal suggests that sirtuin catalysis of protein 
deacetylation and ADP-ribosyltransfers could be the consequence of the versatile 
reactivity of a sirtuin-poised NAD+ electrophile activated to react directly with 
different types of nucleophiles (9).  It has also been suggested that ADPribosyl-
transfer can derive from the reactivity of an intermediate complex (9, 17).  We herein 
provide evidence for the co-existence of these three different reactive mechanisms 
(deacetylation, direct-ADPR transfer and intermediate-dependent ADPR-transfer) 
occurring on the active site of a sirtuin derived from Plasmodium falciparum, called 
Pf-Sir2.     
Our preliminary interest in Pf-Sir2 derived from a proposed role for this 
enzyme in the persistence of malarial infection (300-500 million cases per year 
worldwide, 1-2 million deaths per year), in which Plasmodium falciparum is the most 
responsible pathogen (18). Malaria is difficult to treat, since it typically persists in the 
host far beyond initial infection or treatment. Persistence of infection is linked to 
immune avoidance strategies employed by the parasite. The parasite expresses a 
virulence factor called P. falciparum erythrocyte membrane protein 1 (PfEMP1) on 
infected erythrocytes. Because it is surface-exposed it could enable clearance of the 
7 
parasite via an adaptive response of the immune system. However, the parasite swaps 
the epitope-encoding surface proteins periodically, thereby evading host immunity.  
Specifically, P falciparum has a repertoire of approximately 60 var genes that encode 
functionally similar but epitopically variant PfEMP1 proteins of which only a single 
gene is typically expressed in the host at a time, with the remainder of the genes kept 
silent by chromatin silencing mechanisms (19). This switching strategy of the parasite 
is termed antigenic variation (19). Interestingly, deletion of Pf-Sir2 dysregulates 
silencing of a major subset of var genes (20, 21).  It has been proposed that the role of 
Pf-Sir2 in silencing of var genes is through the enzymatic activity of histone 
deacetylation, which can promote or maintain heterochromatin (20, 21). In fact, the 
prototype sirtuin, yeast Sir2 (silencing information regulator 2), is named for its gene 
silencing functions and it requires intact NAD+ dependent deacetylase activity for 
these functions (2). 
To biochemically characterize the reactivity of Pf-Sir2 we cloned, expressed 
and purified the enzyme.  We confirm it to be a deacetylase of histone H3 and histone 
H4 and other peptide sequences, as predicted.  Unexpectedly, we determined that the 
enzyme has several additional activities, including the capacity to catalyze NAD+ 
solvolysis.  The solvolysis chemistry features separate stereochemical modalities, 
dependent and independent of acetylated substrates. The stereochemically distinct 
solvolytic reactions also exhibit different behaviors with respect to the universal 
sirtuin inhibitor nicotinamide.  Pf-Sir2 provides an instructive and unusual example of 
several competing reactivities, including deacetylation and two types of ADP-
ribosyltransfer, occurring in one sirtuin active site.  The respective solvolysis 
chemistries are first examples of their kind attributed to a wildtype sirtuin.  In 
addition, these reactions illustrate possible mechanisms of protein ADP-ribosyltransfer 
catalyzed by the sirtuin family.     
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 2.3 Experimental Procedures. 
Reagents and Instrumentation.  Synthetic peptides p300: ERSTEL(K-Ac)TEI(K-
Ac)EEEDQPSTS, H3: ARTKQTAR(K-Ac)STGG(K-Ac)APRKQLAS and H4: 
SGRG(K-Ac)GG(K-Ac)GLG(K-Ac)GGA(K-Ac)RHR were synthesized and 
characterized by the Proteomics Resource Center at Rockefeller University. They were 
purified by HPLC before use.  All other reagents were purchased from Aldrich or VWR 
and were of the highest purity commercially available. HPLC analyses were performed 
on a Hitachi elite LaChrom system equipped with Diode array detector using C18 reverse 
phase columns. Radiolabeled samples were counted in a Beckman Coulter LS 6500 
multi-purpose scintillation counter.  
Plasmid Construction and Protein Expression.  The gene encoding Sir2 from 
Plasmodium falciparum (PF13_0152) was cloned from Plasmodium falciparum DNA 
using PCR provide by Kirk Deitsch of Weill Medical College of Cornell University.  
The coding sequence was initially cloned into a pGEM vector and subsequently 
recloned into Pet28a (Novagen) to obtain protein expressed with an N-terminal poly-
histidine tag.  The insert was verified by nucleotide sequencing and checked against the 
published sequence.  PetPFSIR2 vector was transfected into Codon-plus® RIPL cells 
(Stratagene) and protein synthesis was induced by addition of 0.5 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) at OD600 = 0.25. Cells were grown for 6 hours at 37 oC, 
pelleted and lysed by freeze-thaw cycles.  The protein was purified by Ni-column 
affinity chromatography, dialyzed overnight in 20 mM potassium phosphate buffer pH 
7.0, aliquoted in 20% glycerol and 2 mM DTT and flash-frozen and stored at –80 oC.  
Enzyme concentrations were determined by the method of Bradford (22). The protein 
molecular weight was determined by MALDI-TOF (Rockefeller Proteomics Resource) 
and the protein was 95% pure as determined by SDS-polyacrylamide gel 
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electrophoresis. The presence of a catalytically significant histidine residue (position 
162 in our construct) was confirmed by LC-MS/MS analysis of a tryptic digest of the 
purified enzyme performed at Rockefeller University proteomics facility. 
Deacetylation assays.  Deacetylation reactions were typically performed in 150 
mM phosphate buffer pH 7.3 in reaction volumes of 50 μL.  A typical reaction 
contained 400 μM  NAD+, 3 μM Pf-Sir2 enzyme and 0-500 μM acetylated peptide (H3, 
H4 or p300). Reactions were initiated by addition of enzyme, incubated for one hour at 
30o C and then quenched by addition of trifluoroacetic acid.  The reactions were placed 
on ice for one hour after quench to precipitate protein, centrifuged at 13000 g for 2 min 
to pellet insolubles then analyzed by HPLC.   Peptides were separated using a Waters 
Xterra RP-18 column running a gradient of 10% to 40 % acetonitrile in 0.1% TFA and 
chromatograms collected by multi-wavelength diode array with chromatograms 
analyzed at wavelength of 215 nm.  Reactions were quantified by integrating area of 
peaks corresponding to deacetylated peptides (identities confirmed by mass 
spectrometry, Proteomics Resource Center, Rockefeller University).  Rates were plotted 
versus peptide concentration and best fit of points to the Michealis-Menton equation was 
performed by Kaleidagraph®. HPLC observation of nicotinamide and 2′- and 3′-O-
AADPR products was accomplished by performing reaction, quench and injection as 
above, with HPLC elution with 20 mM ammonium acetate pH 7.5. Chromatograms 
were analyzed at wavelength of 260 nm.  To determine nicotinamide inhibition, 
reactions were performed similarly but nicotinamide at concentrations ranging from 0- 
350 μM was also added to reaction mixtures. Rates were plotted and points were fit to 
the equation v = v0 - vinh ([I]/(Ki +[I])) where v is the rate observed for a given 
concentration of nicotinamide, v0 is the uninhibited rate, vinh is the maximal inhibition, 
Ki is the apparent inhibition constant and [I] is the concentration of nicotinamide.  This 
equation to fit nicotinamide inhibition of sirtuins has been used previously (11).   
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14C-Nicotinamide Base Exchange Assay.  Reactions containing 400 μM NAD+, 
500 μM H3 or 200 μM p300 peptide, and 150 mM phosphate buffer, pH 7.5, with 
varying concentrations of [carbonyl-14C]nicotinamide (American Radiolabeled 
Chemicals Inc.) were initiated by addition of Pf-Sir2 enzyme to a concentration of 0.5 
μM.  Reactions were incubated for one hour at 30 oC and quenched by addition of 
trifluoroacetic acid to pH 2. After centrifugation to remove precipitates, reactions were 
injected on HPLC (0.5% TFA eluant) to separate nicotinamide and NAD+.  Eluant 
containing nicotinamide and NAD+ was collected and radioactivity determined by 
scintillation counting. Reactions were run to no more than 10% of the calculated 
equilibrium position for nicotinamide exchange.  Rates were determined as cpm/s 
incorporated into NAD+, and then converted to a turnover rate (s-1) by adjustment for 
specific radioactivity of nicotinamide and enzyme concentration.  Rates were plotted 
versus nicotinamide concentration and best fit of plotted data to the Michaelis-Menton 
curve was performed using Kaleidagraph®.  Incubations of less than and greater than 1 
hour confirmed that product formation versus time was linear during the course of the 
assay.    
Thionicotinamide Base-Exchange Assay. Reactions containing 400 μM NAD+, 
400 μM peptide, and 150 mM phosphate buffer, pH 7.3, were performed in the presence 
of concentrations 0 to 2000 μM thionicotinamide.  Reactions were initiated with 
addition of Pf-Sir2 enzyme to a final concentration of 1 μM after one hour incubation at 
30oC reactions were quenched by addition of trifluoroacetic acid to pH 2.  ThioNAD 
formation was quantified by HPLC on a Waters SymmetryShield RP8 column running 
0.1% TFA with a gradient to 25% MeOH starting at 15 minutes and by comparison to 
an authentic standard for quantitation and identification, prepared via base exchange of 
thionicotinamide into NAD+ catalyzed by CD38 (23).  Product formation rates were 
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plotted versus thionicotinamide concentration and points fit to the Michaelis-Menton 
equation to obtain the Michealis parameters Km and kcat.   
HPLC Assay Measuring Hydrolysis of NAD+. Reaction mixtures containing 400 
μM NAD+, and one of p300, H3 or H4 peptides (of varying concentrations 0 - 800 μM) 
in 150 mM phosphate buffer, pH 7.3, were initiated with the addition of Pf-Sir2 
(typically 2-4 μM final concentration).  Production of ADPR was quantitated by HPLC 
using a 20 mM ammonium acetate isocratic system on a Waters C-18 column. 
Comparison to SIRT1 reactions reacted under similar conditions established minimal 
contribution to apparent hydrolysis from breakdown of AADPR.  As stated in the text, 
Pf-Sir2 added to SIRT1 reactions also did not increase formation of ADPR from 
AADPR.   Moreover, in almost all cases ADPR formation rate exceeded the 
deacetylation rate that forms AADPR by at least 5 fold. Rate of formation of ADPR was 
plotted against peptide concentration and fit to a modified curve kobs = kcat(no peptide) + 
kcat(peptide)[S]/(Km + [S]) where kobs is the observed rate, kcat(no peptide) is the observed rate 
of hydrolysis in the absence of peptide, kcat(peptide) is the component of the observed rate 
of reaction that is dependent on peptide, Km is the Michaelis constant for peptide and [S] 
is the peptide concentration.   
To analyze nicotinamide effects on reactions (in the presence or absence of 
added H3 peptide), varying amounts of nicotinamide, 0-1000 μM, were added to 
reaction mixtures and reactions were assayed as above quantifying rate by observed 
ADPR.   Inhibition curves were of the form v = v0 - vinh ([I]/(Ki +[I])) where v is the rate 
observed for a given concentration of nicotinamide, v0 is the uninhibited rate, vinh is the 
maximal inhibition, Ki is the apparent inhibition constant and [I] is the concentration of 
nicotinamide.   
DEAE-Sephadex Ion-Exchange Assay for Measurement of ADPR formation.  
Reactions were typically performed in 100 mM phosphate and contained 400 μM [2-, 8-
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3H]NAD+ or [8-14C]NAD+ (synthesized by coupling of NMN and [2-, 8-3H]ATP or [8-
14C]-ATP (American Radiolabeled Chemicals Inc.) as previously described (24)) with or 
without peptide.  Reactions were initiated by addition of Pf-Sir2 and allowed to incubate 
for one hour at 37oC.  After quenching with TFA, the reactions were centrifuged to 
remove precipitate and loaded onto columns containing pre-equilibrated DEAE-
Sephadex (equilibrated with 5 mM ammonium acetate pH 7).  The reaction mixture was 
then eluted with eight 2 mL fractions of 10 mM ammonium acetate pH 7 and five 2 mL 
fractions of 100 mM ammonium acetate pH 7.  The radioactivity contained in the eluted 
samples was then quantified by scintillation counter.  Radiolabeled NAD+ eluted in the 
10 mM washes, while ADPR eluted in the 100 mM fractions.  Reactions performed with 
p300 were corrected for AADPR production by HPLC assay of the eluant of 100 mM 
ammonium acetate (which contained ADPR, major species and AADPR, minor species) 
and by independent HPLC determination of deacetylation rate of the peptide under 
identical reaction conditions.   Reactions were corrected with appropriate negative 
controls.   
HPLC Assay for Methanolyses of NAD+catalyzed by Pf-Sir2.  A β-1-methyl-O-
ADPR standard was synthesized using the known methanolysis reaction catalyzed by 
CD-38 (25).  This enzyme was incubated with NAD+ in 150 mM phosphate buffer and 
30% MeOH, and monitored by HPLC.  A single new peak was formed isolated by 
HPLC, NMR was taken and confirmed to be β-1-O-methyl-ADPR.  Mass spectrum by 
MALDI-TOF confirmed the correct mass (m/z = 574, positive ion).  The corresponding 
α-1-O-methyl-ADPR standard was formed by heating NAD+ in 30 % methanol in 50 
mM phosphate pH 7.5 to 80 oC. This procedure is known to generate both methanolysis 
stereochemistries.   The methanolysis product α-1-O-methyl-ADPR was isolated and 
identified by NMR and by MALDI-MS (m/z = 574, positive ion).   
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Methanolysis reactions catalyzed by Pf-Sir2 were carried out in the presence of 
400 μM NAD+, 20% by volume methanol (5.1 M) unless noted otherwise, and varying 
H3 concentrations in 150 mM phosphate buffer, pH 8.5.  The reactions were initiated by 
addition of Pf-Sir2 (final: 8 μM) and then incubated for one hour at 30 oC.  After 
quenching with TFA the solutions were centrifuged to remove precipitate and 
immediately analyzed by HPLC. Standards of β-1-O-methyl-ADPR and α-1-O-methyl-
ADPR were run on the same day and spiked into reaction mixtures to confirm peak 
identity.   To confirm identity of these compounds in Pf-Sir2 reaction mixtures, eluant of 
peaks were collected, lyophilized and analyzed by MALDI-TOF (positive ion mode, 
CHCA matrix).   
2.4 Results. 
Pf-Sir2 has NAD+ Dependent Protein Deacetylase Activity.   Pf-Sir2 has been 
found to localize to heterochromatin in P. falciparum and is proposed to contribute to 
var gene silencing via deacetylation of histones (20, 21). We examined the ability of 
recombinant Pf-Sir2 to catalyze NAD+ dependent protein deacetylase activity by using 
peptides homologous to N-terminal histone sequences of H3 and H4 (see experimental 
for sequences).  Deacetylation activity of Pf-Sir2 was compared with SIRT1 as a 
positive control.  Peptide substrates were reacted with NAD+ in the presence of 
enzyme and peptide deacetylation products were determined by HPLC.  SIRT1 and 
Pf-Sir2 reactions generated similar chromatograms for H4 and H3 reactions (Figure 
2.1A and 2.1B). It is known that SIRT1 predominantly deacetylates at K16 of tetra-
acetylated H4, identical to the sequence used in this study (26).  Based on retention 
time, this same residue is deacetylated by Pf-Sir2 (Figure 2.1B) and was confirmed by 
MS analysis (performed by Rockefeller Proteomics Resource).  Deacetylation of a di-
acetylated H3 peptide by Pf-Sir2 and SIRT1 produced similar HPLC chromatograms 
as well (Figure 2.1A).  SIRT1 deacetylates positions AcK9 and AcK14 of the N-
14 
terminal H3 sequence (26).  The single peak was collected in the SIRT1 and Pf-Sir2 
HPLC elutions and analyzed by MS (performed by Rockefeller Proteomics Resource).  
These results confirmed deacetylation of K9 and K14 for both reactions.  It was 
determined that deacetylation depends on the presence of NAD+, and the Km for NAD+ 
in H3 deacetylation was determined to be 120 μM.  These results corroborate a recent 
study showing that Pf-Sir2 is a histone deacetylase for N-terminal tails of whole 
histones H3 and H4 (27), although Michaelis parameters were not determined and 
only Westerns were used to identify deacetylated products (27).  
Interestingly, a human di-acetylated p300 sequence (ERSTEL(K-Ac)TEI(K-
Ac)EEEDQPSTS corresponding to amino acid positions 1034-1053 of the full p300 
sequence) was determined to be a superior substrate of Pf-Sir2, and the deacetylated 
peptide product is again similar to that formed by SIRT1 as shown by HPLC (Figure 
2.1C).  The preferred site of deacetylation for this sequence by SIRT1 has been 
characterized (28) and corresponds to the AcLys in the peptide corresponding to 
amino acid position 1040 of the full p300 sequence (see above). Acetylation 
modifications in this sequence have been demonstrated to affect p300 functions as a 
transcriptional co-regulator (28).  
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Figure 2.1.  Deacetylation of peptide substrates catalyzed by Pf-Sir2. (A) HPLC 
chromatograms showing the deacetylation of acetylated-H3 by Pf-Sir2  and SirT1 
over time. (B) Deacetylation of H4 .(C) Deacetylation of p300. (D)Saturation curves 
for steady-state deacetylation rates for the three different peptides. 
 
Deacetylation reactions were further studied by HPLC in which peptide 
concentrations were varied in the presence of enzyme and 400 μM NAD+.  Michaelis-
Menton curves fit to determined deacetylation rates versus peptide concentrations are 
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shown in Figure 2.1D.  Km and kcat values are listed for the different peptide substrates 
in Table 2.1. 
 
Table 2.1. Parameters for Deacetylation, Exchange, Hydrolysis and Inhibition 
Reactions for Pf-Sir2 with Various Substrates. 
 
 
 
            Deacetylation 
 
 
 
     Exchangeb   
 
      Hydrolysis 
 
 
kcat  
10-4 s-1 
 
Km  
μM  
 
Ki(ΝΑΜ)a 
μM 
 
 
kcat  
10-2 s-1 
 
Km  
μM 
 
 
kcat  
10-3 s-1 
 
Km  
μM 
 
H3c 
 
2.5 ± 0.4 
 
372 ± 99
 
35 ± 2  
 
2.5 ± 0.1 
 
61 ± 5  
 
1.9 ± 0.1 
 
228 ± 28 
 
H4c 
 
3.5 ± 0.2 
 
176 ± 23
 
 NM  
 
     NM 
 
  NM  
 
2.2 ± 0.1 
 
137 ± 29 
 
p300c 
 
9.2 ± 0.5 
 
85  ± 13 
 
91 ± 4  
 
6.4 ± 0.2 
 
80 ± 7  
 
3.4 ± 0.2 
 
33 ± 15 
 
NAD+d 
 
   NA 
 
   NA 
 
  NA  
 
     ND 
 
  NA  
 
1.2 ± 0.2 
 
   NM 
 
Conditions for measurements are described in experimental section. All reactions 
conducted in the presence of 400 μM NAD+.   a Ki(NAM)is the inhibition constant for 
nicotinamide inhibition of deacetylation. The values are determined by varying 
nicotinamide (NAM) concentrations, measuring deacetylation by HPLC and plotting 
rate of deacetylation versus NAM concentration.   Fits of points to the inhibition curve 
described in experimental determines the value of the parameter. bThe values are 
determined from the saturation curve for 14C-nicotinamide base-exchange. c Peptide 
primary sequence and acetylation are described in the materials and methods section.  
NM: Not Measured. ND: Not detected, highest concentration: 5 mM 14C-NAM. d No 
acetylated peptide is added to these reactions. NA: Not applicable.  
 
Maximal rates for deacetylation of H3 and H4 sequences were similar and 
remarkably slow as indicated by maximal turnover rates of 2.5 × 10-4 s-1 and 3.5 × 10-4 
s-1 respectively (Table 2.1).   The p300 peptide reacted at least 2.5 times faster than 
either H3 or H4 (9 × 10-4 s-1) with a Km value of 85 μM, 2 times smaller than H4 (176 
μM) and 4 times smaller than the Km of H3 (372 μM).   Deacetylation reactions of H3, 
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H4 and p300 substrates were determined to form 2′- and 3′- O-acetyl-ADP-ribose 
(AADPR), known co-products of sirtuin deacetylation reactions (8). 
Pf-Sir2 Catalyzes Nicotinamide Exchange and Inhibits Deacetylation. Sirtuin 
deacetylation reactions are inhibited by the general sirtuin inhibitor nicotinamide, 
which is a product of sirtuin deacetylation chemistry (11, 12, 29, 30).  To interrogate 
inhibition of H3 and p300 deacetylation as a function of nicotinamide concentration, 
an HPLC assay was employed (see experimental for details).  As shown in Figure 
2.2A and 2.2B deacetylation was almost completely inhibited by nicotinamide added 
to reaction mixtures with Ki values for nicotinamide of 35 and 91 μM for H3 and p300 
respectively. These results indicate that Ki may be dependent upon the substrate 
peptide sequence. The inhibition constants are potent and suggest that nicotinamide is 
likely to exert effects on deacetylation activity of Pf-Sir2 enzymes under physiologic 
conditions.  These nicotinamide inhibition constants are similar to those reported for 
inhibitions of deacetylation reactions catalyzed by yeast, human and archaeal sirtuins 
(11, 12). 
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Figure 2.2.  Nicotinamide Base-Exchange Catalyzed by Pf-Sir2. (A) and (B):  
Inhibition of the deacetylation reaction by increasing concentrations of nicotinamide. 
(A) 500 μM H3 peptide, 250 μM NAD+ and 150 mM phosphate buffer, pH 7.3, 
quantified by integration of deacetylated product peaks in the HPLC chromatograms. 
(B) 200 μM p300 peptide, 400 μM NAD+ and 150 mM phosphate buffer, pH 7.5, and 
quantified by integration of deacetylated product peaks in the HPLC chromatograms. 
(C) and (D): Kinetics of the base-exchange chemistry catalyzed by Pf-Sir2 as 
measured by exchange of [carbonyl-14C]-nicotinamide into unlabeled NAD+.  (C) 200 
μM H3 peptide, 400 μM NAD+ and 150 mM phosphate buffer, pH 7.5. (D) 200 μM 
p300 peptide, 400 μM NAD+ and 150 mM phosphate buffer, pH 7.5. 
 
 Nicotinamide inhibition of sirtuin catalyzed deacetylation is linked to a sirtuin 
reaction which catalyzes  nicotinamide exchange into NAD+ called “base-exchange”.  
The base-exchange reaction is thought to compete with the deacetylation reaction for a 
common reaction intermediate, called the ADPR-peptidyl-imidate (11, 12).  Depletion 
of the imidate by base-exchange inhibits the deacetylation reaction (Scheme 2.1). 
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Scheme 2.1.  Reactions of acetylysine peptides in base exchange and deacetylation  
pathways.  Rate constants for deacetylation and base exchange are shown for the 
respective steps.   
  Correlation of Km and Ki is expected since base-exchange and inhibition of 
deacetylation emanate from the same kinetic process (11).  We measured rates of 
base-exchange catalyzed by Pf-Sir2 using [carbonyl-14C]nicotinamide as the exchange 
base, as described previously (11).  Values for rate versus nicotinamide were plotted 
and the points fit to the Michaelis-Menten equation (Figure 2.2C and 2.2D).  As 
expected, Pf-Sir2 catalyzed base-exchange with H3 and p300 as substrates and 
responded saturably with increasing nicotinamide concentrations. Curve fits 
determined Km values of 61 μM (H3) and 91 μM (p300).  Corresponding kcat values 
were 0.025 s-1 (H3) and 0.064 s-1 (p300). These results establish that the kinetic 
parameter Km corresponds well to the corresponding Ki values as predicted (11). The 
steady-state rate of base exchange exceeds the corresponding deacetylation rate by 70 
fold and 100 fold for p300 and H3 respectively. If deacetylation and base exchange 
share the imidate as a common intermediate, then the slow deacetylation rate is caused 
by a rate-limiting step downstream of the imidate, possibly attack of the 2'-OH on the 
imidate (11). The reactivity of the NAD+ and peptide substrate to form the imidate 
(Scheme 2.1) must be at least as fast as the steady state base-exchange rate.    
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 To further probe for substrate specificity in the base-exchange reaction, we 
employed thionicotinamide as the base-exchange substrate.  Thionicotinamide has 
previously been shown to be competent as a base-exchange substrate of the sirtuin 
HST2 (12). Thionicotinamide is proposed to form thioNAD+ upon reaction with an 
imidate or an ADPR-intermediate complex (12). HPLC chromatograms show that 
thioNAD+ formation is catalyzed by Pf-Sir2 in the presence of thionicotinamide 
(Figure 2.3A).   
 
 
Figure 2.3.  Thionicotinamide Base-Exchange Catalyzed by Pf-Sir2.  (A) HPLC 
chromatograms showing the thionicotinamide base-exchange reaction and negative 
control. (B) Steady-state saturation kinetics of the thionicotinamide base-exchange 
reaction as catalyzed by Pf-Sir2 in the presence of 400 μM NAD+ and 400 μM H3 
peptide and increasing concentrations of thionicotinamide. 
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To characterize thionicotinamide exchange, thionicotinamide concentrations were 
varied and the rates of formation of thioNAD+ were determined using H3 as a 
substrate.  Fit of the individual data points to the Michaelis-Menton equation is shown 
in Figure 2.3B.  The Km of thionicotinamide was 495 μM, and kcat was 6 ×10-3 s-1.  
Under similar reaction conditions thionicotinamide reacts approximately 4 times 
slower than nicotinamide and has an 8 times higher Km.   The basis for the slower 
reaction of thionicotinamide is unlikely to reflect intrinsic reactivity differences, since 
nicotinamide and thionicotinamide pKa values are reportedly nearly identical (12). The 
weaker binding of thionicotinamide and slower reaction suggests that substrate 
binding interactions and geometry are less optimal than for reaction of nicotinamide 
on the active site. These results provide an example of how reactivity differences can 
emerge with even slight perturbation of substrate structure, not necessarily related to 
intrinsic reactivity, requiring care in using rate differences in “isosteric substrates” for 
addressing questions of mechanism. 
Pf-Sir2 Catalyzes Hydrolysis of NAD+.  The NAD+ hydrolysis product ADPR 
is often detected in NAD+ dependent deacetylation reactions.  ADPR is typically 
formed by slow non-enzymatic hydrolysis of NAD+, which is the minor pathway, and 
by the uncatalyzed decomposition of AADPR, the product of deacetylation chemistry 
(8), which is the major pathway.  HPLC chromatograms of deacetylation reactions 
containing NAD+ and Pf-Sir2 showed that amounts of ADPR were much higher than 
expected in comparison with reaction of SIRT1 under similar conditions of pH, 
substrates and rate of NAD+ consumption (Figure 2.4A).  We considered the 
possibility that Pf-Sir2 catalyzed decomposition of AADPR. However, purified 
AADPR in the presence of Pf-Sir2 was not decomposed faster relative to a control 
(data not shown).  Moreover, AADPR was not decomposed when Pf-Sir2 was added 
to a SIRT1 reaction mixture (data not shown). 
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Figure 2.4.  Hydrolysis of NAD+ Catalyzed by Pf-Sir2. (A)  HPLC chromatograms 
showing the production of ADPR by SirT1 and Pf-Sir2 under similar conditions.  (B) 
the kinetics of the hydrolysis reaction for varying concentrations of peptide carried out 
in the presence of 400 μM NAD+ and 150 mM phosphate buffer, pH 7.3.   
 
 
This suggested to us that Pf-Sir2 might possess an independent activity capable of 
catalyzing solvolysis of NAD+. Although hydrolysis is catalyzed by a mutated sirtuin 
in which the conserved catalytic histidine in the active site is replaced by alanine 
(H135A, HST2) (10), there are no examples of wildtype sirtuins that have an 
established NAD+ glycohydrolase activity. We did check for the presence of the active 
site histidine in recombinant Pf-Sir2 protein by trypsin digestion. We observed the 
tryptic peptide containing the catalytic histidine by MS analysis (Rockefeller 
Proteomics Resource).  We also sequenced the vector. Finally, the predicted MW of 
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the protein was confirmed by MALDI (predicted 32507.6 found 32504.9). Thus, a 
mutated histidine on Pf-Sir2 could not explain formation of ADPR.   
To quantitate ADPR formation we used HPLC conditions similar to those in 
Figure 2.4 using saturating NAD+ and different acetylated peptides (see experimental 
for details). Determined rates of formation of ADPR are shown in Table 2.1.  
Strikingly, the ADPR formation rate was 3-8 times higher than the maximal 
deacetylation rate for all peptide substrates (H3, H4 and p300). ADPR formation 
increased as a function of the peptide concentration and was dependent on substrate 
identity (H3, H4 or p300) as shown in Figure 2.4.  Quantitating rate of ADPR 
formation as a function of peptide concentration led to the unusual finding that ADPR 
formation was observable even in the absence of a peptide substrate and occurred at a 
rate of 1 × 10-3 s-1 (Figure 2.4B). We fit the rate of ADPR formation to a modified 
Michealis-Menton expression that is described in the experimental section (see Figure 
2.4B). The Km values for peptide substrates in deacetylation and in hydrolysis were in 
good correspondence for all three peptides (Figure 2.1, Figure 2.4B and Table 2.1).  
The best hydrolysis stimulating substrate was p300.  Hydrolysis in the absence of 
acetylated peptide was intriguing since peptide-independent NAD+ hydrolysis has not 
been reported for any sirtuin, mutant or wildtype. In addition, the observation of a 
peptide-stimulated hydrolysis reaction suggested to us that Pf-Sir2 might catalyze two 
different types of hydrolysis, which we sought to further elucidate. 
In the Absence of Peptide, Pf-Sir2 Catalyzes α-face Methanolysis.  We probed 
the mechanism of peptide independent solvolysis by employing methanol as a co-
solvent.  Methanol has previously been used to determine the stereochemistry of 
solvolysis reactions of NAD+ catalyzed by CD38/NAD+ glycohydrolase (25, 31).  
Methanol is superior to water for determining stereochemical outcome, because while 
the hydrolysis product rapidly undergoes mutarotation which randomizes 
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stereochemistry at the anomeric carbon, the methanolysis product retains its original 
stereochemistry and thereby reports on the mechanism of its formation.   The relevant 
α-1-O-methyl-APDR and β-1-O-methyl-ADPR standards were synthesized by known 
methods (see Methods section), and Pf-Sir2 solvolysis reactions were carried out in 
the absence of a peptide substrate but in the presence of methanol (30%).  HPLC 
analysis of the reaction revealed a new reaction product that eluted at the same time as 
the α-1-O-methyl-ADPR standard (Figure 2.5A).   
  
Figure 2.5.  Production of α-face Methanolysis Product. (A) HPLC chromatograms 
showing the α-MeOADPR standard, a Pf-Sir2 reaction run without peptide and in the 
presence of 30% MeOH, and a control reaction containing no enzyme run in the 
presence of 30% MeOH.  (B) MALDI-MS data showing the m/z values for the 
methanolysis products collected from the Pf-Sir2 catalyzed reactions in the presence 
of 30% CH3OH and 30% CD3OH respectively. 
 
The product was collected and analyzed by MALDI-MS and it behaved identically to 
the standard, with a positively charged parent ion M/z = 574 (Figure 2.5B).  
Furthermore, when the reaction was carried out in deuterated methanol, the isolated 
product gave a positively charged ion of m/z = 577, the expected value for the 
deuterated compound α-1-O-CD3-ADPR (data not shown).  Thus, the reaction that 
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generates solvolysis in the absence of a peptide substrate generates a product with 
inverted stereochemistry versus NAD+.  This result confirmed a new mode of 
chemistry for a sirtuin, namely a single-displacement ADP-ribosyltransfer to solvent 
independent of acetylated substrate. The solvolysis is envisioned to occur via binding 
of solvent to the active site pocket typically occupied by an acetylated substrate.  The 
acetylated substrate in the presence of NAD+ processes forward to form an imidate 
(Scheme 2.2), whereas in the absence of the acetylated substrate the poised NAD+ 
could capture the coordinated solvent to produce a product with inverted 
stereochemistry (Scheme 2.2).    
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Scheme 2.2 Proposed reaction of NAD+ in active site of Pf-Sir2 with either solvent of 
acetyllysine. 
 
In the Presence of Peptide, Pf-Sir2 Catalyzes both α- and β- face Methanolysis.  
To investigate the mechanisms of solvolysis reactions stimulated by the presence of 
acetylated peptide substrate, we conducted solvolysis reactions in which  NAD+ and 
H3 were reacted in the presence of Pf-Sir2, in which 30% methanol was present as a 
co-solvent.  An HPLC chromatogram of a reaction mixture showed that the α-
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methanolysis product appeared again, along with an additional new peak (Figure 
2.6A).  
The new product had the same elution time as an authentic β-1′-MeO-ADPR 
standard (Figure 2.6A). We collected this new product and a MALDI-MS spectrum 
determined the mass of the compound (m/z =574) identical to β-1-O-methyl-ADPR.  
As before, the corresponding reaction run in the presence of d4-deuterated methanol 
gave a mass shifted species (m/z = 577) corresponding to the tri-deuterated product.   
Thus, we conclude that in the presence of peptide Pf-Sir2 produces a new solvolysis 
product generated with overall retention of stereochemistry versus NAD+. 
In light of this finding, we considered the possibility that two solvolytic 
mechanisms were occurring on the enzyme, one that happens by one-step single 
displacement mechanism to produce inverted stereochemistry. The second reaction 
was hypothesized to be a peptide dependent double-displacement mechanism, 
probably imidate-dependent, which generates products exhibiting retention of 
stereochemistry versus NAD+ (Scheme 2.3).   If these are the operative mechanisms, 
then these two mechanisms should be competitive in nature, given that the solvent and 
acetylated peptide are proposed to require the same pocket on the enzyme to generate 
the α-solvolysis products or imidate to generate β-solvolysis products. If this idea is 
correct, increasing concentration of peptide should increase β- product formation and 
inhibit α-product formation concomitantly. Thus, a set of reactions were performed 
varying H3 concentrations and analyzed by HPLC to quantitate ADPR, and both 
stereochemical methanolysis products.   
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Figure 2.6.  Production of β-face Methanolysis Product. (A) HPLC chromatograms 
showing the β-MeOADPR standard, and a Pf-Sir2 reaction run in the presence of H3 
peptide and 30% MeOH.  (B) Bottom: Pf-Sir2 catalyzed methanolysis with different 
concentrations of H3 Productions of α-MeOADPR (circle) and β-MeOADPR (square) 
with different concentrations of H3 are shown. The reactions contained 400 μM of 
NAD+ in 100 mM phosphate buffer with 0, 10, 25, 50, 75, 100, 150, 250, 400 and 500 
μM of H3 all at pH 8.5. The following Michaelis parameters were determined by 
fitting the curves with KaleidaGraph: Ki (α-MeO-ADPR) = 70 μM.  k0 = 2.7 x 10-4 s-1. 
Km (β-MeO-ADPR) = 119 μM, k500 = 1.6 x 10-4 s-1 ksolvolysis ([H3] = 0) = 1.38 x 10-3 s-1, 
ksolvolysis ([H3] = 500 μM) = 1.40 x 10-3 s-1 
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As shown, the β-methanolysis product increased with increasing peptide 
concentrations, eventually saturating with Km of 120 μM (Figure 2.6B), while the α- 
product was inhibited to near zero over the same concentration range with a inhibition 
constant for peptide of Ki = 70 μM. (The lower apparent Km (and thus Ki) for H3 under 
these conditions (as compared to the Km values in Table 2.1) may be a consequence of 
methanol effects on H3 binding).  Interestingly, the overall rate of solvolytic turnover 
of NAD+ in the absence and presence of peptide under these conditions are virtually 
identical but the solvolytic mechanism completely changes (See Figure 2.6 legend for 
rates of combined ADPR and 1-O-methyl-ADPR for these conditions). The result 
supports the model that acetylated substrate competes for the α-face of C1' of NAD+, 
displacing solvent from the active site thus preventing the formation of solvolysis 
products with inversion of stereochemistry. 
Correspondingly, the acetylated substrate can react forward to form the imidate 
complex, which is proposed to undergo its own solvolysis reaction (Scheme 2.3) to 
generate overall stereochemical retention and the observed β-1-O-methyl ADPR 
(Scheme 2.3).    
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Scheme 2.3.  Reaction choices of solvolysis with inversion of stereochemistry or 
competition reaction of acetyllysine to form imidate which can react with solvent to 
form product with overall retention of stereochemistry. 
 
Differential Nicotinamide Inhibition of Solvolytic Mechanisms.  Observation of 
two separate solvolytic products, formed through distinct and independent pathways 
suggested to us that nicotinamide might affect solvolysis differently under conditions 
in which peptide is present or absent from reaction mixtures.  As already discussed, 
nicotinamide is a general sirtuin inhibitor and inhibits deacetylation of Pf-Sir2 by 
virtue of its ability to capture the imidate intermediate before it decomposes to 
products.  Nicotinamide does not appear to inhibit Michaelis complex formation, since 
increasing nicotinamide concentration does not inhibit base-exchange chemistry, even 
when the base-exchange rate is fully saturated (Figure 2.2, bottom panels).  Thus, we 
would predict that nicotinamide cannot inhibit peptide independent solvolysis, because 
it does not inhibit NAD+ binding.  Conversely, since peptide dependent chemistry is 
likely imidate-dependent, we predict that nicotinamide should inhibit peptide-
dependent solvolytic reactions. 
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Figure 2.7.  Hydrolysis is Incompletely Inhibited by Nicotinamide. (A) The effect of 
nicotinamide on the hydrolytic activity of Pf-Sir2 in the presence and absence of 
peptide.  The curve fit to the data for hydrolysis in increasing P300 concentrations 
(solid circles) is shown alongside the hydrolysis data obtained by running the reactions 
in 400 μM P300 and increasing nicotinamide concentrations (circles in squares).  The 
hydrolysis rate is incompletely inhibited and plateaus at a level equal to the rate of 
peptide independent hydrolysis (dashed line).  The data for peptide independent 
hydrolysis in varying nicotinamide concentrations is shown (triangles) and is fit by a 
straight line (dashed line). (B) The plot of the ratio of β to α stereochemistry of 
methanolysis products with increasing nicotinamide concentration as determined by 
HPLC. The plotted points were fit to a curve of form r = r0 – rmax ([I]/(Ki +[I])) where 
r is the ratio of stereochemistry observed for a given concentration of nicotinamide, r0 
is the observed stereochemical ratio when no nicotinamide is present, rmax is the 
maximal suppression of the ratio, Ki is the apparent inhibition constant of 
nicotinamide and [I] is the concentration of nicotinamide.   The HPLC chromatograms 
(B-right) illustrate that when nicotinamide is added there is a decrease in the β-1-O-
methylADPR peak, but there is little change in the production of α-1-O-methylADPR.  
The nicotinamide visible in the lower trace was produced by the normal hydrolysis 
and methanolysis of NAD+ catalyzed by Pf-Sir2.  
 
To examine the effect of nicotinamide on hydrolytic rate in the presence and 
absence of peptide, we conducted reactions in the presence of NAD+ with and without 
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p300 added to solution.  In the absence of added peptide, increasing concentrations of 
nicotinamide have no effect on the rate of hydrolysis, as shown by the line of nearly 
zero slope in Figure 2.7A. 
When p300 is added to reaction, it can stimulate the rate of hydrolysis several 
fold over the rate in which no peptide is present (overlaid curve Figure 2.7A).  
Increasing concentrations of nicotinamide inhibit this increase of hydrolysis in the 
presence of sub-saturating p300 (subsaturating conditions allow both peptide-
dependent and peptide-independent mechanisms to occur simultaneously) but does not 
fully inhibit hydrolysis, as shown by the fit of the inhibition data to a curve for non-
linear inhibition (Ki = 75 μM see experimental for details).  The uninhibited solvolysis 
rate is in reasonable agreement with the solvolytic rate when no peptide is present, 
consistent with the idea that only peptide-dependent hydrolysis is inhibited. 
To further probe the idea that only the peptide-dependent solvolysis is sensitive 
to nicotinamide concentrations, we examined the β-stereochemistry ratio of 
methanolysis products as a function of increasing nicotinamide concentrations under 
experimental conditions in which both methanolysis stereoisomers are generated.  As 
shown in the inset of Figure 2.7B, HPLC chromatograms reveal that formation of the 
β- product is inhibited by nicotinamide, whereas, formation of the β- product is not 
inhibited.  The effect of increasing nicotinamide concentrations on β/α product ratio 
was determined by HPLC and plotted, with points fit to a predicted curve as described 
in the figure legend. The ratio decreases to near 0 as a function of increasing 
nicotinamide concentrations, as predicted if nicotinamide selectively inhibits 
hydrolysis from the imidate complex, without inhibiting peptide-independent 
solvolysis of NAD+ (Figure 2.7B).  The peptide-independent hydrolysis of NAD+ by 
Pf-Sir2 establishes the first catalytic activity of a sirtuin that is insensitive to 
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nicotinamide inhibition (other than base-exchange) at concentrations of nicotinamide 
exceeding the mM range. 
2.5 Discussion 
Deacetylase activity. Protein deacetylase activity had been previously 
predicted for Pf-Sir2 based upon biological data implicating this sirtuin in regulation 
of chromatin structure and in silencing of epitope and virulence associated genes 
encoded by the var family (20, 21).  Patterns of var gene expression are involved in 
antigenic variation, a process by which P. falciparum avoids the immune system of the 
host by swapping expression of these genes, while keeping the remainder silent (20, 
21).   We determined that Pf-Sir2 in the presence of NAD+ catalyzes deacetylation of 
N-terminal histone sequences of H3 and H4 identical to N-terminal histone sequences. 
Pf-Sir2 deacetylates H3 peptides at sequences lysine 9 and 14, and also deacetylates 
H4 at lysine 16. Pf-Sir2 deacetylation generates AAPDR as a product. 
Two other recent reports have confirmed deacetylase activity for this enzyme 
(27, 32).  In the process of examining other substrates for Pf-Sir2 we identified a 
human p300 sequence to be a superior substrate for Pf-Sir2 as compared with peptide 
H3 and H4 sequences.  Although we currently do not understand the biochemical or 
functional basis for Pf-Sir2 substrate preference of p300 over histone sequences, we 
speculate that context-dependent factors such as post-translational modifications of 
histone sequences or macromolecular structures of histones and Pf-Sir2 localization to 
histones may affect catalytic efficiency of Pf-Sir2 for histone sequences in a native 
context.  We do not currently know if p300 is a substrate for Pf2-Sir2 in vivo, 
although P falciparum is an intracellular parasite of human cells and could 
theoretically act on human protein sequences. 
The deacetylation reaction is slow, even relative to sirtuin standards, which are 
typically slow turnover enzymes and typically have rates of deacetylation of  0.1 - 
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0.01 s-1.  In the case of H3 and H4 sequences, we determined kcat values of 2.5 and 3.5 
×10-4 s-1 respectively.  For a p300 sequence deacetylation rate was only slightly faster 
with a maximal rate 9 × 10-4 s-1.    A recent study of recombinant Pf-Sir2 with a non-
physiologic 8-mer acetylated substrate determined a similarly slow deacetylation rate 
(32). We propose that the slow rate of deacetylation under steady-state conditions is 
caused by a stalled imidate complex (Scheme 2.1) which is supported in part by the 
determination that the nicotinamide cleavage step, which precedes imidate formation, 
occurs approximately 50-100 times faster (Scheme 2.1).   The rate constants for 
nicotinamide cleavage are no slower than the observed rate of steady-state base-
exchange, which for H3 and p300 are 2.5 × 10-2 s-1 and 6.5 × 10-2 s-1 respectively 
(Scheme 2.1 and Figure 2.2).   
Slow reaction of the imidate and observation of hydrolysis from the imidate. 
Evidence that imidate forward reaction is rate-limiting for deacetylation includes the 
observation that the imidate decomposes via hydrolysis at rates that are 4-10 times 
faster than deacetylation (Table 2.1), suggesting that the 2'-OH attack of the imidate, 
which commits the imidate to deacetylation chemistry, is slower.  Consistently, the 
imidate hydrolysis reaction is interpreted to be a direct consequence of the slow rate of 
deacetylation chemistry (Scheme 2.4, step d) .  Reaction of solvent at the anomeric 
carbon of the Pf-Sir2 imidate is predicted to give overall retention of stereochemistry, 
which was observed in reactions performed in the presence of both acetyllysine 
peptide and methanol. A literature precedent is available for such a reaction, in which 
the conserved active site histidine of the sirtuin HST2 was mutated, causing decreased 
deacetylation rate.  In consequence of slowed deacetylation chemistry, imidate 
hydrolysis was observed, a reaction not observed on the wildtype HST2 enzyme (10).  
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Scheme 2.4. Overall reaction scheme of Pf-Sir2 catalyzed reactions.  Top scheme 
depicts solvolytic chemistry in the absence of peptide which gives inversion of 
stereochemistry (reaction a).  Bottom scheme depicts acetyllysine dependent 
chemistries which occur via the imidate including base exchange (reaction b), 
solvolysis from the imidate (reaction c) and deacetylation (reaction d)  
 
Nicotinamide inhibition of imidate-dependent reactions.  Nicotinamide 
inhibition occurs mainly through the reaction of nicotinamide through the imidate 
complex. Competitive nicotinamide capture of the imidate (Scheme 2.4 reaction b) is 
predicted to inhibit the deacetylation (11, 12) and imidate solvolysis (Scheme 2.4, 
reactions d and c respectively).  This was observed.  Interestingly, the steady-state 
nicotinamide exchange reaction occurs substantially faster than deacetylation or 
solvolysis, implying that the imidate and Michaelis complex (NAD+ and acetylated 
peptide) pseudo-equilibrate when nicotinamide concentrations saturate base-exchange 
(Scheme 2.4).  Analogous pseudo-equilibration effects of base-exchange with an 
active site ADPR-intermediate have been observed with the enzyme CD38 (33).  We 
conclude that the imidate is thermodynamically destabilized with respect to the 
Michaelis complex when nicotinamide saturates the base-exchange reaction, otherwise 
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the imidate concentration would not be depleted and inhibition of deacetylation would 
not be observed (11).  In contrast, in the absence of nicotinamide re-binding to the 
active site, the imidate is kinetically stable with respect to return to the Michaelis 
complex, and partitions between deacetylation and hydrolysis (β-stereochemistry).  
Peptide-independent solvolysis and insensitivity to nicotinamide.  The Pf-Sir2 
enzyme also displayed an unusual capacity to catalyze NAD+ hydrolysis in the 
absence of any added acetylated substrate.  In the absence of acetylated substrate, we 
identified  only α-1-O-methyl-ADPR as a product (no β) in addition to ADPR when 
methanol was added as a probe for stereochemistry of reaction.  This finding 
confirmed that the solvolytic reaction in the absence of peptide occurs with inversion 
of stereochemistry at C1′ (Scheme 2.4, reaction a).  This type of direct displacement 
solvolysis has not been reported for any other sirtuin, although cholera and diphtheria 
toxins, which are NAD+ dependent protein ADP-ribosyltransferases, hydrolyze NAD+ 
in the absence of cognate substrates, presumably via direct displacement mechanisms, 
to give inversion in hydrolysis products (34-36). Interestingly, methanolysis appears to 
be non-reactive in the cholera toxin solvolysis reaction, making confirmation of this 
prediction problematic (37).  
The Pf-Sir2 peptide-independent solvolytic reaction occurs at a rate that 
exceeds the deacetylation rate for H3, but is inhibited by this peptide, as shown by 
inhibition of α-stereochemistry methanolysis with increasing concentrations of 
acetylated peptide.  This suggests to us that acetyllysine and water (or methanol) 
occupy the same site on the enzyme leading to imidate formation or α-hydrolysis, with 
the ratio determined by the relative occupancy of the site. We also determined that 
increased H3 peptide concentration, while inhibiting the α-methanolysis 
concomitantly increases β-methanolysis, implying that H3 peptide provides a 
mechanism for imidate formation and the intermediate solvolysis pathway.  The 
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peptide-independent solvolysis pathway is not sensitive to inhibition by nicotinamide, 
since it does not require imidate formation.        
Implications of this work for understanding mechanisms of ADP-ribosyl 
transfer.  Our findings on Pf-Sir2 are relevant to reports of stable ADP-ribosyltransfer 
to proteins catalyzed by sirtuins, which have thus far remained mechanistically 
uncharacterized.  From a general chemical perspective the two different types of 
solvolysis that occur on Pf-Sir2 define mechanistic examples of two different types of 
stable ADP-ribosyltransfer to nucleophiles.  The first of these examples involves 
direct displacement of NAD+ by a nucleophile to furnish an ADP-ribosyltransfer 
product with α-stereochemistry (inverted) at C1' of ADPR (Scheme 2.5, top).  This 
type of reaction is analogous to that observed for both the ADP-ribosylating toxins and  
the protein modifying ADPribosyltransfer chemistry proposed for the poly-ADP-
ribosylpolymerases.  Interestingly, this reaction chemistry occurs independently of an 
acetylated peptide, although these reactions presumably occur by nucleophile 
occupation of the “acetyllysine pocket”, followed by reaction with enzyme-bound 
NAD+.  Interestingly, we found that nicotinamide cannot inhibit this reaction (Scheme 
2.5), suggesting that nicotinamide only inhibits sirtuin reactions through an imidate 
complex.  We propose that a lack of sensitivity of ADP-ribosyltransfer to nicotinamide 
can be used to infer the lack of an imidate complex in a sirtuin-catalyzed ADP-
ribosyltransfer mechanism. 
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Scheme 2.5. Proposed general mechanisms of ADP-ribosyltransfer catalyzed by 
sirtuins as determined by chemistries reported in this study.  Top chemistry is 
acetyllysine independent, gives inversion of stereochemistry versus NAD+ and is 
insensitive to nicotinamide inhibition.  Bottom chemistry scheme shows ADP-
ribosyltransfer from the imidate complex, to produce ADP-riboysltransfer with 
retention of stereochemistry versus NAD+.  This reaction is predicted to be sensitive 
to nicotinamide inhibition.  
The second type of ADP-ribosyltransfer mechanism determined in this study is 
reaction of the imidate complex to produce a product with β-stereochemistry 
(retention) at C1' of ADPR (Scheme 2.5).  This reaction is inherently sensitive to 
nicotinamide inhibition since nicotinamide can compete for the nucleophile site and 
for reaction with the imidate (Scheme 2.5).  Thus, imidate-dependent ADP-
ribosyltransfer can be distinguished by sensitivity to nicotinamide.  We propose that 
nicotinamide sensitivity can help to determine mechanisms of ADP-ribosyltransfer 
catalyzed by sirtuins.  For example, SIRT4 has been demonstrated to ADP-ribosylate 
glutamate dehydrogenase, and this reaction is inhibited by nicotinamide (6).  Based on 
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our findings, this could imply SIRT4 catalyzes imidate dependent ADP-ribosylation, 
and we are currently investigating this possibility in our laboratory.  
2.6 Conclusions 
Plasmodium falciparum Pf-Sir2 is a chromatin associated enzyme implicated 
in silencing of var genes.  We found that it can deacetylate acetyllysine peptide 
substrates such as histone H3 and H4 N-terminal sequences.  Pf-Sir2 was also found to 
catalyze two stereochemically distinct types of solvolysis, one sensitive to 
nicotinamide inhibition, the other insensitive to nicotinamide inhibition. These are the 
first reported NAD+ glycohydrolase reactions catalyzed by a wildtype sirtuin. The 
biologic role of these hydrolytic reactions, which would generate ADPR in the nucleus 
of the parasite, is not known.  We speculate that the solvolyses may be occurring in 
competition with other kinds of Pf-Sir2 ADP-ribosyltransfer reactions in cells, 
including protein ADP-ribosyl transfer. A recent paper suggests that Pf-Sir2 is able to 
catalyze protein ADP-ribosyltransfer (27) although the mechanism of ADP-
ribosyltransfer remains undetermined.  Investigations to elucidate mechanisms of 
sirtuin-catalyzed protein ADP-ribosyltransfer reactions are underway in our laboratory 
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CHAPTER 3 
CHARACTERIZATION OF NICOTINAMIDASES: STEADY-STATE KINETIC 
PARAMETERS, CLASS-WIDE INHIBITION BY NICOTINALDEHYDES AND 
CATALYTIC MECHANISM  
3.1 Abstract 
Nicotinamidases are metabolic enzymes that hydrolyze nicotinamide to 
nicotinic acid.  These enzymes are widely distributed across biology, with examples 
found encoded in the genomes of Mycobacteria, Archaea, Eubacteria, Protozoa, yeast 
and invertebrates but there are none found in mammals.  The catalytic mechanism of 
these enzymes is not well understood. Recent data shows that nicotinamidases are 
required for growth and virulence of several pathogenic microbes and the enzymes of 
Saccharomyces cerevisiae, Drosophila melanogaster and Caenorhabditis elegans 
regulate lifespan in their respective organisms, consistent with proposed roles in the 
regulation of NAD+ metabolism and organismal aging.  In this manuscript, we 
determine the Michaelis-Menten parameters of nicotinamidase enzymes from C. 
Elegans, S. cerevisiae, Streptococcus pnemoniae (a pathogen responsible for human 
pneumonia), Borrelia Burgdorferei (the pathogen that causes Lyme Disease) and 
Plasmodium falciparum (responsible for most human malaria).  Our findings indicate 
that these enzymes are generally efficient with catalytic rates typically exceeding 1 s-1.  
The Km values for nicotinamide are low and are in the range from 5-80 μM.  In 
addition, we show that nicotinaldehydes are potent competitive inhibitors of these 
enzymes, and bind in the low μM to low nM range for all nicotinamidase enzymes 
tested.  A variety of nicotinaldehyde derivatives were synthesized and evaluated in 
kinetic assays, demonstrating that optimized binding can be obtained by introducing 
substitutions to the nicotinaldehyde ring.  18O exchange studies, sequence comparisons 
and the availability of a complete set of substrate, intermediate and inhibitor crystal 
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structures (see Chapter 4) provide evidence for a shared catalytic mechanism within 
this enzyme class.  A comprehensive catalytic mechanism that explains 
nicotinamidase chemistry is presented involving the intermediacy of a thioester moeity 
and the transient involvement of a Zn-hydroxide complex as an activating base for 
deprotonation of water that promotes thioester hydrolysis on the enzyme.       
3.1 Introduction 
The nicotinamidases hydrolyze nicotinamide to nicotinic acid (Scheme 3.1).   
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Scheme 3.1.  Nicotinamidase hydrolyzes nicotinamide to give nicotinic acid 
 
These enzymes play  important roles in nicotinamide salvage in multiple species of 
bacteria (1), mycobacteria (1-4), yeast (5-7), protozoa (8) and are encoded in genomes 
of plants (9) and many metazoan species as well, such as Drosophila melanogaster 
(10) and Caenorhabditis elegans (10-12).  Nicotinamide salvage is important since 
NAD(P)+ is chemically unstable to non-enzymatic hydrolysis even at physiologic 
temperatures (13-15) and because nicotinamide is the product of multiple NAD+ 
consuming enzymes (13, 14), such as sirtuins that are widely distributed in biology 
(16).  Consistent with their centrality to NAD+ homeostasis, nicotinamidases are 
essential for the viability of several microorganisms that are pathogenic to humans 
such as Borrelia burgdorferi (which causes Lyme disease) (17-19) and  Brucella 
abortus (20). It is possible that a variety of other pathogenic organisms require this 
enzyme as well, since several of these, including Plasmodium falciparum do not 
appear to encode genes for enzymatic components of de novo NAD+ biosynthetic 
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pathways (21). Consequently, it is likely that these organisms are highly reliant on 
salvage of nicotinamide from the human host.  Attractively, human genomes do not 
encode a nicotinamidase, suggesting that small molecule inhibitors of nicotinamidases 
could serve as antimicrobial agents (21).    
Biologically interesting roles for nicotinamidases have also been identified as 
increasers of lifespan in D. melanogaster (10) and in C. elegans (11) and in the 
budding yeast Saccharomyces cerevisiae (22). Importantly, endogenous nicotinamide 
concentrations are implicated in negative regulation of NAD+ dependent deacetylases, 
the sirtuins (16, 23). Lifespan extending effects of overexpression of nicotinamidases 
require sirtuin activity in yeast (24) and in flies (10) consistent with a mechanism in 
which increased nicotinamidase activity can deplete inhibitory nicotinamide 
concentrations in cells, leading to sirtuin activity upregulation.  Consistently, sirtuin 
overexpression within D. melanogaster (25, 26) C. elegans (27, 28) and S. cerevisiae 
(29, 30) also causes increased lifespan.   Stresses that increase lifespan in the yeast, 
such as low calorie stress, induce nicotinamidase activity by increasing nicotinamidase 
transcription and translation (22).  Similarly, oxidative stress increases nicotinamidase 
expression in D. melanogaster (10). These data suggest that these enzymes are central 
to phylogenetically conserved adaptative responses to environmental stress in single-
celled eukaryotes and possibly in multicellular eukaryotes as well.  
Additional interest in these enzymes stem from an important role in 
Mycobacterium tuberculosis, where the endogenous nicotinamidase is responsible for 
activation of the pro-drug pyrazinamide to the active antibiotic pyrazinoic acid and 
mutations in this enzyme are associated with resistance to this drug (Scheme 3.2) (4). 
Recently nicotinamidases have been shown to be important for plant germination as 
well (31). Thus, nicotinamidases are biologically interesting enzymes with diverse 
biological functions associated with their enzymatic activity.  
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Scheme 3.2. Nicotinamidase catalyzes the conversion of pyrazinamide to pyrazinoic 
acid. 
       
The first nicotinamidase activity was reported for the organism Lactobacillus 
arabinosus (32), but decades later, there is still limited insight into the chemical and 
enzymatic mechanisms of these enzymes. Hints to the chemistry of these enzymes was 
obtained from two unliganded structures of nicotinamidases, one of the S. cerevisiae 
enzyme (6), the other from the archaean thermophile Pyrococcus hirikoshii (33).  Both 
structures revealed an active site coordinated metal ion, proposed to be Zn+2, and 
similar structural folds.  A recent structure of the nicotinamidase from Acinetobacter 
baumannii in complex with nicotinic acid provided new insight into the active site 
design for these enzymes (34).  The crystal structure revealed that the pyridine N1 of 
the product is coordinated to the central metal ion, suggesting that coordination of 
nicotinamide to the metal center organizes and electrophilically activates the pyridine 
for attack by a cysteine residue on the amide carbonyl of the substrate (34).  This 
cysteine is universally conserved in all nicotinamidases (Figure 3.1) and previously 
had been proposed to perform a nucleophilic function on the enzyme to form a labile 
thioester of nicotinic acid, which can further hydrolyse to release the free thiol and 
nicotinic acid (33, 34).  
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Figure 3.1.  Multiple sequence alignment of the Pyrococcus horikoshii (PDB entry 
1IM5), Streptococcus pneumoniae, Escherichia Coli, Saccharomyces cerevisiae , and 
Borrelia burgdorferi nicotinamidases.  The alignment was perfomed with ClustalW 
(35) and edited with ESPript (36).  Identical residues are highlighted, and the 
secondary structure elements of the solved P. horikoshii structure (37) are shown 
above the alignment.  Vertical arrows point to the proposed catalytic triad proposed by 
Du et al. that is composed of an aspartate, a cysteine, and a lysine residue.  The 
proposed metal-binding residues are shown with an M under the appropriate residue. 
 
In Chapter 4 we provide extensive structural characterization of a variety of 
liganded states of the nicotinamidase from Streptococcus pnemoniae (SpNic, (38))  
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These structures illuminate important mechanistic states of the enzyme including the 
substrate bound condition, the probable structure of tetrahedral intermediates as well 
as the structure of the proposed thioester intermediate.  In this paper, we characterize 
the Michaelis Menten properties for a number of nicotinamidases from multiple 
sources including S. cerevisiae (Pnc1), B. Burgdorferei (BbNic), P. falciparum 
(PfNic), S. pnemoniae (SpNic) and two nicotinamidase isoforms from C. elegans 
(CePNC1 and CePNC2).  We present the first continuous assay to monitor 
nicotinamidase catalytic function and show that these enzymes have high catalytic 
efficiency for nicotinamide and can also accept a number of additional substituted 
nicotinamide substrates.  In addition we found that all of these enzymes are inhibited 
by nicotinaldehyde with Ki values in the range 1.5 μM to 20 nM.  The kinetics of 
inhibition by nicotinaldehyde for these enzymes reveal competitive binding with 
nicotinamide, consistent with reversible mechanism-based trapping of the enzyme.  
The mechanism of inhibition was determined by the crystallization of nicotinaldehyde 
and 5-O-methyl nicotinaldehyde tetrahedral adducts on the Streptococcus pneumoniae 
enzyme, structures presented in Chapter 4 (38).  Structural variants of nicotinaldehyde 
were also synthesized and biochemically evaluated, establishing the possibility of 
developing potent yet selective inhibitors for nicotinamidases derived from different 
sources. Using information provided by nicotinaldehyde inhibition studies, kinetic 
studies, sequence comparisons, 18O exchange into nicotinic acid catalysed by SpNic, 
and the available structural information (38) we present a detailed chemical 
mechanism to explain nicotinamide hydrolysis catalyzed by this enzyme class.      
3.3 Materials and Methods 
Reagents and Instrumentation. Unless otherwise stated in the text, all reagents 
were purchased from Sigma-Aldrich or VWR and were of the highest purity 
commercially available. UV analyses were performed on a Hitachi U-3010 
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spectrophotometer. Fluorescence analyses were performed on a LJL Biosystems 
Analyst AD 96.384 microplate reader.   
Plasmid Construction and Protein Expression. Standard molecular biology 
techniques were used to clone the genes of interest. Briefly, the nicotinamidase gene 
for Streptococcus pneumoniae was amplified by PCR from genomic DNA (ATCC 
6314D) using primers (5'CAT ATG ATG ACA AAG GCT TTA ATT TGC ATT3' 
and 5'GGA TCC TTA CTC AAA AAG TTC ATT TAG ATT TTC ATC3') 
engineered to contain the NdeI and BamHI restriction endonuclease recognition sites.  
The PCR product was inserted into the pSTBlue vector (Novagen) using the AccepTor 
vector kit (Novagen).  The gene was digested with NdeI and BamHI and ligated into 
similarly digested Pet28a; the presence of the gene was verified by sequencing. The 
protein obtained was called SpNic. The nicotinamidase gene from Borrelia 
burgdorferi was cloned from a construct pBBE22 provided by Steven J. Norris, Ph.D. 
of University of Texas Health Science Center at Houston.  As previously reported (39) 
in order to produce a functional nicotinamidase an additional 48 base pairs upstream 
of the annotated start codon were required.  PCR was used to amplify the extended 
gene using primers engineered to include NdeI and BamHI cut sites (5'CAT ATG 
ATG CCA GTA TCT AAC AGT AAT GAA ATA ATT TCT TTG ATT3' and 5'GGA 
TCC TTA TAT ATT AAG CTT ACT TTG GCT GTC GAA GAT GTC C3').  The 
PCR product was inserted into the pSTBlue vector (Novagen) using the AccepTor 
vector kit (Novagen).  The gene was digested with NdeI and BamHI and ligated into 
similarly digested Pet28a; the presence of the gene was verified by sequencing. The 
protein obtained was called BbNic.  The nicotinamidase gene for Plasmodium 
falciparum was amplified from cDNA provided by Kirk Deitsch of Weill Medical 
College using primers engineered to included the EcoRI and HindIII restriction 
endonuclease sites (5'AGA ATT CAT GAA ATG CCT TGT TAT AGT TGA TGC 
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ACA A3' and 5'GCA AGC TTA TGA CAA AAG TTT TGA TGA GTT AAT AAA 
TTT GAT TCC3').  The PCR product was inserted into the pSTBlue vector (Novagen) 
using the AccepTor vector kit (Novagen).  The gene was digested with NdeI and 
BamHI and ligated into similarly digested Pet28a; the presence of the gene was 
verified by sequencing. The protein obtained was called PfNic. In all cases the 
constructs were transformed into Codon+ cells (Stratagene) and grown with shaking at 
37oC to an O.D. of 0.6 before inducing with 0.5 mM IPTG.  After 6 hours of growth 
post-induction at 37oC the cells were harvested and lysed using lysozyme followed by 
three successive freeze-thaw cycles.  After treatment with DNAse, the cell debris was 
pelleted and the supernatant was added to pre-equilibrated Ni-NTA nickel resin 
(Qiagen).  After successive washes with 5 mM and 10 mM imidazole in 10 mM Tris, 
the protein was eluted from the nickel resin with 250 mM imidazole in 10 mM Tris.  
The elutions were immediately tested for activity and purity of the samples was 
assessed by SDS-polyacrylamide gel electrophoresis.  Active fractions with purity 
greater than 90% were pooled and aliquots were flash frozen in 20% glycerol and 2 
mM DTT.   C. elegans PNC1 and PNC2 (CePNC1 and CePNC2) was expressed and 
purified as described (12) and the expression plasmid of S. cerevisiae Pnc1 was 
received as a gift from Dr. Jeffrey Smith of the University of Virginia and expressed 
and purified as described previously (24).  
GDH Coupled Nicotinamidase Assay. Nicotinamidase activity was monitored 
by coupling the production of ammonia with the consumption of NAD(P)H by the 
enzyme bovine glutamate dehydrogenase (GDH, from Sigma).  A typical reaction 
contained 1 mM α-ketoglutarate, 250 μM NAD(P)H, 1.5 units of GDH per 100 μL of 
reaction volume, and different concentrations of nicotinamide in 100 mM phosphate 
buffer, pH 7.3.  The components were mixed and placed in cuvettes (for analysis by 
UV, 340 nm detection wavelength), or into a 96-well plate (for analysis on a plate 
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reader using fluorescence).  The reaction was initiated by addition of the appropriate 
nicotinamidase enzyme and the absorbance at 340 nm was used to monitor 
concentration of NAD(P)H with time. In plate reader experiments, fluorescence 
intensity was used for this purpose (excitation 360 nm, emission 490 nm).   
HPLC Assay for Nicotinamidase Activity. All HPLC analyses were performed 
on a Hitachi Elite Lachrom system equipped with diode array detector.  A typical 
injection (Macherey-Nagel Nucleosil C-18 250 mm x 4.6 mm) employed 20 mM 
ammonium acetate, pH 6.9 at 1mL/min for 15 min. and was then followed by 20 mM 
ammonium acetate pH 6.9 10% methanol.  Authentic nicotinic acid elutes at 4.2 min. 
and nicotinamide elutes at 16 min using 260 nm as a detection wavelength (typical 
chromatograms are available in Figure 3.2). 
 
Figure 3.2.  HPLC chromatograms showing the conversion of nicotinamide to 
nicotinic acid by nicotinamidases.  A typical reaction was run on a 50 μL scale 
containing 200 μM of nicotinamide in 100 mM phosphate buffer at pH 7.3.  The 
reaction was initiated by addition of nicotinamidase enzyme and  incubated at 25oC to 
allow approximately 50% nicotinamide conversion.  The reaction was quenched by 
addition of 6 μL of 10% trifluoroacetic acid to a final pH 3 and then allowed to 
incubate on ice for 30 minutes.  Prior to injection on HPLC, the sample was 
centrifuged at 13,000 g for 2 minutes to remove precipitates.  Authentic chemical 
standards of nicotinamide and nicotinic acid were injected to determine retention times 
for substrate and product. 
 
52 
In some instances a Waters 300 mm x 7.8 mm Delta-pak C18 column was used for 
HPLC measurements with slight adjustments to the assay method. A typical reaction 
was run in 50 μL total volume containing 200 μM   nicotinamide in 100 mM phosphate 
buffer at pH 7.3.  The reaction was initiated by addition of nicotinamidase enzyme 
(10-200 nM final concentration) and allowed to incubate for 20 minutes at 25 oC.  The 
reaction was quenched by 6 μL addition of 10 % trifluoroacetic acid and incubated on 
ice for 30 minutes.  Prior to injection on HPLC, the sample was centrifuged at 13, 000 
g for 2 minutes to remove precipitates. 
Michaelis-Menten Initial Rate Analysis. For CePNC1 and CePNC2, the GDH 
coupled assay described above was used to determine the Michaelis-Menten 
parameters. Reactions were run in 150 μL total volume containing varying 
concentrations of nicotinamide (0, 10, 20, 30, 40, 50, 75, 100, 200, 400 and 600 μM) 
on a 96-well plate. The reactions were initiated by addition of nicotinamidase (final 
concentration 500 nM PNC1, 2 μM PNC2) and decreasing fluorescence intensity was 
monitored by a microplate reader for a total of 2,500 seconds at 45 seconds intervals. 
The initial rates of reactions were derived from the slope of product formed versus 
time where extent of reaction had not exceeded 15% of substrate in each case.  
Determined rates were plotted against nicotinamide concentrations and fit with the 
Michaelis-Menten equation using Kaleidagraph® (Synergy Software).  
Michaelis-Menten-Progress Curve Analysis. For SpNic and Pnc1, kinetic 
parameters were measured by the GDH coupled assay described above and calculated 
by progress curve analysis. Reactions were run in 600 μL total volume containing 100 
μM of nicotinamide in UV cuvettes. The reactions were initiated by addition of 
nicotinamidase (e.g. final concentration: 200 nM Pnc1).  The absorbance at 340 nm 
was monitored by UV spectrophotometer over a total of 12 to 15 minutes at 16 s 
intervals for SpNic, and 25 s intervals for Pnc1.  Progress curve analysis involved 
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approximating instantaneous rates at a time tx, where product formation at tx-1 and tx+1 
was determined and the ΔP/Δt calculated to determine the instantaneous rate. tx 
represents the mid time point between  tx-1 tx+1 and the tx-1 tx+1 represent the start and 
end points of the time interval. Rates were plotted vs. the substrate concentration at 
each time calculated for each point and the data fit to the Michaelis-Menten equation 
to determine Km and Vmax values.  The method is similar to that published for this 
approach (40). 
Michaelis-Menten HPLC Analysis.  For BbNic and PfNic, The HPLC assay 
described above was used to measure the Michaelis-Menten parameters.  
Nicotinamide was incubated at concentrations of 0, 20, 40, 60, 80, 120, 160, 200 and 
400 μM. For BbNic, the enzyme was used at a final concentration of 5.4 μM.  The 
chromatograms were analyzed at wavelength of 260 nm.  Reactions were quantified 
by integrating areas of peaks corresponding to nicotinamide and nicotinic acid.  Rates 
were plotted versus nicotinamide concentration and best fit of points to the Michaelis-
Menten equation was performed by Kaleidagraph®.  
For P. falciparum nicotinamidase, reactions containing 0, 2.5, 3.75, 5, 7.5, 10, 
20, 25, 50 μM of nicotinamide with 20% [carbonyl-C14]-nicotinamide in 100 mM 
phosphate budder pH 7.3 were initiated with the addition of PfNic, reactions were 
incubated at room temperature for 7 minutes and quenched by addition of 8 μL of 10% 
trifluoroacetic acid.  After centrifugation at 13,000 g for 2 minutes, the reactions were 
injected on HPLC to separate nicotinamide and nicotinic acid. Eluents containing 
nicotinamide and nicotinic acid were collected and radioactivity was determined by 
scintillation counting.  Rates were determined as cpm/s conversion to nicotinic acid, 
and then converted to a turnover rate (s-1) by adjustment for specific radioactivity of 
nicotinamide and enzyme concentration.  Rates were plotted versus nicotinamide 
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concentration and best fit of plotted data to the Michaelis-Menten curve was 
performed using Kaleidagraph®. 
Inhibition Analysis.  To determine inhibition, reactions were performed using 
the GDH coupled assay described above.  Reactions containing 1 mM α-ketoglutarate, 
250 μM NAD(P)H, 1.5 units of GDH per 100 μL of reaction volume, and 200 μM of 
nicotinamide, and varying concentrations of inhibitors in 100 mM phosphate buffer, 
pH 7.3, were initiated with the addition of nicotinamidases. Rates were plotted and 
points fit to equation (1) using Kaleidagraph®: 
                                vinh. = (Vmax*[S])/([S] + (Km (1 + [I]/Ki)                                    (1) 
where vinh. is the inhibited rate for a given concentration of inhibitor, Vmax is the 
uninhibited rate, [S] is the nicotinamide concentration, Km is the Michaelis constant 
for nicotinamide for a given nicotinamidase, [I] is the inhibitor concentration and Ki is 
the binding constant for competitive inhibition.  In some cases relative rates were 
plotted and points fit to equation (2) using Kaleidagraph®: 
                                    vinh/Vmax.= [S]/([S] + (Km*(1 + [I]/Ki)                                       (2) 
where vinh. is the inhibited rate for a given concentration of inhibitor, Vmax is the 
uninhibited rate, [S] is the nicotinamide concentration, Km is the Michaelis constant 
for nicotinamide for a given nicotinamidase, [I] is the inhibitor concentration and Ki is 
the binding constant for competitive inhibition. 
Competition Analysis of Inhibitor.  Nicotinaldehyde, characterized as an 
inhibitor by use of the GDH coupled assay described above, was used for the 
competitive analysis.  Inhibition reactions were performed in 150 μL volumes 
containing 1 mM α-ketoglutarate, 250 μM NADPH, 2.25 units of GDH, and different 
concentrations of nicotinamide (50, 100, 250, 500 and 1000 μM) in 100 mM 
phosphate buffer, pH 7.3.  The inhibitor concentrations were from 0 to twice or five 
times its estimated Ki as indicated in Figure 3.3.  
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Figure 3.3.  The Lineweaver-Burke plots for nicotinamidases.  Curves were obtained 
in the presence of three different concentrations of nicotinaldehyde, demonstrating the 
competitive nature of the inhibitor with substrate.  These curves were used to 
determine the Ki values for nicotinaldehyde in Table 3.4. 
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Reactions were initiated by addition of the nicotinamidase enzymes (varying from 20 
nM to 5 μM). Double reciprocal plots of 1/v versus 1/[Nicotinamide] at different fixed 
concentrations of the inhibitor were plotted, the intersection of the lines at 1/v axis 
indicated competitive inhibition. All data points were fitted to double reciprocal plots 
using Kaleidagraph®. 
Isotope Exchange catalyzed by Streptococcus pneumoniae nicotinamidase.  
Reactions of volume 25µL in 40mM phosphate buffer pH 7.0 containing 90% 18O-
H2O, 1 mM nicotinic acid and 6 μM Streptococcus pneumoniae nicotinamidase. After 
incubation for 0 (pre quenched), 2, 10, 30, 60 min at 37 oC, the reaction was quenched 
with 4 µL of 10% trifluoroacetic acid.  A no enzyme control was run identically  for 
60 minutes and quenched identically.  20 µL of the solution injected into a C-18 
reverse phase column (EC250/4.6 NUCLEODUR 100-5 C18, Macherey-Nagel) to 
separate nicotinic acid from other components using 20mM ammonia acetate pH 7.0 
as the eluent and fractions were collected.  Fractions containing nicotinic acid were 
lyophilized and then dissolved into 10 µL water.  1µL of the sample was spotted on a 
MALDI plate and after drying 1μL of the matrix composed of 10 mg/mL α-cyano-4-
hydroxycinnamic acid (CHCA) and 0.1% TFA (50: 50 v/v) was spotted to the plate 
and dried.  The mass spectrum was acquired by an Applied Biosystems DE-STR 
MALDI-TOF spectrometer (Rockfeller University, Proteomics Resource Center). For 
each sample, the intensity of isotope was recorded through 200 shots in each 
measurement and the measurement was repeated three times.  Non-labeled nicotinic 
acid was detected at m/z = molecular weight of 124.07(5) which represents the twice 
protonated species.  Nicotinic acid incorporating one 18O was detected 126.07(5) and 
nicotinic acid with two 18O isotopes was detected at 128.07(5).  Complete exchange of 
18O into nicotinic acid was observed after an hour and significant exchange was 
measured at 2 minutes.  No exchange was observed for control. The rate of exchange 
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was calculated to be 0.7 s-1.  Formation of 18O nicotinic acids (single and double 
labeled) was confirmed by HRMS (CUNY Hunter Mass Spectrometry Facility).  The 
predicted m/z for single labeled 18O nicotinic acid (C6H5NO[18O]) was calculated to be 
125.0363 and measured to be 125.0365, while for (C6H5N[18O]2) the calculated m/z 
was 127.0405 and the measured m/z was 127.0407. 
Synthesis of Substrate Analogues.  Nicotinamide, 2-chloronicotinamide, 6-
chloronicotinamide, 6-methylnicotinamide, 6-aminonicotinamide, isonicotinamide and 
ethyl nicotinate were purchased from Aldrich.  Thionicotinamide was purchased from 
Acros.  We also thank Peter Tyler of IRL New Zealand for several samples of 
nicotinamides including 5-methylnicotinamide, 6-chloronicotinamide, 6-
methylnicotinamide 6-aminoisonicotinamide and 6-aminonicotinamide used for parts 
of this study. 5-methylnicotinamide was alternatively synthesized as reported (21).  
 5-Methoxynicotinamide was synthesized from the corresponding aldehyde (41). 5-
Methoxy-3-pyridinecarboxaldehyde (400 mg, 2.92 mmol) was dissolved in 4 mL of 
methanol, to this solution was added hydroxylamine hydrochloride (264 mg, 3.80 
mmol). The reaction mixture was allowed to stir at room temperature for 4 hours.  
Solvent was removed under reduced pressure, residue was redissolved in 3 mL of dry 
pyridine, and to this solution was added methanesulfonyl chloride (435 mg, 3.80 
mmol). The mixture was stirred at room temperature for 2 hours, and then water and 
ethyl acetate were added. Combined organic layer was dried over Na2SO4.  Column 
chromatography (hexanes: ethyl acetate = 4:1) afforded 320 mg (2.39 mmol, 82% 
yield) of 3-cyano-5-methoxypyridine as a white solid. 1H NMR (400 MHz, CDCl3), δ 
ppm: 8.49 (d, J= 2.8 Hz, 1H), 8.46 (d, J= 1.5 Hz, 1H), 7.37 (dd, J= 1.6, 2.8 Hz, 1H), 
3.89 (s, 3H). Hydrogen peroxide (4 mL) was added dropwise to a solution of 3-cyano-
5-methoxypyridine (320 mg, 2.39 mmol) and K2CO3 (790 mg, 5.72 mmol) in 3 mL of 
DMSO, the mixture was stirred for one hour before it was diluted with water and 
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lyophilized to dryness.  The crude product was purified by column chromatography 
(ethyl acetate: ethanol = 10:1) followed by recrystallization in ethyl acetate to afford 
200 mg (1.32 mmol, 55% yield) of 5-methoxynicotinamide as white solid. 1H NMR 
(400 MHz, DMSO), δ ppm: 8.62 (d, J= 1.7 Hz, 1H), 8.40 (d, J= 2.9 Hz, 1H), 8.13 (s, 
br, 1H), 7.74 (dd, J= 1.8, 2.8 Hz, 1H), 7.59 (s, br, 1H), 3.86 (s, 3H). 
4-Methoxynicotinamide was synthesized from the corresponding aldehyde 
(41). 4-Methoxy-3-pyridinecarboxaldehyde (180 mg, 1.31 mmol) was dissolved in 2 
mL of methanol, to this solution was added hydroxylamine hydrochloride (118 mg, 
1.70 mmol). The reaction mixture was allowed to stir at room temperature for 4 hours.  
Solvent was removed under reduced pressure, residue was redissolved in 2 mL of dry 
pyridine, and to this solution was added methanesulfonyl chloride (195 mg, 1.70 
mmol). The mixture was stirred at room temperature for 2 hours, and then water and 
ethyl acetate were added. Combined organic layer were dried over Na2SO4.  Column 
chromatography (hexanes: ethyl acetate = 1:2) afforded 135 mg (1 mmol, 78% yield) 
of 3-cyano-4-methoxypyridine as white solid. 1H NMR (400 MHz, CDCl3), δ ppm: 
8.67 (s, 1H), 8.62 (d, J= 6.0 Hz, 1H), 6.90 (d, J= 6.0 Hz, 1H), 3.99 (s, 3H). Hydrogen 
peroxide (1.67 mL) was added dropwise to a solution of 3-cyano-4-methoxypyridine 
(135 mg, 1mmol) and K2CO3 (333 mg, 2.4 mmol) in 3 mL of DMSO, and the mixture 
was stirred for one hour before it was diluted with water and lyophilized to dryness.  
The crude product was purified by column chromatography (ethyl acetate: ethanol = 
10:1) followed by recrystallization in ethyl acetate to afford 100 mg (0.66 mmol, 66% 
yield) of 4-methoxynicotinamide as white solid. 1H NMR (400 MHz, DMSO), δ ppm: 
8.70 (s, 1H), 8.51 (d, J= 5.8 Hz, 1H), 7.64 (s, br, 1H), 7.61 (s, br, 1H), 7.15 (d, J= 5.9 
Hz, 1H), 3.93 (s, 3H). 
2-Aminoisonicotinamide was synthesized as described before (42) with several 
modifications. Briefly, acetylation of 2-amino-4-picoline followed by oxidation using 
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KMnO4 gave 2-acetylamino isonicotinic acid. This compound was subjected to 
amidation in the presence of DCC and ammonia in methanol to yield 2-acetylamino 
isonicotinamide. Further reaction of 2-acetylamino isonicotinamide with ammonia in 
methanol provided the desired 2-aminoisonicotinamide in modest yield. 
4-Methoxyphenyl nicotinate (12) was synthesized from nicotinoyl chloride 
hydrochloride. To a 100 mL round-bottom flask were added nicotinoyl chloride 
hydrochloride (770 mg, 4.33 mmol), 5 mL of triethylamine and 20 mL of THF. To 
this mixture was added 4 mL of pyridine dropwise.  After stirring for 30 minutes at 
room temperature, p-methoxyphenol (805 mg, 6.49 mmol) was added. The reaction 
was kept at room temperature overnight, precipitate was filtered off and solution was 
evaporated under reduced pressure. The residue was redissolved in water and 
extracted with CH2Cl2. The combined organic layer was washed with brine and dried 
over anhydrous Na2SO4.  Solvent was then concentrated in vacuo and crude product 
was recrystallized from ethyl acetate. 1H NMR (500 MHz, CDCl3), δ ppm: 9.37 (t, J= 
1.1 Hz, 1H), 8.82 (dd, J= 1.7, 4.9 Hz, 1H), 8.42 (dt, J= 1.9, 7.9 Hz, 1H), 7.44 (m, 1H), 
7.13 (dd, J=2.3 Hz, 2H), 6.93 (dd, J= 2.3 Hz, 2H), 3.80 (s, 3H). 
1-Methylnicotinamide was synthesized similarly to the method reported by 
Martin and Hull (43). Briefly, three equivalents of iodomethane were added to a 
solution of nicotinamide or isonicotinamide in 2 mL of methanol.  The reaction was 
allowed to stir at room temperature and monitored by TLC.  When the reaction was 
complete (after approximately 30 hours), the solid was filtered off and dried under 
reduced pressure.  The resulting product was purified by recrystallization from 
methanol. 1-Methylnicotinamide 1H NMR (500 MHz, DMSO), δ ppm: 9.4 (s, 1H), 
9.11 (d, J= 6.1 Hz, 1H), 8.90 (d, J= 8.2 Hz, 1H), 8.51 (s, br, 1H), 8.25 (dd, J= 6.1, 8.1 
Hz, 1H), 8.14 (s, br, 1H), 4.42 (s, 3H). 1-methyl-isonicotinamide was prepared 
similarly.  
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Synthesis of Inhibitors. 3-Pyridinecarboxaldehyde, 5-bromo-3-
pyridinecarboxaldehyde, 2-chloro-3-pyridinecarboxaldehyde, 3,5-lutidine, 3,5-
dibromopyridine, 4-methoxypyridine, 3-cyanopyridine, 3-acetylpyridine, 3-
hydroxypyridine and nicotinic acid were purchased from Aldrich.  
5-Methoxy-3-pyridinecarboxaldehyde was synthesized in two steps from 3,5-
dibromopyridine (44). Sodium methoxide in methanol (4 mL, 9.56 mmol) was stirred 
under reduced pressure at 65˚C for 10 minutes.  The remaining solid was dissolved in 
5 mL of DMF.  Solid 3,5-dibromopyridine (1.5 g, 6.33 mmol) was added, and the 
mixture was stirred at 63~68˚C for one hour.  This solution was poured into water and 
then extracted with ethyl acetate.  The combined organic layer was washed with brine 
and dried over anhydrous Na2SO4.  After solvent was evaporated under reduced 
pressure, column chromatography afforded 1 g (5.32 mmol, 85% yield) of 3-bromo-5-
methoxypyridine as a white solid. 1H NMR (400 MHz, CDCl3), δ ppm: 8.31 (s, 1H), 
8.26 (s, 1H), 7.35 (s, 1H), 3.88 (s, 3H).  To a stirred solution of 3-bromo-5-
methoxypyridine (1 g, 5.3 mmol) in 20 mL of anhydrous THF at -90˚C was added 
nBuLi (2.9 mL, 5.8 mmol) over 5 minutes.  The solution was allowed to stir for 
another 20 minutes at -90˚C, and then DMF (0.53 mL, 6.9 mmol) was added.  The 
reaction mixture was stirred for 30 minutes and the cold mixture was poured directly 
into brine and extracted with ethyl acetate.  The combined organic layer was dried 
over anhydrous Na2SO4.  After solvent was evaporated under reduced pressure, 
column chromatography afforded 0.5 g (3.65 mmol, 68% yield) of 5-methoxy-3-
pyridinecarboxaldehyde as a pale yellow solid. 1H NMR (400 MHz, CDCl3), δ ppm: 
10.08 (s, 1H), 8.63 (d, J= 1.5 Hz, 1H), 8.53 (d, J= 3 Hz, 1H), 7.58 (dd, J= 1.5, 3 Hz, 
1H), 3.89 (s, 3H). 
5-Methyl-3-pyridinecarboxaldehyde was synthesized in three steps from 3,5-
lutidine.  3,5-lutidine was converted to 5-methylnicotinic acid as described previously 
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(45).  5-methylnicotinic acid (100 mg, 0.73 mmol), triphenylphosphine (382 mg, 1.46 
mmol) and methanol (47 mg, 1.46 mmol) were dissolved in 1 mL of anhydrous THF, 
and to this solution was added DIAD (295 mg, 1.46 mmol) at 0°C dropwise. The 
reaction mixture was allowed to warm to room temperature and stir overnight. 
Saturated brine was added to quench the reaction and then the aqueous layer was 
extracted with ethyl acetate.  The combined organic layer was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure.  The crude product was purified by 
column chromatography to afford 70 mg (0.46 mmol, 64% yield) of 5-methylnicotinic 
acid methyl ester as white solid. 1H NMR (500 MHz, CDCl3), δ ppm: 9.01 (s, 1H), 
8.59 (s, 1H), 8.09 (s, 1H), 3.93 (s, 3H), 2.38 (s, 3H). To a solution of 5-
methylnicotinic acid methyl ester (70 mg, 0.46 mmol) in 2 mL of toluene was added 
DIBAL-H (3.2 mL, 3.2 mmol) dropwise at -78°C. The reaction was kept at -78°C for 
one hour before being quenched by methanol at -20°C. To the reaction mixture was 
then added 0.1 M HCl and ether, the aqueous phase was extracted with ether, the 
combined organic phase was washed with saturated NaHCO3, water and brine, and 
then dried over anhydrous Na2SO4.  Solvent was evaporated under reduced pressure 
and crude product was purified by column chromatography to afford 50 mg (0.41 
mmol, 89% yield) of 5-methyl-3-pyridinecarboxaldehyde as colorless oil. 1H NMR 
(500 MHz, CDCl3), δ ppm: 10.08 (s, 1H), 8.87 (s, 1H), 8.67 (s, 1H), 7.95 (s, 1H), 2.43 
(s, 3H). 
6-Fluoro-3-pyridinecarboxaldehyde was synthesized from the corresponding 
carboxylic acid. In general, the acid was reduced with 1.1 equivalents of lithium 
aluminum hydride in refluxing anhydrous THF overnight.  After quenching with ethyl 
acetate and water, the precipitate was filtered off, solvent was removed under reduced 
pressure and the alcohol was used for the next step without further purification.  The 
alcohol was added to two equivalents of sodium nitrite followed by one equivalent of 
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acetic anhydride and stirred at 0oC (46).  The reaction was monitored by TLC and 
upon completion the product was extracted with diethyl ether.  The aldehyde was 
further purified by column chromatography. 1H NMR (500 MHz, CDCl3), δ ppm: 
10.08 (s, 1H), 8.75 (d, J= 1.5 Hz, 1H), 8.32 (dt, J= 2.1, 8.2 Hz, 1H), 7.11 (dd, J= 2.5, 
8.4 Hz, 1H).   
4-Methoxy-3-pyridinecarboxaldehyde was synthesized in one step from 4-
methoxy-pyridine (44).  To a solution of tBuLi (1.7 M in pentane, 16.6 mL, 28 mmol) 
in 30 mL of anhydrous THF at -78˚C was added 2.2 g of 2-bromomesitylene (1.66 
mL, 11 mmol).  After strring at -78˚C for 1 hour, a pale yellow heterogeneous mixture 
was formed.  To this mixture was then added 1.09 g of 4-methoxypyridine (1 mL, 10 
mmol), and stirring was continued at -78˚C for 1 hour, at -23˚C for 1 hour and at room 
temperature for 1 hour.  The mixture was again cooled to -78˚C, and 0.954 g of DMF 
(1 mL, 13.1 mmol) was added dropwise.  After stirring at -78˚C for another hour, the 
reaction was quenched by saturated NaHCO3 solution.  The aqueous layer was 
extracted with ethyl acetate (3 x 10 mL), and the organic layers were combined and 
dried over anhydrous Na2SO4.  After solvent was evaporated under reduced pressure, 
column chromatography afforded 0.88 g (6.4 mmol, 64% yield) of 4-methoxy-3-
pyridinecarboxaldehyde as a pale yellow solid. 1H NMR (400 MHz, CDCl3), δ ppm: 
10.42 (s, 1H), 8.86 (s, 1H), 8.61 (d, J= 6 Hz, 1H), 6.91 (d, J= 6 Hz, 1H), 3.98 (s, 3H). 
3.4 Results 
Cloning and Protein Expression.  The genes encoding the nicotinamidase 
enzymes from Borrelia burgdorferi (BbNic), Streptococcus pneumoniae (SpNic) and 
Plasmodium falciparum (PfNic) were cloned into appropriate expression vectors as 
described in the Materials and Methods section.  Expression plasmids for the two C. 
elegans nicotinamidases, CePNC1 and CePNC2 (12), and S. cerevisiae Pnc1 (24) 
were previously described. Expression and purification of the respective proteins are 
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described in the Methods and Materials.  When assayed by HPLC under standard 
reaction conditions (200 μM nicotinamide, 100 mM phosphate, pH 7.3), all enzymes 
were found to catalyze the conversion of nicotinamide into nicotinic acid as shown by 
chromatograms stacked in Figure 3.2. 
Nicotinamidase Assay Development.  In order to monitor the activity of 
purified enzymes in real time, we developed a robust and straightforward assay that 
could continuously monitor one of the two products of the nicotinamidase reaction, 
ammonia.  Bovine glutamate dehydrogenase (GDH), which is commercially available, 
was found to be an ideal enzyme for this purpose.  GDH catalyzes the reaction of α-
ketoglutarate, ammonia and NADPH (or NADH) to form glutamate and the oxidized 
dinucleotide (Scheme 3.3).  The ammonia produced by conversion of nicotinamide to 
nicotinic acid is reacted by the coupling enzyme, which in turn consumes NADPH 
stoichiometrically.  NADPH conversion to NADP+ can be measured by absorbance of 
NADPH at a wavelength of 340 nm where NADP+ has no absorbance (Δε340nm = 6200 
M-1 cm-1).  Alternatively, the method was readily adapted to a plate reader which can 
detect fluorescence emission of NADPH (360 nm excitation, 490 emission).  NADPH 
is measured by amount of emitted light and rates determined by changes in light 
emission versus time. Both methods were used to monitor nicotinamidase activity in 
this study.   
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Scheme 3.3.  The nicotinamidase assay developed couples the release of ammonia to 
the consumption of NAD(P)H via glutamate dehydrogenase.  The synthesis of 
glutamate by GDH occurs in the presence of ammonia and α-ketoglutarate and is 
dependent upon the stoichiometric oxidation of NAD(P)H.  The conversion of 
NAD(P)H to NAD(P)+ can be followed by monitoring the decrease in absorbance at 
340 nm or the decrease in fluorescence (excitation 360 nm, emission 490 nm). 
 
 
 
Figure 3.4. Glutamate dehydrogenase assay. (A) The GDH assay was performed with 
varying concentrations of ammonium acetate. (B) The GDH-coupled assay was 
performed with varying concentrations of nicotinamide. Reactions containing 1 mM 
α-ketoglutarate, 250 μM of NADPH, 1.5 units GDH per 100 μL of reaction volume in 
100 mM phosphate buffer pH 7.3 were initiated with the addition of PfNic to a final 
concentration of 320 nM.  The reactions were measured by monitoring the absorbance 
at 340 nm over time.  (C) SpNic activity scales nicely with varying concentrations of 
enzyme.  Reactions containing 1 mM α-ketoglutarate, 250 μM of NADPH, 1.5 units 
GDH per 100 μL of reaction volume in 100 mM phosphate buffer pH 7.3 were 
initiated with the addition of SpNic to the final concentrations indicated in the figure.  
The reactions were measured by monitoring the absorbance at 340 nm over time. The 
slopes for 0, 36, 72 and 108 pmoles of SpNic are -2.23 × 10-5, -2.39 × 10-4, -4.79 × 10-
4 and –7.30 × 10-4, respectively. 
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The quantity of NADPH consumed correlates well to nicotinamide or 
ammonia quantities added to a sample as shown in Figure 3.4 A and B.  In addition, 
the rate of nicotinamidase activity scales linearly with amount of enzyme added, 
demonstrating that sufficient coupling enzyme is present so that GDH is not limiting 
for determination of catalytic velocity (Figure 3.4 C).   This assay is effective for 
monitoring a wide range of nicotinamide concentrations and can accurately detect 
rates generated by low micromolar concentrations of nicotinamide, particularly 
because of a low Km for NADPH of 28 μM, and an excellent rate of turnover (>9 s-1, 
calculated from kinetic parameters) (47).  Favorably, the equilibrium position also 
very strongly favors the oxidized dinucleotide product at pH 7.0 (48).  Interference of 
GDH from nicotinamide and nicotinic acid was found to be neglible, and the 
components of the GDH assay did not interfere with nicotinamidase enzymatic 
activity as compared against HPLC (data not shown).  The components of this assay, 
nicotinamidase and GDH, were recently combined in a coupled assay to detect and 
measure activity of nicotinamide forming enzymes, such as sirtuins, that degrade 
NAD+ to nicotinamide (49). 
Kinetics Parameters for Nicotinamidase Enzymes.  Kinetic properties of 
nicotinamidase enzymes cloned or isolated from a variety of organisms have been 
determined including Arabidosis thaliana (9),  Mycobacterium tuberculosis (3) 
Mycobaceterium smegmatis (2), Lactobaccillus arabinosis (50, 51) Torula cremoris 
(7), Flavobacterium peregrinum (52) and S. cerevisiae (53-58).  Of the enzymes 
considered in this study, nicotinamidase activity of the P. falciparum enzyme was 
previously detected in crude dialyzed lysates derived from P. falciparum infected 
erythrocytes (59).  With a reliable assay available, we sought to determine the kinetic 
parameters for Pnc1 as the prototype enzyme.  In addition, the kinetic parameters for 
the Streptococcus pneumoniae, Borrelia burgdorferi, Plasmodium falciparum and 
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both Caenorhabditis elegans nicotinamidases were determined for the first time.  
Enzymes were expressed in E. coli and isolated by Ni2+ column chromatography.  
Although enzymes from different sources have been reported to have different central 
metal requirements (3, 9, 34), enzymes were active as purified without reconstituting 
them (Figure 3.2).   
Employing standard conditions of assay (100 mM potassium phosphate, pH 
7.3 with or without GDH components for detection of ammonia formed by 
nicotinamidase reaction, as described in Materials and Methods) we determined 
Michaelis-Menten parameters for each enzyme by varying nicotinamide concentration 
and plotting initial rates versus concentration of nicotinamide to determine Km and V-
max values (Figure 3.5, and Table 3.1).  Maximum velocities were confirmed by HPLC 
assay using at least 10 fold Km concentration of nicotinamide.  
 
Table 3.1. Kinetic parameters of nicotinamidases 
 
Enzyme Km (μM)a Vmax (s-1)a 
BbNic 36.7 ± 7.5 0.0030 ± 0.00017b 
PfNic 3.1 ± 1.2 0.30 ± 0.032b 
Pnc1 10.6 ± 0.54 3.8 ± 0.060b 
SpNic 5.1 ± 0.38 5.5 ± 0.13b 
PNC1 83.5 ± 12.9 1.9 ± 0.11 
PNC2 45.6 ± 6.6 0.12 ± 0.0056 
 
 
 
 
 
 
 
 
aKm and Vmax values were determined by fitting the data to the Michaelis-
Menten equation using the Kaleidagraph software package (Synergy 
Software).  Error values represent the error in the fit to the data as calculated 
by the curve-fitting algorithm. 
bCalculated Vmax values were confirmed by HPLC assay for several enzyme 
concentrations. 
 
For the Pnc1 and SpNic enzymes we used progress curve analysis (40), which 
was preferable due to a very low Km for nicotinamide determined for these enzymes.  
A potential caveat with these analyses is product inhibition, which generally causes 
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increases in apparent Km, but we showed that nicotinamidase rates do not vary when 
concentrations of  nicotinic acid up to 500 μM are present (data not shown). 
Consistently, the Pnc1 and SpNic were determined to have Km values of 10 and 5 μM 
for nicotinamide and corresponding values of kcat of 3.8 s-1 and 5.5 s-1.  
For other nicotinamidases, we used the GDH method (CePNC1 or CePNC2) or an 
HPLC method (PfNic and BbNic) to determine initial reaction rates as a function of 
nicotinamide concentration.  All data are summarized in Table 3.1 and shown 
graphically in Figure 3.5.  All Km values were found to be below 100 μM, with kcat 
values in the range 0.3-10 s-1.  Only the BbNic deviated from the pattern.  An 
examination of the BbNic sequence against the others (Figure 3.1) shows that the 
genetically encoded enzyme is approximately 20 residues (52) shorter at the N-
terminus.  This region contains a DXQXD sequence that is highly conserved in 
nicotinamidases (Figure 3.1). Thus, we introduced additional sequence at the N-
terminus to create active enzyme (as was originally reported (19)).  It remains possible 
that BbNic is imperfectly reconstituted in sequence or in other requirements, 
accounting for its poor catalytic properties. 
Substrate Specificity.  We probed the specificity of nicotinamidases to 
hydrolyze a variety of nicotinamide analogues.  Using both HPLC analysis and the 
GDH coupled assay, we determined relative rates for a number of compounds showing 
structural similarity to nicotinamide (Table 3.2).  In the cases of SpNic, Pnc1, and 
PfNic substitutions at the 5- position were well tolerated, and interestingly, 5-methyl 
and 5-O-methyl substitutions caused up to 4 .5 fold rate enhancement (in kcat, see 
Table 3.3) over nicotinamide.  The Km and kcat values for a small subset of the 
substrate analogues on the SpNic, Pnc1 and PfNic enzymes are provided in Table 3.3.  
These data indicate that the pattern of rate enhancement provided by the 5-position 
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substitutions is not associated with changes in Km (Table 3.3) suggesting no steric 
interference in the binding of these substrates to the active site.  
 
 
 
Figure 3.5.  The kinetics of the nicotinamidase enzymes from S. cerevisiae (A), B. 
burgdorferi (B), P. falciparum (C), S. pneumoniae (D), C. elegans PNC1 (E) and C. 
elegans PNC2 (F).  A and D were derived from progress curve analysis (see 
experimental) of the nicotinamidase reaction run in the presence of 100 μM 
nicotinamide, B and C are from HPLC analysis of reactions run in varying 
nicotinamide concentrations, and E and F are from the GDH coupled fluorescence 
assay with various concentrations of nicotinamide.  In all cases, the data was fit with 
the Michaelis-Menten equation using KaleidaGraph graphing software. 
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Table 3.2.  Relative rates of nicotinamidase enzymes for nicotinamide analoguesa 
Substrate BbNicb PfNic pnc1 SpNic 
nicotinamide 1.00 1.00 1.00 1.00 
1 0.51 1.50 0.80 1.63 
2 2.21 4.80 2.06 1.37 
3 0 0 0 0 
4 0 0 0.02 0.08 
5 0.45 0.40 0 0.11 
6 0.78 0.45 0.20 0.36 
7 0.20 0.12 0.09 0.10 
8 0.94 0.03 0.17 0.02 
9 0.57 0.10 0.15 0.03 
10 0 0 0.44 0 
11 ND 0.39 0.05 0.04 
12 ND 0 0.07 0.04 
13 ND 0 0 0.03 
14 ND 0 0 0 
 
a Reactions were run in 150 μL total volume containing 1 mM α-ketoglutarate, 250 
μM NADPH, 3 units of GDH, and 500 μM of nicotinamide analogue in 100 mM 
phosphate buffer, pH 7.3.  For control experiments, reactions containing 500 μM of 
nicotinamide were run in parallel. Reactions were initiated by addition of 
nicotinamidase enzymes, decreasing of fluorescence intensity was monitored by a 
microplate reader.   
 bND = Not determined. 
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Table 3.3. Kinetic parameters of some nicotinamide analogues (μM)a 
a Reactions containing various concentrations of nicotinamide analogues in 100 mM 
phosphate buffer at pH 7.3 were initiated by addition of nicotinamidase enzymes and  
allowed to incubate for 20 minutes at 25oC.  The reaction was quenched by addition of 
8 μL of 10% trifluoroacetic acid to a final pH of 3 and then allowed to incubate on ice 
for 30 minutes.  Prior to injection on HPLC, the sample was centrifuged at 13, 000 g 
for 2 minutes to remove precipitates.  Chromatograms were analyzed at wavelength of 
260 nm.  Reactions were quantified by integrating areas of peaks corresponding to 
nicotinamide analogue and nicotinic acid analogue. Rates were plotted versus 
nicotinamide analogue concentration and best fit of points to the Michaelis-Menten 
equation was performed by Kaleidagraph. 
pnc1 PfNic SpNic 
Substrate 
Km (μM) Vmax (s-1) Km (μM) Vmax (s-1) Km(μM) Vmax (s-1) 
      NAM  10.6 ± 0.54 3.8 ± 0.06 3.1 ± 1.2 0.30 ± 0.03 5.1 ± 0.38 5.5 ± 0.13 
5-Me-
NAM  8.9 ± 0.7 3.5 ± 0.2 4.2 ± 0.5 0.6 ± 0.1 4.1 ± 0.6 8.8 ± 0.8 
5-OMe-
NAM  8.2 ± 0.56 7.7 ± 0.27 2.1 ± 0.2 1.9 ± 0.4 6.2 ± 0.4 7.5 ± 0.5 
2-Cl-NAM  NSb NS NS NS NS NS 
6-Cl-NAM NS NS 1200.3 ± 70.1 
0.004 ± 
0.00015 
1825.6 ± 
122.7 
0.31 ± 
0.015 
bNS = not a substrate 
 
The origin of the 5-substitution effect on catalytic rate is unclear, and although 
it could be a steric effect it could also be an electronic effect.  Moving the OMe group 
to the 4-position caused slowing of all enzymes to 9%-20% of the rate observed for 
nicotinamide (Table 3.2 and Table 3.3).  Again, we are not clear if these changes in 
reaction rate are largely dictated by steric or electronic effects, although data from 
inhibitor studies sheds some light on these effects.  Nicotinamidases (BbNic, PfNic, 
Pnc1 and SpNic) were weakly active against isonicotinamides and 1-methyl 
isonicotinamide and 1-methyl-nicotinamide derivatives.  These results suggest that 
coordination of nicotinamide to the metal center is a prerequisite to catalysis as 
suggested in a recent mechanistic proposal (34), and that the spatial relationship of the 
carbamide group to the pyridine N is crucial for successful catalysis. The 2-
chloronicotinamide and 6-chloronicotinamide were not well accepted either, this again 
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could be due to steric proximity of the 2 and 6-groups to the coordinating metal and 
since electron withdrawing groups deactivate ligand interactions with metals.  6- 
methyl and 6-aminonicotinamide were substrates for the 4 nicotinamidases but these 
nicotinamides were still slower than nicotinamide (0.09-0.78 relative rate versus 
nicotinamide, Table 3.2).  Nicotinate esters, particularly ethylnicotinate, could be 
hydrolyzed as well, although more poorly than nicotinamide.  
Sensitivity to substitutions showed similar trends for the four enzymes for 
which substrate specificity was broadly evaluated, although there were differences in 
the overall tolerance between organisms.  B. burgdorferi appeared to be the most 
promiscuous enzyme, turning over at a moderate rate for a wide range of substrates, 
despite a slower rate of turnover for all substrates versus other enzymes.  The Pnc1 
and SpNic were the least tolerant of substitutions, showing little or no turnover for a 
large number of the substrates tested.  The P. falciparum nicotinamidase saw the 
largest relative rate increases, with the 5-substituted compounds up to 4.8 times faster 
than nicotinamide. 
Inhibition by Nicotinaldehyde.  A report that S. cerevisiae nicotinamidase 
could be weakly inhibited by nicotinaldehyde Ki = 68 μM (53) led us to wonder if 
nicotinaldehydes might be general inhibitors of nicotinamidases. Unusual to this 
report, it was suggested that nicotinaldehyde inhibited the yeast enzyme by a non-
competitive mechanism with nicotinamide, via Schiff’s base formation.  We sought to 
reinvestigate this inhibition.  Nicotinaldehyde could potently inhibit nicotinamidases 
from all sources we examined (Table 3.4).  Double reciprocal plots confirmed 
competitive inhibition with nicotinamide in all cases, and with surprising potency 
(Figure 3.3).  Table 3.4 shows that the determined Ki values were in the range of 1.5 
μM for the yeast enzyme, whereas Ki values were 13, 69 and 88 nM for the 
corresponding enzymes from P. falciparum, S pnemoniae and B burgdorferei 
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repsectively.  Moreover, nicotinaldehyde could competitively inhibit both C. elegans 
enzymes with 136 nM  and 400 nM Ki values for PNC2 and PNC1 respectively 
(Figure 3.3 and Table 3.4). 
 
Table 3.4.  Ki Values of Nicotinamidase Inhibitors (μM) 
a ND= not determined. 
Substrate BbNic PfNic pnc1 SpNic CePNC1 CePNC2 
15 0.088 ± 0.025 
0.013 ± 
0.0011 
1.5 ± 
0.11 
0.069 ± 
0.0040 
0.45 ± 
0.11 
0.14 ± 
0.01 
16 1.8 ± 0.20 0.59 
4.5 ± 
0.80 
0.072 ± 
0.022 
0.20 ± 
0.058 
0.32 ± 
0.055 
17 1.3 ± 0.43 
0.052 ± 
0.0045 
5.0 ± 
0.54 
0.14 ± 
0.017 
0.54 ± 
0.30 
0.43 ± 
0.12 
18 1.1 ± 0.13 
0.018 ± 
0.0019 
0.76 ± 
0.070 
0.068 ± 
0.0054 ND
a ND 
19 370 NIb 5000 110 ND ND 
20 19 4.9 NI 0.83 ± 0.29 ND ND 
21 153 1.1 ± 0.11 68 50 8.7 ± 1.0 
1.3 ± 
0.19 
22 2000 1000 85 500 ND ND 
23 342 10 46 60 ND ND 
24 NI NI NI NI ND ND 
nicotinic 
acid NI NI NI 2000 NI NI 
b NI = no inhibition detected. 
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Nicotinaldehydes as inhibitors of nicotinamidases.  To more completely 
explore the potency of nicotinaldehydes as inhibitors of nicotinamidases we 
synthesized a number of substituted analogues of nicotinaldehyde, with variable 
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substituents (as shown in Table 3.4).  The Ki values for those compounds that showed 
inhibition of the nicotinamidase activity for the enzymes are listed in Table 3.4.  We 
also tested several other compounds for inhibitory activity including acetylpyridine, 3-
cyanopyridine, 3-hydroxypyridine and nicotinic acid (Table 3.4).  Consistent with 
observations that 5-substituted nicotinamides are excellent substrates, 5-substituted 
nicotinaldehyde analogues were potent inhibitors of all of nicotinamidases tested 
(Table 3.4).  All enzymes tolerated even a bulky 5-bromo substituent (Table 3.4).  
Consistent with observations that 4-O-methyl substitution was poorly tolerated in 
substrates, 4-O-methylnicotinaldehydes were weaker inhibitors with higher Ki values 
(Table 3.4).  However, 4-O-methylnicotinaldehyde was a fair inhibitor of the CePNC2 
enzyme, with a 6 fold selectivity over CePNC1, suggesting that variations in chemical 
structure of these compounds can lead to inhibitor specificity for isoforms.  It should 
also be noted that the product of the nicotinamidase reaction, nicotinic acid, was not 
observed to inhibit the enzymes tested when applied at 1 mM.  However, 3-
acetylpyridine and 3 cyanopyridine could inhibit some enzymes, although with weaker 
Ki values than substrate Km values, suggesting these 3-substituted pyridines bind 
competitively with nicotinamide.  As suggested by the x-ray structures in Chapter 4 
(38) these compounds likely coordinate to the central metal atom found at the active 
site of nicotinamidases. 
Chemical Exchange of Nicotinic Acid Oxygens with 18O Water. The crystal 
structure of a stabilized thioester complex co-crystallized on SpNic as reported in 
Chapter 4 (38) indicated to us that the enzyme can react with nicotinic acid reversibly 
to form the thioester.  To more firmly establish this chemistry, we co-incubated 
nicotinic acid and S. pneumoniae enzyme with 18O water and asked if the enzyme 
could support 18O exchange into the carboxy oxygens of nicotinic acid which would 
be presumed to occur if nicotinic acid could reform the thioester.  The cycling of 
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nicotinic acid to the thioester and back to nicotinic acid would be predicted to cause 
loss of 16O in the carboxy oxygens and replacement with 18O.  We used mass 
spectrometry to monitor this exchange.  As shown in Figure 3.6, nearly immediate loss 
of unlabeled nicotinic acid is observed when 1 mM nicotinic acid is treated with 6 μM 
SPNic enzyme.   
 
Figure 3.6.  Mass spectra demonstrating time dependent 18O exchange catalysed by 
SpNic.  Data is plotted as percent intensity versus time, where the total intensities of 
peaks in mass spectra at m/z = 124, 126, 128 are summed to reach 100 percent.  124 is 
the mass of unlabeled nicotinic acid as a twice protonated cation (M+1).  126 is the 
molecular mass of nicotinic acid incorporating a single 18O label, and 128 is the mass 
of nicotinic acid incorporating two 18O atoms.  For ease of presentation, mass 
intensities of single and double labeled nicotinic acid are summed.  The data shows 
that the mass spectrum of nicotinic acid treated with SpNic in the presence of 18O 
becomes rapidly depleted of intensity for the peak corresponding to m/z = 124, 
whereas there is a corresponding enrichment in m/z = 126 and m/z = 128 peak 
intensities, demonstrating rapid 18O incorporation into nicotinic acid.  Control does not 
exchange.  
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This loss is evident by depletion of m/z= 124 intensity in the MALDI, and is 
accompanied by increase in intensities for m/z = 126 and 128 (Figure 3.6).  This 
process occurs in as little as 2 minutes, and the calculated rate for the process is 0.7 s-1, 
indicating it is quite fast at pH 7.  To more firmly establish that nicotinic acid was 
fully exchanged with 18O water, we further analyzed the collected nicotinic acid after 
incubation with nicotinamidase by HRMS, which corroborated our result (see 
experimental).  These results firmly establish that the nicotinic acid is able to undergo 
facile 18O exchange, most likely by thioester formation from nicotinic acid catalyzed 
by the enzyme.  
3.5 Discussion 
Mechanism of Inhibition.  As described in Chapter 4, the mechanism of 
aldehyde inhibition parallels, to some extent, the mechanism of catalysis (38).  
Nicotinamide initially coordinates the central metal atom, and is attacked by an active 
site cysteine to form a tetrahedral adduct that subsequently decomposes by elimination 
of ammonia to yield an enzyme stabilized thioester (38).  Subsequent hydrolysis of the 
thioester completes nicotinic acid formation on the enzyme.  Nicotinaldehydes bind 
the enzyme analogously via coordination of the pyridine N and are electrophillically 
activated by this coordination similar to substrate (Scheme 3.4).  The subsequent 
attack of the cysteine on the aldehyde occurs analogously to that envisioned for 
substrate, except that instead of forming an unstable intermediate that can decompose 
to a thioester, the thiohemiacetal tetrahedral adduct is unable to decompose forward 
and is stalled by enzymatic features that stabilize its tetrahedral geometry, namely the 
oxyanion hole created by Leu 132 and Cys 136 in the case of SpNic (Scheme 4).  An 
analogous inhibition mechanism has been observed for very potent aldehyde inhibitors 
that target the caspase enzymes, wherein thiohemiacetal adducts have been 
demonstrated by x-ray crystallography (60). 
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Scheme 3.4.  Mechanism for nicotinaldehyde inhibition of S. pneumoniae enzyme. 
 
The tetrahedral adduct formed can decompose only by reaction reversal to the 
initial aldehyde-metal complex.  We propose that these adduct formations are fully 
reversible with solution nicotinaldehyde because the inhibitions observed are clearly 
competitive with nicotinamide present (Figure 3.3), no bi-phasic onset is apparent for 
reaction progress curves when aldehydes are present, and preincubation does not 
change inhibitor potency (data not shown).  Since Ki values for nicotinaldehyde are 
smaller than the Km for nicotinamide by anywhere from 72-420 across all enzymes 
studied (with the exception of yeast where Km/Ki is 6.7), we propose that the enzyme 
is designed to stabilize the oxy-intermediate formed upon attack of cysteine with the 
substrate amide.  This stabilization is detectable by use of aldehyde, which cannot 
progress further along the reaction coordinate but because of the tetrahedral 
intermediate stabilization, it potently inhibits the enzyme.  We consider this more 
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formally in Scheme 3.4, where we depict the inhibition as depending upon the initial 
coordination of the aldehyde to the metal center, characterized by a binding constant 
Kd, and then being further stabilized by a factor 1/Kint, where Kint  is the equilibrium 
constant for the cysteine adduct that is proposed to be formed (state 3) versus the 
metal complexed aldehyde (state 2).  The inhibition constant can thus be deduced to be 
Ki = Kd(Kint)-1.  This is also qualitatively visualized in the reaction coordinate 
presented in Scheme 3.5.  This thermodynamic explanation is completely supported by 
the crystallographic demonstration that the aldehydes are stabilized in thioacetal 
adducts on the enzyme active site (38). 
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Scheme 3.5.  Mechanism for nicotinic acid reversal to the nicotinoyl-thioester 
complex. The mechanism explains the ability of SpNic to catalyse 18O exchange into 
nicotinic acid.  A key feature of the proposed mechanism is the formation of a Zn-
hydroxide complex upon thioester formation from nicotinic acid. 
  
For the most part, with only a few exceptions, inhibition profiles were not 
significantly improved by 5-substitution.  Although data from substrates with 5-
substitutions suggests that the enzyme can readily tolerate these groups, and in fact 
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catalytic acceleration was observed with the electron rich 5-substituted nicotinamides, 
this was not translated into inhibitor improvement.  On the one hand, this seems 
somewhat surprising, since one imagines that the affinity of the pyridine for the metal 
atom would be improved by increased basicity (decreased Kd, Scheme 3.4).  On the 
other hand, increased ring electron density can reduce the thiolate ability to react with 
the aldehyde, and reduced stabilization of the tetrahedral complex is also possible 
(decreased Kint) from increased electron richness, which would seemingly oppose 
increased metal affinities.  Conversely in the case of an electron withdrawing 
substituent, like 5-bromo, the effects may work in the opposite direction, with weaker 
metal binding countered by increased intermediate stabilization.  Thus, we found no 
significant improvements in inhibitory potency with 5-substitution, although these 
compounds are still similarly potent to unsubstituted nicotinaldehyde.  These findings 
suggest that 5-substitution could still be interesting for making bioavailable 
nicotinamidase inhibitors that are not directly metabolized to nicotinic acid.  Also 
interesting was the development of some isoform selectivity when modifying the 
nicotinaldehyde substitution pattern.  Substitution improved to 5.8 fold for 
nicotinaldehyde preference on C. elegans PNC2 versus PNC1 with the 4-O-methyl-
nicotinaldehyde versus 2.8 fold in the case of nicotinaldehyde 
18O Exchange Mechanism and Catalytic Mechanism of Nicotinamidases.  
Structural data of multiple complexes, including a coordinated nicotinamide adduct, 
thioacetal tetrahedral adducts from aldehydes and a thioester intermediate provide a 
remarkably clear picture of how nicotinamidases accomplish chemistry (38).  
However, additional insight was obtained by the measured potencies of inhibitor 
complexes, which suggest that the enzyme is very good at stabilizing the tetrahedral 
adduct formed from substrate, as well as from data showing that 18O can be exchanged 
into the product nicotinic acid.  To explain 18O exchange we develop a mechanism to 
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consider in Scheme 3.5.  Coordination of nicotinic acid to the Zn-aqua center is 
accompanied by a deprotonated Asp 8 residue and a protonated thiol. 
Crystallographic data suggests that Asp8 can interact equally with the thiol as 
well as the nicotinate oxygen, and we suppose that the thiol proton can be transferred 
between each of the three heteroatoms.  When the proton becomes shared between 
Asp 8 and the nicotinic acid with the Cys 136 in thiolate form, we envision that the 
nicotinic acid can be reacted and form a tetrahedral adduct in which full deprotonation 
of Asp 8 occurs, and a tetrahedral intermediate results.  This sp3 center bears a 
hydroxyl substituent, an oxyanion substituent (which sits in the oxyanion hole) and a 
thioether substituent (Cys136).  Oxyanion electron donation eliminates the hydroxyl 
substituent.  We envision that expulsion of the hydroxyl group would be 
thermodynamically challenging, but could be facilitated by protonation of the oxygen 
by the aqua-Zn.  This process converts the aqua-Zn to a hydroxyl Zn.  We advocate 
this mechanism because the deprotonation of aqua-Zn should be facile relative to 
accommodation of naked hydroxide in the active site.  There is a 6-8 order of 
magnitude difference in predicted pKa of 14 for water,  versus the Zn-water species 
where the pKa = 7-8 (61).  This creates a far better thermodynamic tradeoff for the 
reaction of a thiolate (pKa = 7-8) with the acid if the species formed has a comparable 
pKa value, and this rationalizes the observed ease of reversal of thioester formation on 
the enzyme.  Importantly, at this point, we argue that the thioester is likely 
decomposed during normal catalytic turnover by a Zn-hydroxide.  Water occupying 
the site for attack of the thioester can be deprotonated by the Zn-hydroxide as shown 
in Scheme 3.5.  The crystallization of the thioester in the form of the aqua-Zn at pH 
6.0 in the accompanying manuscript (38) may have been a consequence of proton 
quenching of the hydroxyl-Zn species, which according to the proposed mechanism 
would stabilize it a slow decomposition  to nicotinic acid. 
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This mechanistic insight brings the total reaction mechanism into better focus 
and suggests a reason for the incorporation of a Zn2+ aqua center in the active site, 
besides its ability to organize substrate, and to electrophilically activate the 
nicotinamide substrate for nucleophilic attack.  The proposed overall mechanism is 
shown in Scheme 3.6.  Nicotinamide coordinates the Zn water complex as determined 
by crystallography (38).  Aspartate 8 deprotonates Cys136 to form the thiolate which 
can readily proceed to the tetrahedral intermediate.  Proton transfer to the amino group 
of the tetrahedral intermediate facilitates oxyanion electron flow to form the thioester.  
Interestingly, ammonia is quite basic and with no other protons in vicinity, it can 
deprotonate the aqua-Zn to form a Zn-hydroxide species prior to its departure from the 
active site as ammonium.  This reaction completes the first half of the reaction 
coordinate and is probably irreversible (Scheme 3.6).  Thus, our argument that the 
exchange reaction requires a Zn-hydroxide at the thioester complex is probably 
realistic, as the ammonia product provides the driving force and kinetic access to form 
the suggested Zn-hydroxide during turnover from substrate.  Water then enters the 
active site to initiate the chemistry that accomplishes hydrolysis of the thioester, in 
which the water is deprotonated by the Zn-hydroxide acting as the activating base 
identical to what was suggested in the mechanism for 18O exchange (Scheme 3.5). 
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Scheme 3.6.  Proposed mechanism of nicotinamidases.  Numbering of residues is 
consistent with that of SpNic.  The ammonia generated in the first half of the reaction 
coordinate generates a Zn-hydroxide by deprotonation prior to departure from the 
active site.  The intermediacy of a Zn-hydroxide is envisioned to act as a base catalyst 
that activates a solvent derived nucleophilic water in the second half of the catalytic 
reaction.   
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With a wealth of new data on nicotinamidase inhibition, crystal structures (38), 
18O exchange data and the structural identification of the thioester intermediate, we 
have provided a considerable new perspective on the nicotinamidase enzymes, 
including providing a comprehensive mechanism that explains the chemistry of these 
enzymes.  Since these enzymes possess so many common residues (Figure 3.1) and 
are highly conserved, we anticipate that the mechanism we have proposed is likely to 
apply to individual nicotinamidases from different phylogenetic sources.  The 
advancement of our view of the chemistry of these enzymes increases the likelihood 
that they can be targeted for inhibitor design, and provides testable hypotheses for 
further determination of the chemical principles that enable catalysis by 
nicotinamidases. 
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CHAPTER 4 
HIGH RESOLUTION STRUCTURES OF STREPTOCOCCUS PNEUMONIAE 
NICOTINAMIDASE IN INHIBITOR, SUBSTRATE AND INTERMEDIATE 
COMPLEXES 
4.1 Abstract 
Nicotinamidases are salvage enzymes that convert nicotinamide to nicotinic 
acid.  These enzymes are essential for the recycling of nicotinamide into NAD+ in 
most prokaryotes, most single-celled and multicellular eukaryotes, but not in 
mammals.  The significance of these enzymes for nicotinamide salvage and for NAD+ 
homeostasis has increased interest in these enzymes as possible antibiotic targets.  
Nicotinamidases are also regulators of intracellular nicotinamide concentrations, 
thereby regulating signaling of downstream NAD+ consuming enzymes, such as the 
NAD+-dependent deacetylases (sirtuins).  Here, we report several high resolution 
crystal structures of the nicotinamidase from Streptococcus pneumoniae (SpNic) in 
unliganded and ligand-bound forms.  The structure of the C136S mutant in complex 
with nicotinamide provides details about substrate binding while a trapped nicotinoyl-
thioester complexed with SpNic reveals the structure of a putative thioester reaction 
intermediate.  Examination of the active site of SpNic reveal several important 
features including a metal ion that coordinates the substrate and the catalytically 
relevant water molecule, and an oxyanion hole which both orients the substrate and 
offsets the negative charge that builds up along the reaction coordinate.  Structures of 
this enzyme with bound nicotinaldehyde inhibitors elucidate the mechanism of 
inhibition and provide further details about the catalytic mechanism.  In addition, we 
provide a biochemical analysis of the identity and role of the metal ion that orients the 
ligand in the active site and activates the water molecule responsible for hydrolysis of 
the substrate.  These data provide structural evidence for several putative reaction 
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intermediates and allow for a more complete understanding of the catalytic mechanism 
of this enzyme. 
4.2 Introduction 
Nicotinamide adenine dinucleotide (NAD+) and its phosphorylated and 
reduced forms, NADP+, NADH, and NADPH, are central to cellular metabolism and 
energy production.  Maintenance of NAD+ concentrations is important for cell and 
organism viability, and the strategies of cells to replete NAD+ from nicotinamide 
(NAM), nicotinic acid (NA), nicotinamide riboside and via de novo routes are quite 
elaborate (1).  The complexity of NAD+ biosynthesis in most organisms is likely 
linked to the importance of the dinucleotides in central metabolism, and targeting 
NAD+ biosynthesis as an antibiotic approach has recently been the subject of 
increased investigation (1-3).  In addition to biosynthetic production, salvage 
pathways operate to offset depletion of NAD+ stocks by NAD+ consuming enzymes 
and non-enzymatic hydrolysis, which can occur even at physiologic temperatures and 
pH (4, 5).   
An important difference between human NAD+ homeostasis and that of most 
prokaryotes, unicellular eukaryotes and multicellular eukaryotes involves the 
mechanism of NAD+ production and/or salvage.  In most organisms nicotinamide is 
recycled back to NAD+ by first being converted into nicotinic acid by the enzyme 
nicotinamidase, the genes of which are also known as pyrazinamidase/nicotinamidase 
(PncA) (Figure 4.1A).  Mammalian genomes do not encode nicotinamidases but 
instead convert NAM directly into nicotinamide mononucleotide (NMN) using 
nicotinamide phosphoribosyltransferase (Nampt).  NMN is then adenylated by 
nicotinomide mononucleotide adenyltransferase to form NAD+ (6, 7).  Mammals also 
retain the capacity to utilize nicotinic acid to make NAD+, doing so using the Preiss 
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Handler pathway.  This pathway is biochemically similar to the way most organisms 
recycle nicotinic acid (Figure 4.1B) (7). 
 
 
 
Figure 4.1. Nicotinamidase chemistry and function.  (A) PncA hydrolyzes 
nicotinamide to give nicotinic acid (top reaction) and is also able to catalyze the 
conversion of the drug pyrazinamide to pyrazinoic acid (bottom reaction).  (B) Sirtuin 
chemistry.  Sirtuins deacetylate an acetylated peptide in an NAD+-dependent manner, 
releasing nicotinamide in the process.  Heightened levels of nicotinamide inhibit 
sirtuin chemistry.  (C) and (D)  NAD+ recycling. A schematic of the NAD+ recycling 
pathways in humans (C) and microbes (D).   
 
The importance of the nicotinamidase activity to organisms that are pathogenic 
to humans, combined with its absence in human NAD+ biosynthetic pathways has 
increased interest in this enzyme as a possible drug target.  Recent work on the 
spirochaete Borrelia burgdorferi indicates that host nicotinic acid levels are too low to 
support pathogen survival and that a plasmid-encoded nicotinamidase is essential for 
viability (8).  Similarly, a nicotinamidase deficient mutant from Brucella abortus 
failed to replicate in cells but was rescued by the addition of nicotinic acid (9).  In 
addition, an increased nicotinamidase activity has been observed in Plasmodium 
falciparum infected erythrocytes (10).  A need for nicotinamidase activity for viability 
is consistent with the idea that some organisms lack a de novo NAD+ biosynthetic 
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pathway and therefore rely upon recycling and salvage of host NAM for growth (1, 2, 
11, 12). 
Nicotinamidase activity was first reported by Williamson and Hughes in 
extracts from Lactobacillus arabinosus (13) and this activity was later observed in 
many other microorganisms (14-19).  Nicotinamidases have also been confirmed in 
plants (20, 21), Caenorhabditis elegans (22), and Drosophila melanogaster (23).  In 
addition to proposed roles in NAD+ homeostasis, nicotinamidases are reported to 
regulate the NAD+ dependent deacetylase activity of sirtuins (22, 24, 25).  This is 
accomplished through modulation of in vivo concentrations of nicotinamide, a potent 
inhibitor of sirtuins (Figure 4.1C) (26-28).  Increased nicotinamidase expression 
increases Sir2-dependent gene silencing (24, 29, 30) and increases replicative lifespan 
in yeast (31), D. melanogaster (23, 32) and C. elegans (22, 33).   
In addition to its known biological functions, nicotinamidase activity is 
required for activation of the front-line tuberculosis prodrug, pyrazinamide.  
Nicotinamidase encoded by Mycobacterium tuberculosis hydrolyzes pyrazinamide to 
form the active form of the drug, pyrazinoic acid (Figure 4.1A).  Despite the 
effectiveness of pyrazinamide, drug resistant strains of M. tuberculosis have emerged 
that are unable to metabolize this drug.  Resistance arises from point mutations on the 
nicotinamidase enzyme (34) and these mutations have been mapped to catalytic 
residues as well as to residues predominantly structural in nature (35, 36).    
With considerable interest in these enzymes for their biological effects, their 
potential as antibiotic targets, and a long history of investigation, it is somewhat 
surprising that the structural and chemical basis for the catalytic function of these 
enzymes has remained largely undetermined.  Until recently, only unliganded crystal 
structures of nicotinamidases, from Saccharomyces cerevisiae (37) and Pyrococcus 
horikoshii (38), had been reported.  While the active site within both structures was 
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putatively identified through similarity to known structures and by the presence of a 
coordinated metal, few conclusions could be made about ligand binding or the reaction 
mechanism.  Recently a structure of the Acenitobacter baumanii nicotinamidase with 
nicotinic acid bound at the active site was reported in which the pyridine nitrogen of 
the ligand was determined to be coordinated to the central metal ion (39).  The results 
suggest that nicotinamidases utilize metal coordination of the pyridine nitrogen to 
orient the substrate and possibly also to activate it for catalysis.   
In this manuscript we report several crystal structures, both unliganded and of 
several trapped intermediates, of the nicotinamidase from the human pathogen, 
Streptococcus pneumoniae (SpNic).  In addition, we provide an analysis of role and 
identity of the active site metal ion.  These structures provide insight into key active 
site interactions and provide snapshots of several presumed reaction intermediates.  
The structure of the C136S mutant with nicotinamide bound provides details about 
substrate binding while the nicotinyl thioester observed in the structure of nicotinic 
acid treated crystals provides evidence for a thioester intermediate.  The structures of 
the SpNic-aldehyde complexes reveal a covalent adduct with tetrahedral geometry, 
analogous to another putative reaction intermediate.  These structures, along with the 
biochemical evidence presented, allow us to propose a catalytic mechanism for the 
nicotinamidase catalyzed reaction and provide a likely rationale for the inhibition by 
aldehyde analogues of nicotinamide. 
4.3 Materials and Methods 
Cloning and Mutagenesis.   The PncA gene for S. pneumoniae TIGR4 
(accession number NC_003028) was amplified by PCR from genomic DNA (ATCC 
6314D) and engineered to contain the NdeI and BamHI restriction endonuclease 
recognition sites.  The PCR product was inserted into the pSTBlue vector (Novagen) 
using the AccepTor vector kit (Novagen).  The gene was then digested with NdeI and 
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BamHI restriction endonucleases and ligated into similarly digested Pet28a; the 
presence of the gene was verified by sequencing.  The C136S mutant plasmid was 
made at the Cornell Protein Characterization and Production Facility by using site-
directed mutagenesis of the native gene.  Briefly, site-directed mutagenesis was 
performed on SpNic by a standard PCR protocol using PfuTurbo DNA polymerase 
(Invitrogen) and DpnI (New England Biolabs) to digest the methylated parental DNA 
prior to transformation.  The presence of the mutated residue was verified by 
sequencing. 
Protein Expression and Purification.  Plasmid DNA was transformed into the 
Rosetta 2(DE3) pLysS (Novagen) E. coli cell line.  Cells were grown in LB medium at 
37 °C with shaking (180 rpm) to an OD600 of 0.6.  SpNic expression was induced by 
the addition of 0.5 mM IPTG and cells were incubated at 37 °C with shaking for an 
additional 10 h.  Cells were harvested by centrifugation, resuspended in lysis buffer 
(300 mM NaCl, 50 mM Na2PO4 and 5 mM imidazole, pH 7.6) and lysed by 
sonication.  The lysate was then centrifuged at 30 000 g for 60 min at 4 °C.  The 
cleared lysate was loaded onto Ni-NTA resin (Qiagen) that had been pre-equilibrated 
with the lysis buffer.  After loading, the lysate was washed with lysis buffer and then 
with wash buffer (300 mM NaCl, 50 mM Na2PO4, 10% glycerol and 25 mM 
imidazole, pH 7.6).  Finally, the protein was eluted with 300 mM NaCl, 50 mM 
Na2PO4 and 250 mM imidazole, pH 7.6 and then buffered exchanged using an Econo-
Pac 10DG column (BioRad) into 30 mM NaCl and 10 mM Tris, pH 7.6.  The protein 
was concentrated using a centrifugal filter with a 10 kDa molecular weight cutoff 
(Amicon) to a final concentration of 25 mg/mL as measured by the method of 
Bradford (40).  Protein purity was verified to be greater than 95 % by SDS-PAGE. 
Synthesis of 5-methoxynicotinaldehyde.  5-methoxynicotinaldehyde was 
synthesized in two steps from 3,5-dibromopyridine as previously reported (41).  
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Protein Crystallization, Data Collection and Structure Determination.  
Crystallization experiments were conducted using the hanging drop vapor diffusion 
method at 18 °C by combining equal volumes of protein and reservoir solution.  Initial 
crystallization conditions were determined by sparse matrix screening (Hampton 
Research, Emerald Biostructures).  After optimization, diffraction quality crystals 
were grown from 18 – 22 % PEG 3350, 0.2 – 0.3 M NaCl and 0.2 M sodium 
malonate, pH 6.3 at 18 °C.  To obtain the SpNic-small molecule complexes, the 
crystals were soaked for 12 hours in the crystallization solution containing 2 mM 
ZnCl2, and 2 mM of the ligand (nicotinaldehyde, 5-methoxynicotinaldehyde, NA or 
NAM).  Prior to flash-freezing in liquid nitrogen, crystals were soaked in a solution 
containing the crystallization buffer, 2 mM ZnCl2, 2 mM ligand and 18% glycerol.  
Data sets were collected at the Advanced Photon Source (APS) beamline 24-ID-C 
using an ADSC Quantum 315 detector at a wavelength of 0.9795 Å.  The data 
collection statistics are provided in Table 4.1. 
The structure of SpNic was solved by molecular replacement using the 
program Molrep (42) with an all-alanine monomer of P. horikoshii pyrazinamidase 
(PDB code 1IM5) as the search model.  The models were refined by iterative cycles of 
restrained refinement using Refmac5 (43) and CNS (44) and by manual model 
building using the interactive graphics program Coot (45).  Water molecules were 
added using Coot only after the refinement of the protein structure had converged.  
Ligands were directly built into the corresponding difference electron density and the 
model was then subject to an additional round of refinement.  Refinement statistics for 
the model are listed in Table 4.2. 
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Table 4.1.  Summary of Data Collection Statistics 
 
 SpNic-Zn SpNic-Zn-
nicotin-
aldehyde 
SpNic-Zn- 
5-OMe-
nictotin-
aldehyde 
SpNic-Zn-
NA 
SpNic-
Cys136Ser-
Zn-NAM 
resolution (Å) 1.95 1.63 1.9 1.91 1.60 
wavelength (Å) 0.9795 0.9795 0.9795 0.9795 0.9795 
Space group P21 P21 P212121 P21 P21 
a (Å) 60.8 60.8 61.2 61.2 61.2 
b (Å) 120.9 120.0 114.5 121.2 120.8 
c (Å) 63.2 62.8 120.9 115.3 62.8 
β (o) 114.3 114.9 90 94.3 114.7 
# of reflections 185471 452705 336232 692648 425812 
unique reflections 54280 96559 67241 128796 106320 
average I/σ 11.3 (2.2) 14.7 (1.9) 14.3 (4.7) 16.5 (4.5) 18.9 (3.8) 
Redundancy 3.4 (2.1) 4.7 (2.5) 5.0 (4.9) 5.4 (4.9) 4.0 (3.4) 
completeness(%) 88.2 (73.7) 95.1 (79.4) 99.0 (99.9) 99.5 (98.8) 97.7 (86.2) 
Rsyma (%) 13.2 (29.2) 9.3 (17.7) 9.8 (35.3) 9.9 (28.9) 5.1 (18.9) 
Numbers in parentheses correspond to the highest resolution shell 
a IIIR i Σ−ΣΣ= /isym , where I  is the mean intensity of the N reflections with 
intensities Ii and common indices h, k, l  
  
 
Table 4.2.  Summary of Data Refinement Statistics 
 
 SpNic-Zn SpNic-
Zn-
nicotin-
aldehyde 
SpNic-Zn- 
5-OMe-
nicotin-
aldehyde 
SpNic-
Zn-NA 
SpNic-
Cys136S
er-Zn-
NAM 
resolution (Å) 1.95 1.63 1.9 1.91 1.60 
total no. of atoms 6128 6160 6032 6061 6080 
no. of ligand atoms 4 36 44 36 40 
no. of water atoms 564 431 606 593 853 
reflections in working set 51163 77657 62379 66830 103397 
reflections in test set 2719 4097 3328 3542 5312 
R factora 20.5 18.4 17.4 20.1 16.4 
Rfreeb 24.6 21.8 21.7 24.5 20.0 
rmsd bonds (Å) 0.021 0.012 0.014 0.023 0.027 
rmsd angles (o) 1.83 1.35 1.44 1.90 2.18 
mean B factor (Å2) 30.1 30.4 27.3 29.9 15.8 
Ramachandran      
  most favored (%) 91.2 92.2 92.0 90.3 91.9 
  additionally allowed (%) 8.8 7.5 7.8 9.2 8.1 
  generously allowed (%) 0.0 0.3 0.2 0.5 0 
  disallowed (%) 0 0 0 0 0 
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a R factor ∑−Σ= hkl obscalcobshkl FFkF / , where Fobs and Fcalc are observed and 
calculated structure factors respectively. 
b For Rfree, the sum is extended over a subset of reflections excluded from all stages of 
refinement 
 
Estimation of Coordinate Error.  While the variances and covariances of 
parameters used in structural refinement can be obtained through the inversion of the 
full least-squares matrix, this calculation is computationally very challenging and 
difficult to realize for protein structures, given the number of parameters needed for 
refinement.  Alternatively, approximations can be used to compute an estimate of 
coordinate error in a model.  To determine the approximate coordinate error for the 
Zn2+ and water atoms bound in the SpNic active site, the method of Cruickshank (46), 
called the diffraction-component precision index (DPI), was used.  This method uses 
the number of atoms in the structure (Ni), the number of reflections (nobs), the 
completeness of the data (C), the maximum resolution (dmin), and the Rfree value to 
estimate the mean coordinate error as follows: 
   ( ) min3/12/12/1 /3)( dRCnNB freeobsiavgDPIr −=σ    
Because of the high degree of correlation between the B-factor and coordinate error 
(46, 47), individual coordinate errors can be estimated using the following formula 
(48): 
    i
avg
avg
DPI
r
ir BB
B )(~
,
σσ = .          
Total Elemental Analysis of Protein Samples.  Elemental analysis of protein 
samples was performed by the Cornell Nutrient Analysis Laboratory (49) following 
EPA protocol 3051-6010.  This method involves microwave assisted nitric acid 
digestion of samples followed by analysis by inductively coupled plasma – atomic 
emission spectrometry.  Prior to treatment of samples, the 6-His tag was cleaved from 
the protein using TEV protease.  An aliquot was set aside to use as an untreated 
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sample and the remaining was incubated with 2 mM EDTA and 2 mM 1,10-
phenanthroline for 24 hours at 4 °C.  Samples were buffer exchanged on a centricon 
10 kDa cutoff centrifugal device (Millipore) into 30 mM Tris, 10 mM NaCl.  Three 
subsequent centrifugation runs were carried out using a 20:1 ratio of new buffer to 
concentrated sample on each run.  Metal salts were added to a final concentration of 2 
mM to 5 mg/mL solutions of protein and incubated for 16 h.  These samples were 
buffer exchanged to remove unbound metal ions as described above and sent for 
analysis at a concentration of 2 mg/mL. 
Metal Dependence Measurements.  SpNic protein used for metal dependent 
kinetics analysis had the 6-His tag removed, treated with chelators and buffer 
exchanged as detailed above.  After addition of Zn(OCH3)2, Fe(II)SO4, MnCl2, CoCl2, 
NiSO4, or Fe(III)Cl3, (in concentrations ranging from 0 to 2 mM for each metal salt) 
the solutions were incubated for 6 h and buffer exchanged using spin columns to 
remove excess metals.  This step is necessary as the metal ions can interfere with the 
coupling enzyme.  The rate of reaction was monitored on a 96-well plate using a 
glutamate dehydrogenase coupled assay (41).  Control reactions using ammonium 
sulfate with each enzyme solution without added NAM were run to ensure that the 
coupling enzyme was not limiting the reaction. 
4.4 Results 
Structure of Unliganded SpNic.  The stucture of SpNic is a homotetramer 
(Figure 4.2A), consistent with molecular weight estimates determined by size 
exclusion chromatography (data not shown).   
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Figure 4.2.  Structure of SpNic.  (A) SpNic tetramer.  (B) SpNic monomer and 
topology diagram of SpNic.  The yellow arrows represent β-strands and red cylinders 
represent α-helices. 
 
SpNic is an α/β protein with a six-stranded β-sheet flanked by three helices on one 
side and four helices on the opposite side (Figure 4.2B).  The interface between 
protomers is dominated by polar contacts of α5 on one side and by π-stacking and 
polar interactions of α6 and α7.  The four active sites of the SpNic tetramer are located 
in solvent-accessible pockets in each protomer that are formed primarily by three loop 
regions containing residues 55 through 75 (between β1 and α3), residues 104 through 
112 (between β3 and α5) and residues 133 through 136 (between β4 and α6).  While one 
of the open sides of the active site is bordered by two residues (Thr176 and His172) of 
α7 from a neighboring protomer, all interactions necessary for substrate binding and 
catalysis, including those that coordinate the metal ion, are provided by a single SpNic 
protomer. 
Organization of Metal Binding Site.  The metal center is coordinated by two 
histidines (His55 and His71), an aspartate (Asp53) and a glutamate (Glu64).  Two 
additional coordination interactions are provided by a single water molecule and by 
the pyridyl nitrogen of the ligand (Figure 4.3), or by two water molecules in the 
absence of a ligand, in each case furnishing full octahedral coordination to the metal 
ion. 
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Figure 4.3.  SpNic active site.  A) Stereoview of the active site of SpNic shown with 
NAM bound as observed in the Cys136Ser–NAM structure.  The grey and red spheres 
represent zinc and water respectively.  Phe-14 (not shown) is situated in front of NAM 
in the plane of the paper and makes an additional π-stacking interaction with the NAM 
ring.  B)  Schematic of the active site of the Cys136Ser SpNic mutant in complex with 
NAM.  The distances shown are heavy atom to heavy atom distances in angstroms. 
 
The magnitude of the electron density peak at the metal ion binding site was low when 
crystals were grown without exogenous metal added.  Crystallization solution 
supplemented with Zn2+ ions, however, led to a clear, strong peak.  Supplementation 
of the well solution with other ions, including Mn2+, Fe2+, Fe3+, Co2+, Ni2+ or Ca2+ did 
not lead to improvement over crystals grown in the absence of exogenous metals.   
Metal Ion Dependence of SpNic.  To determine the metal dependence of 
SpNic, the enzyme was first treated with EDTA and phenanthroline, buffer exchanged 
to remove chelators and then treated with various metal ion solutions.  These solutions 
were further buffer exchanged to remove unbound metals and then tested for activity.  
Addition of Fe2+, Mn2+, Co2+, and Zn2+ restored various levels of enzyme activity, 
with Zn2+ showing the highest level (Table 4.3).  Addition of Fe3+ or Ni2+ resulted in 
no detectable activity.  Moreover, analysis of metal content of untreated native 
enzyme showed the presence of Zn2+ ions only (Table 4.3).  Similarly, soaks of SpNic 
by metals after treatment with chelators showed that, while both Fe2+ and Mn2+ can 
bind, Zn2+ is observed at the highest concentration under equivalent conditions. 
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Table 4.3.  Analysis of Metal Content 
 
Sample S (μM) [SpNic]1 
(μM) 
Mn (μM) Fe (μM) Zn (μM) Co, Cu, 
Ca, Mg, 
K (μM) 
Untreated 203 34 < det < det 5 < det 
No metal 
added 
119 20 < det < det < det < det 
Zn2+ 144 24 < det < det 142 < det 
Mn2+ 144 24 18 < det 17 < det 
Fe2+ 122 20 < det 51 < det < det 
< det = below detection limit 
1 [SpNic] was calculated from the sulfur content determined by analysis of metal 
content 
 
  Active Site Water Molecule and Metal-Water Relationship.  In addition to 
four bonds to the enzyme and an interaction with the pyridyl nitrogen of the ligand, a 
water molecule is coordinated to the metal in the SpNic active site (Figure 4.3, red 
sphere).  This water is located from 5 - 6 Å from the carbonyl carbon of the ligand in 
the SpNic structures.  Water molecules coordinated to metals can be activated for 
catalysis and the degree of activation of the water has implications for the mechanism 
of the enzymatic reaction.  The length of the metal-water bond can indicate the type of 
species present in the structure.  The distances between the metal ion and the water in 
the SpNic structures vary from 2.2 Å to 2.4 Å.  The method of Cruickshank (46) was 
used to estimate the coordinate error present in the model and from this information 
and the individual B-factors, approximate coordinate errors for the water and metal ion 
were calculated (see Materials and Methods).  The estimated coordinate error for both 
the metal ion and the water varied between 0.12 Å and 0.19 Å. 
Structure of C136S SpNic with Bound Nicotinamide.  To assess the roles of 
active site residues, the structures of several SpNic complexes were determined.  The 
structure of an inactive form of SpNic, the C136S mutant, reveals several important 
features of the active site (Figures 4.3 and 4.4A).  The orientation of the ligand in the 
active site is facilitated by several π-stacking interactions of the pyridyl ring with 
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Phe14, Phe68 and Tyr106 and through coordination of the pyridyl nitrogen to the 
observed metal ion.  Additional contacts are made to the amide nitrogen by Asp8, and 
the backbone carbonyls of Val131 and Ser136.  A putative oxyanion hole, which 
forms H-bonds with the backbone amines of Leu132 and Ser136 in this structure, is 
also observed (Figure 4.3A).  In addition, the carbonyl carbon of nicotinamide is 
situated less than 3 Å from the suspected catalytic residue (136) while an aspartate 
residue (Asp8) is approximately equidistant from the amide nitrogen and the oxygen 
of Ser136 (Figure 4.3B).  
Structures of SpNic-Aldehyde Complexes.  To further probe the active site of 
SpNic, we solved the crystal structures of SpNic in complex with the aldehyde 
inhibitors nicotinaldehyde and 5-MeO-nicotinaldehyde.  While the organization of the 
active site remains essentially unchanged, the observed geometry about the carbonyl 
carbon varies in the differently liganded structures of SpNic.  In both of the 
nicotinaldehyde complexes, tetrahedral geometry is observed at what was the carbonyl 
carbon center (Figure 4.4B and C and Figure 4.5).  The difference density observed in 
these structures allows for the unambiguous placement of the proposed thiohemiacetal 
in the active site (Figures 4.4B and 4.4C).   
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Figure 4.4.  Electron densities of bound ligands to SpNic.  Each section shows a stereo 
diagram of the various ligand-bound complexes; the zinc ion (grey sphere) and Asp8 
are shown for reference.  All electron density shown is from 1FO – FC maps and 
density shown, contoured at 2.5σ, was calculated prior to adding the ligand to the 
model.  For the covalent complex maps, the Cys136 side chain was also omitted from 
the model in order to illustrate the linkage (A) Cys136Ser SpNic mutant with NAM 
bound.  (B) SpNic complex with nicotinaldehyde.  (C) SpNic complex with 5-OCH3-
nicotinaldehyde.  (D) SpNic thioester complex formed in the presence of nicotinic 
acid. 
 
Structure of SpNic Treated with Nicotinic Acid.  As was observed for the 
aldehyde soaks of SpNic, treatment of this enzyme with nicotinic acid had little effect 
on the overall organization of the active site.  The observed ligand density, however, 
was distinct from the other liganded structures.  The electron density observed from 
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data collected on soaks of SpNic treated with nicotinic acid corresponded to a covalent 
adduct with sp2 hybridization at the carbonyl carbon.  A covalent nicotinyl thioester 
linkage between the ligand and Cys 136 of SpNic was a good fit to the observed 
density (Figure 4.4D). 
4.5 Discussion 
Structural Similarity to Other Proteins.  The crystal structure of SpNic was 
compared to other proteins contained within the PDB using the Dali server (50).  The 
overall fold of SpNic is shared by several classes of enzymes, most of which belong to 
the cysteine hydrolase family.  These enzymes predominantly catalyze the hydrolysis 
of amides, esters or ethers and share a conserved catalytic cysteine residue.  The most 
closely related enzymes, structurally, are the N-carbamoylsarcosine amidases (PDB 
codes 3EEF and 1NBA), and the isochorismatases (1NF9, 2FQ1 and 2A67).  N-
carbamoylsarcosine amidohydrolases (CSHases) hydrolyze N-carbomoylsarcosine to 
sarcosine, carbon dioxide and ammonia.  While the fold of this enzyme is quite similar 
to that of SpNic the shape and nature of substrates accommodated is quite different.  
In addition, CSHase catalyzes the removal of an amide group and does not employ a 
metal ion in catalysis or substrate binding (51).  The isochorismatase enzymes catalyze 
the conversion of isochorismate to 2,3-dihydroxybenzoate and pyruvate via the 
hydrolysis of a vinyl ether bond.  Despite the structural similarities between these 
enzymes and PncA, isochorismatases lack the conserved cysteine residue and catalyze 
unrelated chemistry (52). 
 Key Active Site Residues.  There are several features of the SpNic active site 
that are significant for substrate binding and catalysis.  Structurally, the pyridine ring 
of the ligand is oriented in the active site through coordination to the metal ion and 
through π-interactions made with the aromatic sidechains Phe14, Phe68 and Tyr106; 
additional polar contacts are made with the amide moiety through both side chain and 
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backbone atoms.  The SpNic-aldehyde complex structures clearly indicate that Cys136 
is the catalytic residue responsible for nucleophilic attack of the carbonyl carbon.  
Asp8, nearly equidistant from Cys136 and the –NH2 of the amide, is poised to both 
deprotonate the catalytic cysteine and to transfer a proton to the amine leaving group 
(Figure 4.3).  Studies of PncA mutants, predominantly carried out in Mycobacterium 
tuberculosis, have shown that a complete loss of activity occurs upon mutation of 
either the active site cysteine or aspartate (35, 36, 53).  One interesting case, the 
Borrelia bergdorferri PncA, is annotated as having an N-terminally truncated PncA 
which lacks the aspartate residue equivalent to Asp8.  Studies on the activity of this 
enzyme showed that an additional 48 basepairs 5' of the designated start codon (16 
amino acid residues) were needed to reconstitute PncA activity (54).  When aligned 
with SpNic, this leading sequence contained an aspartate residue equivalent to Asp8 in 
SpNic. 
 Another active site mutation known to eliminate PncA activity is Lys96 in M. 
tuberculosis (equivalent to Lys103 in SpNic) (35, 36).  It has been speculated that, 
along with the cysteine and aspartate residues, the lysine completes a catalytic triad in 
the PncA active site (55).  There has been no evidence put forth, however, to indicate a 
direct role for the lysine residue in catalysis.  Our structures indicate that the role of 
Lys103 is likely ancillary.  This residue makes salt bridges with Asp8 and Asp53 (one 
of the residues that coordinates the metal ion) as well as interacting with Cys136 in the 
SpNic active site.  Its likely role, therefore, is to orient these residues before and 
during catalysis and to help to offset the negative charges that develop along the 
reaction pathway.  
A further notable feature of the SpNic active site is the presence of a putative 
oxyanion hole.  In this pocket, the backbone amines of Leu132 and Cys136 make 
favorable contacts to the carbonyl oxygen of the ligand (Figure 4.3).  This site is 
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structurally configured by a cis-peptide bond between Val131 and Leu132 that is 
conserved amongst nicotinamidases as well as in two other proteins with a similar 
fold, N-carbamoylsarcosine amidohydrolase from Arthrobacter sp. (56) and YcaC 
from Escherichia coli (57).  This oxyanion hole presumably acts by both contributing 
to the proper orientation of the ligand in the active site, donating hydrogen bonds to 
the carbonyl oxygen, and by stabilizing negative charge that builds up along the 
reaction coordinate. 
 Identity and Role of the Metal Ion.  Previous structural and biochemical studies 
on the PncA from M. tuberculosis (36) and P. horikoshii (55) have shown that this 
enzyme binds a metal ion.  For the former, either Fe2+ or Mn2+ was sufficient to 
reconstitute activity and a 1:1 stoichiometry of Fe2+:Mn2+ was found bound in the 
native enzyme (36).  Kinetic analysis of the P. horikoshii PncA, however, showed a 
19-fold increase in enzyme activity in the presence of zinc (55).  In the case of SpNic, 
elemental analysis indicates that both Zn2+ and Fe2+ can bind to the enzyme, although 
zinc was the only metal isolated from the native protein.  Clearly, Zn2+ can occupy the 
active site of SpNic as both the ligand and metal electron density in our structures was 
very clear when crystals were grown in the presence of ZnCl2.  In addition, our 
analysis of the metal dependence of SpNic kinetics shows that, while several divalent 
metals can participate in catalysis, the most catalytically active is Zn2+ (Table 4.4)  
These data suggest that this enzyme is most suited to utilize zinc in the metal site, but 
can also accommodate other divalent ions. 
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Table 4.4.  Recovery of SpNic activity by addition of metal ions 
 
Sample Relative Rate1 
 Untreated 1.0 
Metals Removed 0.0 ± 0.01 
Zn2+ 0.90 ± 0.04 
Mn2+ 0.27 ± 0.02 
Fe2+ 0.13 ± 0.03 
Co2+ 0.13 ± 0.02 
Fe3+ or Ni2+ 0.0 ± 0.02 
 
1The data are represented as mean of triplicate test ± standard deviation 
 
The number and nature of the amino acid residues coordinated to the metal 
differs between the P. horikoshii PncA, S. cerevisiae PncA and SpNic.  In both P. 
horikoshii and S. cerevisiae, the metal ion is coordinated by two histidine residues and 
an aspartate (55, 58).  An additional glutamate residue is present in the SpNic enzyme 
(Figure 4.3).  Mutational studies of the M. tuberculosis PncA suggest that this enzyme 
also coordinates the metal through four sidechain interactions, however these residues 
are putatively identified as three histidines and one aspartate (36).  These findings 
indicate that the identity of the bound metal may depend upon the organism and is 
dictated by the nature of the coordinating residues.  One possible explanation for this 
phenomenon is a divergent evolved specificity for particular metal(s) in distinct 
organisms due to differing environmental conditions.  In this case, the ability for 
SpNic to utilize different metals for catalysis could have provided a competitive 
advantage and thus provided evolutionary pressure towards promiscuity.   
Catalytic Water Molecule.  In addition to four bonds to the enzyme and an 
interaction with the pyridyl nitrogen of the ligand, a water molecule is coordinated to 
the metal in the SpNic active site (Figure 4.3, red sphere).  In order to complete the 
hydrolysis of NAM, an –OH donor is needed, which presumably originates from a 
water molecule.  Since the metal bound water molecule is the only water less than 10 
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Å from the catalytic cysteine, it is reasonable to assume that this molecule may act as 
the –OH donor.  While the distance from this water to the carbonyl carbon of the 
ligand is approximately 5.5 Å, all of our SpNic-ligand complexes show the carbonyl 
of the ligand oriented in such a way that this water molecule has a clear line of attack 
to the carbonyl carbon (Figure 4.4). 
Water molecules coordinated to metals can be activated for catalysis.  The 
degree of activation of the water has implications for the mechanism of the enzymatic 
reaction.  In some cases the water is deprotonated upon coordination to the metal thus 
being activated as a hydroxide ion.  The nature and number of coordinated ligands to a 
metal affects the overall ligand-metal bond strengths, with higher coordination leading 
to weaker bonds (59).  In the case of water coordinated to a zinc ion, bond lengths of 
less than 2 Å generally indicate a metal-hydroxide moiety, while bonds greater than 2 
Å in length indicate zinc-bound water (59).  The metal-water bond length in our 
structures ranges from 2.3 to 2.5 Å with an estimated coordinate error at each atom of 
0.1 to 0.2 Å.  In addition, it has been observed that hydrogen bonds to the metal-bound 
water/hydroxide moeity orient it for attack (59).  In the SpNic structure both Glu64 
and Asp53 are ideally positioned to accept hydrogen bonds from the water molecule 
coordinated to zinc (Figure 4.3A).  Considering the octahedral coordination, the metal-
water bond length and the presence of two hydrogen bond acceptors, it is likely that, 
while the water may be activated for nucleophilic attack, it is coordinated as a water 
molecule and not as a hydroxide ion. 
SpNic-Inhibitor Complexes and Mechanism of Inhibition.  Nicotinaldehydes 
are known competitive inhibitors of nicotinamidase enzymes (19, 41).  To examine the 
mechanism of inhibition we solved the structure of SpNic in complex with both 
nicotinaldehyde and 5-MeO-nicotinaldehyde (Figures 4.4B and C).  These structures 
reveal a covalent adduct, formed between the carbonyl carbon and Cys136, that has 
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tetrahedral geometry at the (formerly) carbonyl carbon.  This observation is consistent 
with the hypothesis that Cys136 acts as the nucleophile during catalysis.  With the 
exception of the amide nitrogen, the inhibors are structurally identical to the substrate 
and therefore share the same enzyme-substrate interactions in the active site.  The 
methoxy group at the 5- position of 5-OMe-nicotinaldehyde extends into a relatively 
open region of the active site, causing a slight shift in Phe68, but otherwise appears to 
have little effect on the orientation of the molecule or the active site residues.   
The observation of a covalently linked tetrahedral structure suggests that the 
enzyme is reacting with the inhibitor but is unable to proceed past a relatively stable 
intermediate.  In the absence of a good leaving group, the intermediate formed by 
reaction of the inhibitor with SpNic persists in the active site for a long enough time 
period to form the product observed in the structures.  The presence of the oxyanion 
hole, which could stabilize the negative charge of a tetrahedral intermediate, suggests 
that the observed SpNic-thiohemiacetal adducts are formed as outlined in Figure 4.5B.  
This mechanism involves deprotonation of Cys136 by the nearby Asp8 followed by 
attack at the carbonyl carbon of the inhibitor.  The charge buildup is stabilized by the 
oxyanion hole.  In the absence of a leaving group the intermediate either proceeds in 
the reverse direction to reform the inhibitor or gains a proton from the solvent, leading 
to the structure observed.  
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Figure 4.5.  Mechanism of SpNic inhibition by nicotinaldehyde.  A) Stereo diagram of 
the structure of the SpNic-nicotinaldehyde complex showing the trapped tetrahedral 
adduct.  In the structure carbon atoms are colored green, oxygen atoms red, nitrogen 
atoms blue, sulfur is yellow and the zinc atom is grey.  The red sphere is the water 
molecule that is coordinated to the zinc ion.  B)  The mechanism of inhibition whereby 
a tetrahedral adduct is formed by reaction with Cys136 to the carbonyl of the inhibitor 
resulting in a stalled complex due to the inability of the aldehyde hydrogen to act as a 
leaving group. 
 
Structure of Trapped Thioester.  The nicotinamidase reaction has been 
proposed to proceed through a thioester intermediate formed after attack of the 
substrate by the catalytic cysteine and concomitant liberation of ammonia (39, 55).  
While biochemical and structural evidence supports this hypothesis, there has been no 
direct evidence reported for this type of intermediate.  The structure of SpNic from 
crystals soaked with nicotinic acid, however, suggests that such a reaction 
intermediate is likely formed along the nicotinamidase reaction pathway.  This 
structure shows a covalently linked intermediate with planar geometry at the carbonyl 
carbon center.  The difference density for the ligand allows for unambiguous 
 
111 
placement of a nicotinyl thioester linked to Cys136 of SpNic (Figure 4.4D).  This 
structure not only provides evidence for a thioester intermediate, but also indicates that 
the final steps in the reaction are fully reversible.  This observation is supported by 18O 
exchange experiments wherein facile exchange of 18O was observed in the presence of 
both unlabelled and 18O-nicotinic acid (41).  These data, together with the C136S 
SpNic-NAM and SpNic-Inhibitor complexes, suggest a reaction mechanism whereby 
the putative thioester intermediate is accessible in both the forward and reverse 
directions.   
Implications for Catalysis.  The structures presented herein elucidate several 
important features of substrate binding and catalysis, and provide evidence for two 
putative intermediates in the nicotinamidase reaction pathway.  Our analysis suggests 
that SpNic catalyzes a ping-pong type reaction that proceeds through two half 
reactions separated by the reactive thioester intermediate.  The proposed mechanism 
for the SpNic catalyzed reaction is given in Figure 4.6C.  Nicotinamide is first 
oriented in the SpNic active site through π-stacking with several aromatic side chains 
and by coordination to the active site metal ion, which may also serve to activate the 
ligand for nucleophilic attack (Figures 4.6A and 4.3A).  Additional interactions occur 
between the carbonyl oxygen of the substrate and the backbone amine groups that 
constitute the oxyanion hole.    Catalysis is initiated by deprotonation of the catalytic 
cysteine, Cys136, by the nearby Asp8, followed by attack of the carbonyl carbon by 
the nucleophilic thiol of Cys136.  This leads to the formation of the putative 
tetrahedral intermediate.  The negative charge that builds up on the carbonyl oxygen 
of this species is stabilized by the oxyanion hole.  This proposed intermediate is 
analogous in structure to that observed between SpNic and nicotinaldehyde (Figures 
4.4B, 4.4C and 4.5A).  The tetrahedral intermediate then collapses to form a thioester, 
as the amino group of the ligand is protonated by Asp8 and leaves as ammonia.  This 
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aspartate residue is observed in the C136S SpNic-nicotinamide structure to be nearly 
equidistant from the nucleophile and the leaving group, aligned ideally for proton 
transfer between these two groups.   
 
 
 
Figure 4.6.  Mechanism of SpNic Catalyzed Hydrolysis of Nicotinamide.  A)  Stereo 
diagram showing the Cys136Ser mutant in complex with NAM.  B)  Stereo diagram 
showing the trapped thioester intermediate formed by soaking native SpNic with NA.  
For both A) and B) carbon atoms are colored green, oxygen atoms red, nitrogen atoms 
blue, sulfur is yellow and the zinc atom is grey.  The red sphere is the water molecule 
that is coordinated to the zinc ion.  C) The proposed mechanism of the SpNic 
catalyzed reaction.  See text for details of the steps. 
 
The thioester intermediate, presumably equivalent to what is observed for the 
nicotinic acid treated SpNic, can then undergo nucleophilic attack by a water molecule 
to lead to a second tetrahedral intermediate.  While our structures cannot 
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unequivocally determine the source of the water that ultimately hydrolyzes the 
nicotinamide, the most likely source of this nucleophile is the water coordinated to the 
zinc ion.  This water is ideally positioned for attack at the carbonyl carbon and is 
properly oriented by Asp53 and Glu64 to carry out this chemistry.  In addition, 
coordination to the metal ion likely activates this molecule for attack.  Despite this 
evidence it cannot be ruled out, however, that deprotonation of the water molecule 
occurs prior to attack, yielding a hydroxide moiety as the nucleophile.     
The final stages of the reaction, leading from the second tetrahedral 
intermediate to product, are analogous to the first steps but occur in the reverse order.  
Deprotonation of the bound water by Asp8 prevents reversal of the reaction as 
collapse of the intermediate expels the thiol group of Cys136.  The product, nicotinic 
acid, dissociates, likely driven by unfavorable interactions between Cys136 and Asp8 
of the enzyme and the acid group of the product.  The catalytic cycle is completed by 
the return of the proton from Asp8 to Cys136.   
In summary, we have presented several crystal structures of the nicotinamidase 
enzyme from the human pathogen, Streptococcus pneumoniae, and provided a 
biochemical analysis of the role and identity of the active site metal.  The structures 
allow us to define many of the key active site interactions and provide details about 
the mechanism by which aldehyde analogs of nicotinamide inhibit this enzyme.  These 
structures also provide a glimpse of the putative reaction intermediates and provide 
much needed insights into the catalytic mechanism of this important enzyme. 
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CHAPTER 5 
INTRODUCTION TO PART II 
 Purines and their derivatives comprise a large percentage of biomass and are 
essential for many of the processes necessary for life.  They are a major component of 
nucleic acids, are important for protein synthesis and signaling and play a major role 
in energy transfer and storage.  In addition, purines can be a major source of nitrogen 
and carbon for many plants and microorganisms (1, 2). 
 In some organisms purines can be utilized as the sole nitrogen source, 
particularly when other sources are limited (1, 2).  This can occur aerobically or 
anaerobically, but does so by different pathways.  The various purine substrates are 
first converted to xanthine which is then hydrolyzed to uric acid by xanthine 
dehydrogenase, steps which are not strongly influenced by the presence of oxygen (1).  
The catabolism of uric acid occurs over many steps and involves a suite of enzymes 
that can differ between organisms.  Two recent genetic studies reported a cluster of 
genes found to be responsible for the degradation of uric acid in Klebsiella 
pneumoniae (3, 4).  The proposed pathway for the catabolism of uric acid in this 
organism is shown in Figure 5.1. 
The degradation of uric acid and the intermediates in the pathway are of 
importance to human health for many reasons.  The inability for humans to degrade 
uric acid can lead to the formation of crystals in joints, causing gout (5).  The ability of 
Klebsiella pneumoniae to degrade allantoin has been linked to the production of liver 
abscesses with metastatic complications (6).  In addition, one of the products of uric 
acid degradation, allantoin, has seen widespread commercial use.  This molecule is 
commonly added to many cosmetic and pharmaceutical products primarily because of 
its moisturizing and keratolytic properties. 
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Figure 5.1.  Uric acid catabolic pathway in Klebsiella pneumoniae.  The pathway from 
uric acid to oxalurate is shown with the compound names given below their structures.  
The enzyme names from K. pneumoniae for each reaction are given below the arrows.  
The conversion of ureidoglycine to ureidoglycolate is shown as an alternative pathway 
for ureidoglycine degradation that occurs in other organisms.  Oxalurate can be further 
catabolized by additional enzymes present in K. pneumoniae. 
  
 In the following three chapters, the structural and biochemical characterization 
of several of the enzymes that play a role in purine catabolism in Klebsiella 
pneumoniae is presented.  In chapter 6, the biochemical and structural characterization 
of a previously unreported transformation, the aminotransfer between ureidoglycine 
and an α-keto acid, is reported.  K. pneumoniae HpxJ is shown, using HPLC, pre-
steady state kinetics and x-ray crystallography, to be an aminotransferase that 
preferentially takes ureidoglycine as a substrate.   
 Chapter 7 outlines the structural characterization of K. pneumoniae HpxQ, the 
enzyme that converts 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) to 
(S)-allantoin.  This is the first structurally characterized prokaryotic OHCU 
decarboxylase.  In addition to the structures provided, an OHCU decarboxylase 
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 inhibitor is identified and characterized.  The structural and biochemical data, along 
with modeling studies of substrates and intermediates, allow for insights into the 
mechanism of the HpxQ catalyzed reaction.  
 The final chapter in this section details the structure and function of an 
allantoin racemase, HpxA, from K. pneumoniae.  This work represents the first 
structural characterization of an allantoin racemase from any organism.  The 
structures, which include an unliganded form and complexes of HpxA mutants with 
allantoin and with 5-acetyl hydantoin, provide details about ligand binding and the 
putative two base mechanism of catalysis. 
 These structural and biochemical studies, along with the studies of K. 
pneumoniae 5-hydroxyisourate hydolase (HpxT - Appendix I) and urate oxidase 
(HpxO - (7, 8)), provide a thorough examination of the enzymes responsible for the 
conversion of uric acid to oxalurate in this organism.  Their characterization provides 
examples of some previously unknown chemistries, and expands our knowledge of 
purine metabolism.  Further exploration of this unusual pathway will no doubt lead to 
the discovery of additional interesting and unexpected enzymatic transformations.             
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CHAPTER 6 
BIOCHEMICAL AND STRUCTURAL CHARACTERIZATION OF A 
UREIDOGLYCINE AMINOTRANSFERASE IN THE KLEBSIELLA 
PNEUMONIAE URIC ACID CATABOLIC PATHWAY  
6.1 Abstract 
Many plants, fungi, and bacteria catabolize allantoin as a mechanism for 
nitrogen assimilation.  Recent reports have shown that in plants and some bacteria the 
product of hydrolysis of allantoin by allantoinase is the unstable intermediate 
ureidoglycine.  While this molecule can spontaneously decay, genetic analysis of some 
bacterial genomes indicates that an aminotransferase may be present in the pathway. 
Here we present evidence that Klebsiella pneumoniae HpxJ is an aminotransferase that 
preferentially converts ureidoglycine and an α-keto acid into oxalurate and the 
corresponding amino acid. We determined the crystal structure of HpxJ, allowing us to 
present an explanation for substrate specificity. 
6.2 Introduction, Results and Discussion 
The uric acid catabolic pathway is the final stage of purine catabolism and 
functions in plants and some bacteria to provide a source of nitrogen, particularly 
when other nitrogen sources are depleted (1, 2).  Uric acid catabolism begins with the 
oxidation of uric acid by uricase followed by ring opening and decarboxylation 
reactions catalyzed by 5-hydroxyisourate hydrolase and 2-oxo-4-hydroxy-4-carboxy-
5-ureidoimidazoline decarboxylase, respectively (3-6).  The latter two steps lead to the 
production of allantoin, a process that also occurs non-enzymatically after oxidation of 
uric acid (1, 4). Allantoin can then be further degraded to allantoate by an allantoinase 
enzyme (1). 
The further catabolism of ureides follows one of two pathways.  The 
degradation of allantoate is catalyzed by either allantoicase or allantoate 
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 amidohydrolase.  The former produces urea and ureidoglycolate, both of which require 
further catabolism for full nitrogen assimilation.  The latter pathway, which is found in 
plants and some bacteria (1, 2), also results in ureidoglycolate, but has been 
demonstrated to proceed via ureidoglycine, a molecule now known to be the product 
of the allantoate amidohydrolase catalyzed reaction (7). 
Characterization of the fate of ureidoglycine has been complicated by the fact 
that it is unstable in aqueous environments and is subject to rapid non-enzymatic 
decay (7, 8).  A recent report by Werner et al., however, demonstrated that 
ureidoglycine can be hydrolyzed by ureidoglycine aminohydrolase (9).  The resulting 
ureidoglycolate can be consumed by ureidoglycolate amidohydrolase or the urea-
releasing ureidoglycolate hydrolase (ureidoglycolate lyase) (2, 9).  Alternatively, in 
some organisms, ureidoglycolate can be oxidized to oxalurate which can be used in 
subsequent reactions to generate ATP and ammonia (1, 10).   
Two recent genetic studies have identified a gene cluster encoding a purine 
degradative pathway in Klebsiella sp. that proceeds through similar intermediates as 
those outlined above, but does so using different catalytic strategies (11, 12).  Scheme 
6.1 outlines the proposed enzymes and intermediates in this pathway (7, 9, 12).  One 
surprising finding in the gene cluster encoding these enzymes was the presence of a 
gene for a protein that belongs to the pyridoxal-5´-phosphate (PLP)1-dependent 
aspartate aminotransferase superfamily.  An examination of the intermediates along 
the degradative pathway reveals that only ureidoglycine has the requisite amino group 
needed to participate in an aminotransfer reaction.  Also notable is the absence of an 
enzyme capable of oxidizing ureidoglycolate to oxalurate.  Taken together, this 
suggests that the pathway could proceed from ureidoglycine to oxalurate directly in 
some organisms.  The presence of an aminotransferase associated with purine 
degradation is not unique to Klebsiella sp.  In a recent cross-organism protein 
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 association analysis, a gene encoding an aminotransferase was found linked to 
allantoate amidohydrolase in several organisms, particularly those lacking a 
ureidoglycine aminohydrolase (9).  
 
      
 
Scheme 6.1. Uric acid catabolic pathway in Klebsiella pneumoniae. The enzyme 
names are taken from the K. pneumoniae degradative pathway.  The dashed line 
indicates an alternative route that operates in other organisms. 
In order to determine if a ureidoglycine aminotransferase participates in the 
purine degradative pathway, we have biochemically and structurally characterized the 
K. pneumoniae enzyme with this putative function.  To establish if HpxJ had 
aminotransferase activity, we first examined its ability to catalyze the transfers of an 
amino group between aspartate and glyoxylate.  To quantitate the amino acid content 
in the reaction mixtures, we treated the mixtures with DABS-Cl prior to HPLC 
analysis.  Figure 6.S1 shows HPLC chromatograms of the aminotransfer reaction in 
the presence and absence of HpxJ.  A clear peak that coelutes with the glycine 
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 standard appears in the enzyme catalyzed reaction while the aspartate peak diminishes 
in size.  The production of glycine was enzyme dependent and also required the 
presence of an amino donor.   
 
Figure 6.S1:  A) HPLC chromatograms of the aminotransfer reaction of aspartate with 
glyoxylate or pyruvate as catalyzed by KpHpxJ.  The top panel is the control reaction 
run in the absence of KpHpxJ.  The second panel is the aminotransfer between 
aspartate and glyoxylate as monitored by the production of glycine.  The third panel 
shows the aminotransfer reaction between aspartate and pyruvate as measured by the 
production of alanine.  B) Overlaid HPLC chromatograms of keto-acid acceptor 
molecule standards.  The products of the aminotransfer reaction with oxaloacetate and 
ureidoglycine (from Figure 6.1B - bottom panel) is shown as a reference.  C) HPLC 
chromatograms of the aminotransfer reaction of ureidoglycine with different amino-
acceptor molecules.  The top left panel shows the amino acid product standards while 
the other panels show the reaction using the amino-acceptor molecule listed.  Note that 
the gradient used to separate these samples was different than that used for Figure 1. 
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   Having established that HpxJ was capable of catalyzing aminotransfer, we 
then wished to determine if ureidoglycine would be a substrate for this enzyme.  Since 
this molecule is known to be unstable in solution we employed E. coli allantoate 
amidohydrolase (AAH) to synthesize ureidoglycine in situ.  This enzyme and the 
chemistry of the AAH reaction have been recently characterized (7).  The production 
of ureidoglycine by AAH reaction can be followed by monitoring the production of 
ammonia with a glutamate dehydrogenase coupled assay (Figure 6.S2). 
    
 
 
Figure 6.S2.  Quantitative conversion of allantoate to ureidoglycine.  A) The 
production of ureidoglycine from allantoate by EcAAH (B) could be monitored by 
following the release of ammonia.  The ammonia produced could be tracked by 
coupling its release to consumption of NADH by the enzyme glutamate 
dehydrogenase (GDH).  The incorporation of ammonia is accompanied by 
stoichiometric consumption of NADH (C).  Conversion of NADH to NAD can be 
monitored at 340 nm.  For this reaction, 125 μM allantoate was mixed with 1 mM 
ketoglutarate, 500 μM NADH, and 10 units of glutamate dehydrogenase.  The reaction 
was initiated by the addition of 50 μM EcAAH.  The non-enzymatic decay of 
ureidoglycine could also be monitored with this assay.  The rate of decay 
(approximately 2 × 104 s-1) was negligible over the time scale of the aminotransfer 
reactions. 
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 The amino acid products of the HpxJ-catalyzed aminotransfer reaction between 
ureidoglycine and pyruvate were followed by HPLC after derivatization with DABS-
Cl.  A peak corresponding to alanine was observed in the presence of the enzyme 
when pyruvate was the amino-acceptor (Figure 6.1A, bottom panel).  We also 
observed a small amount of glycine being produced both in the presence and absence 
of added pyruvate (Figure 6.1A, bottom two panels).  This can be explained by the 
non-enzymatic decay of ureidoglycine.  The decay of this molecule produces 
glyoxylate (7, 8) which can then be used as a substrate for the reaction.  HPLC traces 
of standards and additional aminotransfer reactions are provided in the supporting 
material.   
The products of the aminotransfer reaction between ureidoglycine and an α-
keto acid are an amino acid and oxalurate.  For further evidence that HpxJ catalyzes 
the aminotransfer reaction, we derivatized the keto-acid products of the reaction with 
o-phenylenediamine and followed them by HPLC.  Figure 6.1B shows that oxalurate 
is produced in the presence of either pyruvate (Figure 6.1B, third panel) or 
oxaloacetate (Figure 6.1B, fourth panel) as amino acceptors.  As with the amino 
products of the reaction, a small oxalurate peak was also observed in the absence of 
added amino-acceptor (Figure 6.1B, second panel). 
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Figure 6.1.  Characterization of K. pneumoniae HpxJ.  A) HPLC traces of the amino 
products of the HpxJ aminotransfer reactions.  From top to bottom:  control reaction 
run with HpxJ in the absence of ureidoglycine, control reaction run in the absence of 
HpxJ with all other components present, the reaction with HpxJ and ureidoglycine in 
the absence of exogenous amino acceptor, and the HpxJ catalyzed reaction run in the 
presence of ureidoglycine and pyruvate.  B)  HPLC traces of the keto-acid products of 
the HpxJ aminotransfer reaction.  From top to bottom:  control in the absence of HpxJ, 
reaction with HpxJ and ureidoglycine in the absence of exogenous amino acceptor, 
transfer reaction in the presence of pyruvate, and the transfer reaction in the presence 
of oxaloacetate.  Note that any unreacted allantoate in the reaction is hydrolyzed to 
glyoxylate during the derivatization work-up.  C)  UV absorbance spectra of native 
HpxJ (solid line) and reduced HpxJ (dashed line).  D)  Pre-steady state kinetics of the 
first half reaction catalyzed by HpxJ and rates from a fit to an exponential function.  
Note that the alanine and ureidoglycine traces have been shifted down the y-axis for 
clarity. 
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 One of the conserved features of the aspartate aminotransferase family is the 
dependence upon the cofactor PLP.  The absorbance spectrum of HpxJ (Figure 6.1C) 
is characteristic of enzymes with bound PLP in the imine form.  Treatment of this 
enzyme with sodium borohydride causes the loss of the peak at 420 nm and a shift of 
the 333 nm peak to a slightly lower wavelength.  This is consistent with the reduction 
of the PLP-imine to the amine form, a phenomenon that is also observed in the first 
half of the transfer reaction as PLP is converted to PMP (13).  It was also observed 
that this reduced form of HpxJ was unable to catalyze the aminotransferase reaction 
for any of the amino-donor/acceptor pairs that we tried (data not shown).   
Aminotransferases are known to be promiscuous in regards to the identity of 
amino donor and acceptors (14, 15).  To examine the specificity of HpxJ for different 
amino acids, we measured the pre-steady state rate for the first half reaction of the 
transfer by monitoring the conversion of PLP to PMP.  The curves and calculated rates 
for the different amino acids are shown in Figure 6.1D.  It is clear from this data that 
ureidoglycine is the favored substrate, turning over an order of magnitude faster than 
the next fastest substrate, aspartate.   
In order to further examine this novel aminotransferase and its preference for 
ureidoglycine, we crystallized and determined the structure of HpxJ using molecular 
replacement with PDB 1VJ0 (16) as a search model.  Details about the structure 
solution and model building, including collection and refinement statistics, can be 
found in the supplemental material.  The crystal structure of HpxJ showed a 
homotetramer as the biologically relevant unit (Figure 6.S3), an observation that was 
verified by size exclusion chromatography.   
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Figure 6.S3.  Structure of KpHpxJ.  The overall fold of the KpHpxJ monomer is 
shown on the left and is colored by secondary structure.  The tetramer of the enzyme is 
shown on the right and displays the four molecules colored separately. 
 
Since this enzyme was highly similar to other PLP-dependent 
aminotransferases, it was not surprising to find a covalently bound PLP molecule in 
the active site (Figure 6.2A).  The electron density allowed for the unambiguous 
placement of the PLP in an orientation that superimposed well with PLP in 
homologous structures. 
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Figure 6.2. The active site of HpxJ.  A)  The structure of the PLP binding site of HpxJ 
showing a molecule of PLP covalently bound to lysine 200.  FO - FC density is shown 
contoured at 3σ around the PLP and lysine residue.  B)  Superposition of the active 
site of HpxJ (green) and A. aegypti alanine glyoxylate aminotransferase (grey).  
Ureidoglycine is shown docked in the active site (yellow, ball and stick).  
 
While the members of the alanine-glyoxylate aminotransferase superfamily are 
highly structurally conserved, there is a relatively large degree of variation amongst 
active site residues.  With the exception of the highly conserved amino acids that 
interact with the PLP molecule, differences in active site residues account for the 
observed differences in substrate selectivity (see Figure 6.S4 for a sequence 
alignment).  A superposition of HpxJ with structurally homologous aminotransferases 
shows several obvious differences in the active sites of these proteins.  The most 
notable of these is an asparagine (Asn264) in place of a tyrosine residue and a 
glutamine (Gln39) in place of a histidine.  The side chains of these residues point into 
the active site and are well positioned to make contacts with incoming substrates. 
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 To better understand the selectivity of HpxJ for ureidoglycine over other amino 
acids, we modeled the ligand into the active site of our solved structure.  Despite 
starting from several different conformers of ureidoglycine, all of the simulations 
converged to a similar orientation of the ligand in the active site.  The structure of the 
HpxJ active site with the energy minimized ligand bound is shown in Figure 6.2B.  
What is apparent from this model is that, in addition to interactions with the amino and 
acid groups made by the PLP molecule, backbone atoms of a conserved proline-
proline (Pro19 and Pro20) and a conserved arginine (Arg360), the ureidoglycine tail 
makes several hydrogen bonding contacts with Asn 264 and Gln39.  These amino 
acids, which replace bulkier tyrosine and histidine residues seen in other 
aminotransferases, not only allow space for the larger substrate but also appear to 
directly interact with the substrate.     
In summary, we have confirmed that HpxJ is an aminotransferase that 
catalyzes a novel transfer reaction between ureidoglycine and an α-keto acid.  We 
have provided biochemical and structural evidence for this enzyme's specificity for 
ureidoglycine.  Our data provide an explanation for the presence of this gene in the K. 
pneumoniae Hpx gene cluster and elucidate a novel branch in the ureide catabolic 
pathway. 
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Figure 6.S4.  Sequence alignment of KpHpxJ with several similar aspartate 
aminotransferases (identified by the NCBI conserved domain database; 2HUF (16), 
2CH1 (17), 1VJO (18), 2YRI and gi_7290721).  Residues highlighted and boxed in 
red are completely conserved, while those shown with red text are structurally 
conserved residues.  The two residues highlighted in yellow are the two active site 
residues (Q39 and N64) that are otherwise conserved in the other aminotransferases.  
Blue arrows indicate residues that make hydrogen bonds with the PLP molecule.  The 
red star is the lysine that forms a covalent attachment to the PLP molecule. 
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 6.3 Supporting Material - Materials and Methods 
Cloning, expression and purification of Enzymes. Both Klebsiella pneumoniae 
ureidoglycine-glyoxylate aminotransferase (KpHpxJ, YP_001335423) and E. coli 
allantoate amidohydrolase (EcAAH, NP_415049) were cloned, expressed and purified 
using the same procedure.  The proteins were expressed from a Pet-28 based plasmid 
containing an N-terminal 6-his tag and a TEV cleavage site.  These constructs, 
denoted HpxJ-THT and EcAAH-THT, were provided by the Cornell Protein 
Production Facility and were cloned from genomic DNA using standard molecular 
biology techniques.  The KpHpxJ gene was cloned from genomic DNA from 
Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan MGH78578 (ATCC 
700721).  The EcAAH gene was cloned from Escherichia coli (Migula) Castellani and 
Chalmers, MG1655 (ATCC 700926).  BL21(DE3) cells were transformed with these 
plasmids and grown in LB media supplemented with a final concentration of 50 
μg/mL kanamycin.  A 10 mL starter culture, grown overnight, was used to inoculate 
one litre LB cultures.  These were grown at 37oC with shaking until the O.D.600 
reached 0.4.  The temperature was reduced to 20oC and after 30 minutes expression 
was induced with 0.5 mM IPTG.  The cells were grown for a further 16 hours and then 
harvested by centrifugation and stored at – 20oC. 
The cells were suspended in 50 mM Tris buffer, pH 7.6, containing 300 mM 
NaCl and 10 mM imidazole.  After lysis by sonication the cellular debris was removed 
by centrifugation and the cleared lysate applied to a column containing Ni-NTA resin.  
The column was washed with 100 mL of 50 mM Tris buffer, pH 7.6, containing 300 
mM NaCl, 25 mM imidazole and 10% v/v glycerol.  The protein was eluted with 50 
mM Tris buffer, pH 7.6, containing 300 mM NaCl and 250 mM imidazole.  The eluted 
protein was further purified by gel filtration on a ACTA explorer FPLC with a HiLoad 
26/60 Superdex prep grade G200 column running 10 mM Tris, buffer pH 7.6, with 30 
 
138 
 mM NaCl.  After purification, the protein was concentrated to 12 mg/mL for KpHpxJ 
and 2 mg/mL for EcAAH and aliquots were flash frozen and stored at – 80oC. 
 Pre-column Derivatization of Amino Acids with DABS-Cl.  In order to quantify 
amino acid reactants and products, pre-column derivatization with 
dimethylaminoazobenzenesulfonyl chloride (DABS-Cl) was carried out (19, 20).  
Stock solutions of DABS-Cl were made at 4 mM in acetonitrile just prior to use.  To 
50 μl of sample was added 50 μl of 100 mM sodium bicarbonate, pH 8.2, and 200 μl 
of 4 mM DABS-Cl solution.  This was vortexed, heated at 80o for 20 minutes and then 
cooled for 5 minutes on ice.  Once cooled, 300 μl of reaction diluent (50 mM sodium 
phosphate, pH 7.0, in 50% ethanol) was added.  The samples were centrifuged at 14 
000 rpm on a microcentrifuge for 2 minutes to remove precipitates prior to injection 
on HPLC.   
 Synthesis of Oxalurate.  Oxalurate was synthesized from uracil as reported 
(21).  Briefly, a solution of uracil (0.5 g) in phosphate buffer, pH 7.0 (100 mL), was 
mixed with a solution of potassium permanganate (1.41 g) in water (80 mL).  The 
mixture was kept at 37o C for 18 hours.  Manganese dioxide was removed by 
centrifugation and the supernatant was concentrated to approximately 5 mL and left at 
25o C.  White crystals (MP 206-208°C) formed over time, and after 24 hours were 
removed by filtration.  The mass was confirmed by ESI-MS (m/z = 130.99, Figure 
6.S5).  The purity was estimated to be greater than 90% by analysis of the MS 
spectrum.  
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Figure 6.S5.  ESI-MS spectrum of oxalurate.  The sample was collected in negative 
ion mode and the observed mass (m/z = 130.99) agrees well with the calculated mass 
(131). 
 
 Pre-Column Derivatization of Keto Acids.  In order to quantify keto acids 
produced in the KpHpxJ reaction, pre-column derivatization with o-phenylenediamine 
(OPD) was performed.  The OPD was purchased from Sigma-Aldrich and used 
without further purification.  To make the keto acid derivatives, 50 μl of sample was 
added to 100 μl of water and 100 μl of a 100 mM OPD solution (in 2M HCl).  The 
mixture was heated for 30 minutes at 85oC followed by cooling on ice for 5 minutes.  
Before injecting on the HPLC, 500 μl of 1 M phosphate buffer, pH 7.5, was added and 
the solution was centrifuged to remove any precipitate. 
 HPLC Analysis of Aminotransferase Reactions.  Aminotransferase reactions 
were carried out in 100 μl volumes at 25oC.  In a typical reaction, 1 mM amino acid 
and 1 mM α-keto acid were mixed in 50 mM phosphate buffer, pH 7.3.  The reaction 
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 was initiated by the addition of 10 μl of 250 μM KpHpxJ.  After 30 minutes at 25oC, 
the reaction was quenched by the addition of 1 μl of 50% acetic acid and then put on 
ice for 5 minutes.  After centrifuging to remove precipitated protein, a sample of the 
reaction was immediately derivatized with DABS-Cl or OPD.  50 μl of derivatized 
sample was run on a Hewlett-Packard 1100 Series HPLC with an Agilent Eclipse Plus 
reverse-phase C18 column (4.6 x 150 mm) using a gradient from 2% acetonitrile to 
50% acetonitrile in water with 0.1% TFA.  Chromatograms were recorded at 436 nm 
and 220 nm for DABS-Cl derivatives and 335 and 220 nm for OPD derivatives. 
 For reactions involving ureidoglycine as a starting material, this compound 
was made in situ immediately prior to running the reaction.  To generate 
ureidoglycine, 1 - 5 mM allantoate (diureidoacetic acid) was mixed with 10 - 50 μl of 
100 μM EcAAH in 50 mM phosphate buffer, pH 7.3.  The EcAAH protein solution 
contained 500 μM MnCl2 as this enzyme is known to depend upon manganese for 
activity (22, 23). The rate of reaction could be followed by observing the liberation of 
ammonia using a glutamate dehydrogenase coupled assay (Figure 6.S2) (7, 24).  
Sufficient EcAAH was used to ensure that complete conversion of allantoate to 
ureidoglycine was finished within 2 minutes, and the conversion was judged to be 
quantitative.    The enzyme was removed by filtration through a 10 000 MWCO 
microconcentrator device.  The resulting ureidoglycine was used immediately in 
aminotransferase reactions.   
 Unless otherwise specified, control reactions were run with all components 
present, including donor or acceptor molecules, but without adding the enzyme.   
 Pre-Steady State Measurements.  Pre-steady state kinetics measurements were 
carried out on a Kintek model SF-2004 stopped-flow instrument.  The first step of the 
PLP-dependent reaction was monitored by following the decrease in absorbance at 
418 nm as PLP was converted to PMP.  For each measurement 1000 time points were 
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 measured over the course of the run.  The dead time of the instrument was 
approximately 15 ms.  The experiments were carried out at 15 μM KpHpxJ and 5 mM 
amino acid and were followed over 1 to 120 seconds.  The data was fit by non-linear 
regression to the following equation (25): 
 
   [PLP] = Ae-kt + C 
 
In this equation, A is the amplitude of the pseudo-first order process, k is the rate, t is 
time and C is the initial absorbance. 
 Crystallization, Data Collection and Processing.  The protein was crystallized 
using the hanging-drop vapor-diffusion method at 18o C.  The crystallization 
conditions for KpHpxJ consisted of 34% 3-methyl-1,5-pentanediol (MPD) and 100 
mM NaCl in 100 mM Tris buffer, pH 7.5.  The thin rod-shaped crystals grew over 
seven to ten days and were yellow in color.  Prior to data collection, the crystals were 
cryoprotected using the crystallization solution without additional additives.  The data 
were collected at the NE-CAT 24ID-E beamline of the Advanced Photon Source of 
Argonne National Lab at a wavelength of 0.979 Å.  The data collection statistics are 
provided in Table 6.S1.  Data was collected over 180o with a 1o oscillation angle and 
an exposure time of 1 s.  The data were indexed, integrated and scaled using HKL-
2000 (26). 
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 Table 6.S1.  Data Collection Statistics 
 KpHpxJ (P21) KpHpxJ (P21212)a 
resolution (Å) 50.0 - 2.59 50.0 - 2.59 
wavelength (Å) 0.9795 0.9795 
space group P21 P21212 
a (Å) 142.2 141.7 
b (Å) 149.2 146.9 
c (Å) 198.0 197.6 
β (°) 90.3 90.0 
no. of reflections 575 940 529 674 
unique reflections 242 484 122 273 
Average I/σ 8.6 (1.9) 9.1 (2.0) 
redundancy 2.4 (2.3) 4.3 (3.9) 
completeness (%) 95.9 (96.8) 94.0 (95.9) 
Rsymb (%) 13.1 (40.9) 13.7 (45.4) 
Numbers in parentheses correspond to the highest resolution shell 
a While the structure was solved using a monoclinic space group, the statistics for the 
apparent orthorhombic unit cell are included for completeness. 
b IIIR i Σ−ΣΣ= /isym , where I  is the mean intensity of the N reflections with 
intensities Ii and common indices h, k, l  
 
Structure Solution and Refinement.  The initial phases for the structure were 
provided by molecular replacement using the program Molrep (27) with an all-alanine 
version of PDV 1VJ0 as the model.  Initially, the data for the KpHpxJ crystals scaled 
in an orthorhombic space group with unit cell dimensions of a = 141.7 Å, b = 146.9 Å, 
and c = 197.6 Å, with eight molecules predicted for the asymmetric unit (data 
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 collection statistics provided in Table 6.S1).  All attempts at molecular replacement 
using this space group failed.  After rescaling in P21 with unit cell dimensions a 
=142.2 Å, b = 149.2 Å, c = 198.0 Å, and β = 90.3°, a solution with sixteen molecules 
in the asymmetric unit (four complete tetramers) was found immediately.  
Examination of the symmetry related molecules in the unit cell showed apparent 
twofold-screw symmetry along the short axes and apparent twofold symmetry along 
the long axis, which would result in the non-standard space group P22121.  Further 
examination after the appropriate transformation and reindexing of the data revealed 
that a slight shift of one of the molecules in the unit cell precluded ant symmetry 
higher than monoclinic.  Twinning tests performed by SFCHECK (28) and the 
program xtriage in the Phenix suite (29) found a high degree of pseudo-merohedral 
twinning with a twin operator of h, -k, -l.  The twin fraction was estimated to be 
between 37% and 42% for the monoclinic dataset.     
        
 
 
Figure 6.S5.  Active site of HpxJ.  Stereo diagram of the active site residues of HpxJ 
with the putative substrate, ureidoglycine (white), modeled in.  The PLP molecule 
(blue) is covalently linked to Lys 200. 
 
  The model was refined through successive rounds of manual model building 
using COOT (30) and restrained refinement using Refmac5 (31) and Phenix (29).  
Calculation of twin fraction and detwinning was performed automatically by the 
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 refinement program.  Water molecules were added only after refinement converged 
and was followed by additional rounds of refinement.  The covalently bound PLP was 
added directly to difference density and followed by an additional round of 
refinement.  The refinement statistics are given in Table 6.S2. 
Table 6.S2.  Data Refinement Statistics 
 KpHpxJ 
resolution (Å) 2.59 
no. of protein atoms 50620 
no. of ligand atoms 92 
no. of water atoms 1228 
no. of reflections in working set 230 277 
no. of reflections in test set 12 155 (5.3%) 
R factora 21.5 
Rfreeb 23.9 
rmsd bonds (Å) 0.006 
rmsd angles (o) 1.11 
mean B factor (Å2) 33.7 
Ramachandran plot  
   most favored (%) 96.8 
   additionally allowed (%) 2.7 
   generously allowed (%) 0.5 
   disallowed (%) 0.1 
a R factor ∑−Σ= hkl obscalcobshkl FFkF / , where Fobs and Fcalc are observed and 
calculated structure factors respectively.  
b For Rfree, the sum is extended over a subset of reflections excluded from all stages of 
refinement 
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 Modeling of Ureidoglycine in the KpHpxJ Active Site.  The modeling of the 
ligand in the active site of KpHpxJ was performed using version 9.7.211 of the 
program Macromodel (32, 33).  The protein was truncated to a shell containing all 
atoms within 20 Å of the ligand.  Water molecules were removed and the protein 
preparation utility was used to add hydrogens and to ensure proper ionic states of 
amino acid side chains.  In order to model the substrate, ureidoglycine was first placed 
in the active site by superposition to the alanine from PDB 1H0C (34).  A 
conformational search of ureidoglycine was used to generate starting conformers for 
the calculations.  Modeling runs were carried out both allowing only the ligand to 
move and allowing the ligand and active site residues freedom to move.  In order to 
maintain a reasonable proximity between the PLP to the ligand, the Cα and C1 of 
ureidoglycine were constrained with a force constant of 100.    The calculations were 
completed using the AMBER* force field (35, 36) with a distance dependent dielectric 
that was further attenuated by a factor of 4.  The energy minimization relied upon the 
truncated Newton conjugate gradient (TNCG) technique (37) and was considered to 
have converged when the energy gradient was less than 0.01 kJ/mol.     
All of the figures presented herein were prepared using PyMol (38).  The 
structure of KpHpxJ has been deposited in the Protein Data Bank with identifier 
3NNK. 
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CHAPTER 7 
STRUCTURAL AND MECHANISTIC STUDIES ON KLEBSIELLA PNEUMONIAE 
2-OXO-4-HYDROXY-4-CARBOXY-5-UREIDOIMIDAZOLE DECARBOXYLASE  
7.1 Abstract 
The stereospecific oxidative degradation of uric acid to (S)-allantoin was 
recently shown to proceed via three enzymatic steps.  The final conversion is a 
decarboxylation of the unstable intermediate 2-oxo-4-hydroxy-4-carboxy-5-
ureidoimidazoline (OHCU) and is catalyzed by OHCU decarboxylase.  Here we 
present the structures of Klebsiella pneumoniae OHCU decarboxylase in unliganded 
form and with bound allantoin.  The structures provide evidence that ligand binding 
organizes the active site residues for catalysis.  Modeling of the substrate and 
intermediates provides additional support for this hypothesis.  In addition we 
characterize the first reported OHCU decarboxylase inhibitor, allopurinol, a structural 
isomer of hypoxanthine.  This molecule is a competitive inhibitor of K. pneumoniae 
OHCU decarboxylase with a Ki of 30 ± 2 μM.  Circular dichroism measurements 
confirm structural observations that this inhibitor prevents the necessary organization 
of the active site.   Our structural and biochemical studies also provide further 
mechanistic insights into the mechanism of catalysis of OHCU decarboxylation. 
7.2 Introduction 
The ability to metabolise uric acid, a key intermediate in the degradation of 
purines, varies by organism.  Humans, birds, reptiles and some bacteria, for example, 
lack the enzymes necessary to break down this compound (1, 2).  This inability to 
process uric acid in humans leads to high serum concentrations of urate which can 
crystallize in joints and cause gout.  In plants and some bacteria, however, the high 
nitrogen content of the ureides make them attractive sources of nitrogen, particularly 
when other sources are limited.  Organisms that possess the ability to degrade uric acid 
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utilize a conserved pathway that converts this molecule into (S)-allantoin (1).  
Allantoin can be further degraded by plants and some bacteria for use as a nitrogen, 
carbon and energy source. 
The currently accepted degradative pathway from uric acid to allantoin is 
shown in Scheme 7.1. 
 
      
Scheme 7.1.  The catabolic pathway from uric acid to allantoin.   
 
Until recently it was believed that only a single enzyme, urate oxidase, was 
responsible for the conversion of urate to allantoin.  Over the last few years, however, 
several reports have conclusively proven that the pathway proceeds through two 
intermediates and utilizes two additional enzymes (3-5).  The actual product of the 
urate oxidase reaction is the unstable intermediate, 5-hydroxyisourate (HIU1).  The 
conversion of HIU to another unstable compound, 2-oxo-4-hydroxy-4-carboxy-5-
ureidoimidazoline (OHCU) is catalyzed by HIU hydrolase.  OHCU can then be 
stereospecifically decarboxylated to yield (S)-allantoin. 
Despite recent efforts, the enzyme responsible for the final step in this pathway, 
OHCU decarboxylase, is not well characterized.  Very little is known about the 
mechanism of this decarboxylation reaction, and only two structures of this enzyme, 
both from eukaryotes, have been solved and deposited in the Protein Data Bank.  
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These two structures report a similar architecture for OHCU decarboxylase, but 
display some distinct differences.  While both the structure from zebrafish (2O70) (6) 
and the structure from Arabadopsis thaliana (2Q37) (7) report dimeric structures, they 
differ in how the two monomers interact (6, 7).  In addition, the structures reported 
with the bound product, allantoin, differ in which enantiomer is bound in the active 
site. 
Beyond what has been inferred from the crystal structures, very few details 
about the kinetics or mechanism of the OHCU decarboxylase reaction are known.  
Sequence analysis of this enzyme reveals that it is unrelated to previously 
characterized decarboxylases and biochemical analyses of the decarboxylation 
reaction by circular dichroism (CD) have shown that the reaction proceeds in the 
absence of exogenous cofactors.  With the exception of a few relatively rare radical 
mechanisms, decarboxylation reactions generally require the presence of an electron 
sink or a leaving group in order to accommodate the electrons from the cleavage of the 
bond to the carboxylate moiety (8).  This role is usually played by cofactors such as 
PLP or thiamine pyrophosphate (8, 9).  Few enzymes are known that catalyze 
decarboxylation reactions independent of cofactors.  One notable example is orotidine 
5'-monophosphate decarboxylase (OMPDC) (10, 11).  This protein has been 
extensively studied, in large part due to its extremely high catalytic proficiency (rate 
acceleration on the order of 1016) (12).   
In this work we report the high resolution crystal structures of the cofactor-
independent OHCU decarboxylase from Klebsiella pneumoniae, both in unliganded 
form and with bound allantoin.  Our structures reveal a prochiral, enol form of 
allantoin bound in the active site.  This isomer more closely resembles the putative 
reaction intermediate than either of the individual isomers.  The crystal structure with 
allantoin bound reveals an extensive hydrogen bonding network in the active site.  
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Modelling of the substrate, putative reaction intermediate and products provides 
additional details about the likely mode of catalysis.  In addition, we have identified a 
novel competitive inhibitor of this enzyme and examined the method of inhibition 
using both X-ray crystal structures and circular dichroism measurements.  The 
structure, modeling and kinetic analysis allow us to propose a mechanism for the 
OHCU decarboxylase catalyzed reaction. 
7.3 Experimental Procedures 
Cloning and Mutagenesis.  KpOHCU decarboxylase was expressed from a 
pET-28 based plasmid containing an N-terminal 6-His tag and a TEV cleavage site.  
The hpxQ gene was cloned from genomic DNA from K. pneumoniae subsp. 
pneumoniae (Schroeter) Trevisan MGH78578 (ATCC 700721).  This construct, 
denoted HpxQ-THT, was provided by the Cornell Protein Production Facility and was 
cloned using standard molecular biology techniques.  The Q88E mutant plasmid was 
made at the Cornell Protein Production Facility using site-directed mutagenesis of the 
native gene.  Briefly, site-directed mutagenesis was performed on KpOHCU 
decarboxylase by a standard PCR protocol using PfuTurbo DNA polymerase 
(Invitrogen) per the manufacturer's instructions and DpnI (New England Biolabs) to 
digest the methylated parental DNA prior to transformation.  Clones were screened for 
the mutant by PCR with a screening primer and the T7 promoter primer.  All clones 
and the mutant were verified by sequencing. 
Protein Expression and Purification.  BL21(DE3) cells were transformed with 
the HpxQ-THT plasmid and grown in LB media supplemented with 50 mg/mL 
kanamycin.  A 10 mL starter culture, grown overnight, was used to inoculate one litre 
LB cultures.  These were grown at 37 °C with shaking until the OD600 reached 0.4.  
The temperature was reduced to 20 °C and after 30 minutes at this temperature 
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expression was induced with 0.5 mM IPTG.  The cells were grown for a further 16 
hours and then harvested by centrifugation and stored at –20 °C. 
The cells were suspended in 50 mM Tris buffer, pH 7.6, containing 300 mM NaCl and 
10 mM imidazole.  After lysis by sonication the cellular debris was removed by 
centrifugation and the cleared lysate applied to a column containing pre-equilibrated 
Ni-NTA resin.  The column was washed with 100 mL of 50 mM Tris buffer, pH 7.6, 
containing 300 mM NaCl, 25 mM imidazole and 10% v/v glycerol.  The protein was 
eluted with 50 mM Tris buffer, pH 7.6, containing 300 mM NaCl and 250 mM 
imidazole.  The eluted protein was further purified by gel filtration on an ACTA 
Explorer FPLC with a HiLoad 26/60 Superdex prep grade G200 column running 10 
mM Tris buffer, pH 7.6, with 30 mM NaCl.  After purification, the protein was 
concentrated to 12 mg/mL using a centrifugal concentrator and aliquots were flash 
frozen and stored at –80 °C. 
Crystallization, Data Collection and Processing.  The protein was crystallized 
using the hanging-drop vapor-diffusion method at 18 °C.  The crystallization 
conditions for unliganded KpOHCU decarboxylase consisted of either 20 % w/v PEG-
3000 in Tris-HCl, pH 7.0, with 0.2 M calcium acetate or 22 – 26 % w/v PEG-8000 in 
sodium cacodylate, pH 6.5, with 0.25 M sodium acetate.  Prior to data collection, the 
crystals were cryoprotected in the above solutions supplemented with 15 – 20 % 
ethylene glycol.  For the KpOHCU decarboxylase–allantoin complex, crystals were 
soaked for 5 min in cryosolution that contained 10 mM allantoin.  For the allopurinol 
treated structures, the crystals were either soaked directly in cryosolution containing 
10 mM allopurinol or first treated with cryosolution containing 10 mM allantoin for 5 
min and then transferred to cryosolution containing 10 mM allopurinol and removed 
for data collection after either one minute or ten minutes.  The crystals of the 
unliganded protein belonged to space groups P41 (rod-shaped crystals) and P1 (plate-
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like crystals).  After soaking the latter crystals with allantoin or allopurinol, the space 
group changed to C2.  Attempts to soak ligands into the tetragonal crystals caused 
considerable crystal damage and yielded unusable data.   
Data were collected at the NE-CAT 24-ID-E beamline of the Advanced Photon 
Source of Argonne National Lab at a wavelength of 0.979 Å and at 0.978 Å at the 
Cornell High Energy Synchrotron Source.  In all cases, the data were indexed, 
integrated and scaled using HKL-2000 (13).  The data collection statistics are 
summarized in Table 7.1. 
 
Table 7.1.  Data Collection Statistics. 
 KpOHCU 
decarboxylase 
(P1) 
KpOHCU 
decarboxylase 
(P41) 
KpOHCU 
decarboxylase 
- allantoin 
KpOHCU 
decarboxylase - 
allopurinol 
soak 
resolution (Å) 1.79 1.55 2.00 1.98 
wavelength (Å) 0.987 0.987 0.987 0.987 
beam line Chess A1 Chess A1  Chess A1 Chess A1 
space group P1 P41 C2 C2 
a (Å) 46.80 88.18 91.18 91.40 
b (Å) 49.34 88.18 47.32 46.70 
c (Å) 51.69 40.22 50.21 47.30 
α (°) 113.18 90 90 90 
β (°) 116.49 90 123.13 118.99 
γ (°) 94.26 90 90 90 
no. of reflections 54 203 367 405 29 217 27333 
unique reflections 31 805 49 837 12 101 11639 
average I/σ 27.8 (4.7) 28.7 (7.3) 16.5 (2.6) 17.3 (1.9) 
redundancy 1.7 (1.5) 7.4 (7.2) 2.4 (2.0) 2.3 (1.8) 
completeness (%) 93.8 (75.0) 99.9 (100.0) 98.6 (94.1) 94.7 (58.0) 
Rsyma (%) 3.0 (14.2) 9.6 (37.0) 7.6 (26.3) 6.9 (32.6) 
Numbers in parentheses correspond to the highest resolution shell 
a IIIR i Σ−ΣΣ= /isym , where I  is the mean intensity of the N reflections with 
intensities Ii and common indices h, k, l  
 
Structure Solution and Refinement.  All initial attempts at molecular 
replacement using Phaser (14), Molrep (15) or CNS (16) with various forms of the A. 
thaliana OHCU decarboxylase (PDB identifier 2Q37) or the OHCU decarboxylase 
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from zebrafish (PDB identifier 2O70) failed to produce a solution for the higher 
resolution tetragonal data.  Using the P1 data, however, a molecular replacement 
solution was found using Phaser with an all alanine search model derived from 2Q37.  
The model was refined through successive rounds of manual model building using 
COOT (17) and restrained refinement using Refmac5 (18).  Water molecules were 
added only after the model converged and followed by two additional rounds of 
refinement.  The solution of the P1 crystal form was used as a model for molecular 
replacement for the other data sets.  Refinement of the initial model was carried out as 
detailed above.  For the KpOHCU decarboxylase-allantoin complex structure, the 
ligand position was added directly to the difference Fourier map after the initial rounds 
of refinement.  For this structure, water molecules were added only after the ligand 
was placed.  The refinement statistics are given in Table 7.2 
 
Table 7.2.  Data Refinement Statistics. 
 KpOHCU 
decarb. (P1) 
- unliganded 
KpOHCU 
decarb. (P4) - 
unliganded 
KpOHCU 
decarb. - 
allantoin 
KpOHCU 
decarb. - 
allopurinol 
soak 
resolution (Å) 1.79 1.55 2.00 1.98 
protein atoms 2440 2273 1260 1057 
ligand atoms 0 0 11 0 
water atoms 290 655 95 85 
reflections in working set 30202 47280 11525 11067 
reflections in test set 1603 3493 576 554 
R factora 23.8 20.5 22.9 22.5 
Rfreeb 26.1 22.6 25.4 25.9 
rmsd bonds (Å) 0.005 0.005 0.005 0.006 
rmsd angles (o) 0.83 0.822 0.91 0.945 
mean B factor (Å2) 19.6 10.6 24.5 34.2 
Ramachandran plot     
  most favored (%) 97.0 97.3 96.6 95.1 
  additionally allowed (%) 2.7 2.7 3.4 4.9 
  generously allowed (%) 0.3 0 0 0 
  disallowed (%) 0 0 0 0 
a R factor ∑−Σ hkl obscalcobshkl FFkF /= , where Fobs and Fcalc are observed and 
calculated structure factors respectively.  
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b For Rfree, the sum is extended over a subset of reflections (5%) excluded from all 
stages of refinement 
 
Substrate and Product Modeling.  The modeling of the ligands in the active 
site of KpOHCU decarboxylase was performed using version 9.7.211 of MacroModel 
(19, 20).  The protein was truncated to a shell containing all atoms within 20 Å of the 
ligand.  Water molecules were removed and the protein preparation utility was used to 
add hydrogen atoms and to ensure proper ionic states of amino acid side chains.  In 
order to model the substrate, OHCU was positioned in the active site by superposition 
to the allantoin from the KpOHCU decarboxylase-allantoin complex structure.  A 
conformational search of OHCU was used to generate starting conformers for the 
calculations.  For the modeling runs, both the ligand and active site residues were 
allowed freedom to move.  To model the products of the reaction in the active site, the 
minimized OHCU molecule was used as a starting point.  The calculations were 
completed using the AMBER* force field (21) with a distance dependent dielectric 
that was further attenuated by a factor of 4.  The energy minimization relied upon the 
TNCG technique (22) and was considered to have converged when the energy 
gradient was less than 0.01 kJ/mol.     
All of the figures presented herein were prepared using PyMOL (23) and 
ChemBioDraw (CambridgeSoft).  The structures have been deposited in the Protein 
Data Bank with identifiers XXXX (P1 – unliganded), XXXX (P41 – unliganded), 
XXXX (C2 – allantoin complex), and XXXX (C2 – allopurinol soak). 
Steady State Kinetics Measurements–The substrate was generated in situ by 
treating a urate solution with uricase and HIU hydrolase enzymes.  The OHCU was 
made just prior to injection by incubating 140 μM urate in 500 μL of 50 mM 
phosphate buffer, pH 8.0, with 5 μL of a 5 mg/mL uricase solution and 1 μL of a 5 
mg/mL HIU hydrolase solution (HpxT from K. pneumoniae).  This amount of enzyme 
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was sufficient to completely convert the urate into OHCU in less than one minute 
(monitored by the disappearance of the absorbance peak at 300 nm (4)).  The 
decarboxylation reaction was initiated by the addition of 20 μL of 2.5 μM KpOHCU 
decarboxylase (0.024 nmoles).  All reactions were carried out at pH 8.0 in 50 mM 
phosphate buffer in 500 μL total volume.  The rate of reaction was monitored by 
observing the change of absorbance at 256 nm.  The initial rate was calculated from 
the first 15 seconds after addition of the enzyme, at which point the reaction had not 
proceeded beyond 10% towards completion.  Duplicate reactions were carried out at 
each of the various OHCU concentrations.  The initial rate data was plotted and fit to 
the Michaelis-Menten equation using the Kaleidagraph software package (Synergy 
Software).    
Inhibition by Allopurinol.  Reaction rates for inhibition studies were measured 
as described above.  To various concentrations of OHCU (generated in situ) was 
added a solution of 2.5 μM KpOHCU decarboxylase containing allopurinol.  The 
initial rate of reaction, calculated from the first 15 seconds after addition of enzyme, 
was recorded for the various substrate concentrations.  The reaction rates were 
measured at concentrations of 150, 350 and 600 μM allopurinol.  A double reciprocal 
plot was constructed (Fig. 7.3C) and linear fits to the data were extrapolated to the y-
intercept to determine the Ki.  The reported Ki is the average of the three calculated 
values from the fits to the data at 150, 350 and 600 μM allopurinol. 
Circular Dichroism Measurements.  The KpOHCU decarboxylase protein was 
buffer exchanged into a solution of 10 mM phosphate buffer, pH 7.6 and used at a 
final concentration of 0.1 mg/mL.  Data were collected separately for the protein 
alone, with 1 mM allantoin added, and with 1 mM allopurinol added.  The CD spectra 
were collected on an AVIV Biomedical (Lakewood, NJ) CD spectrometer, Model 
202-01.  The data were collected at 25 °C from 190 to 260 nm with a 1 nm step size 
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and a 1 nm bandwidth.  A 1 mm cell was used and in all cases, the data reported are an 
average of three measurements after subtraction of the background signal.  Samples 
run without enzyme present showed that the ligands tested did not contribute to the 
CD signal at the concentrations used.  The programs K2D2 and DicroProt (24, 25) 
were used for prediction of secondary structure content from the collected data. 
7.4 Results 
Overall Structure of KpOHCU Decarboxylase.  The OHCU decarboxylase of 
K. pneumoniae crystallized with two different morphologies and yielded data in three 
different space groups.  The long rod-shaped crystals that grew in PEG-3000 belonged 
to space group P41 with two molecules per asymmetric unit and a calculated solvent 
content of 42.5%.  Crystals grown in the PEG-8000 condition were plate-like and 
belonged to space group P1.  This crystal form had two molecules per asymmetric unit 
with a calculated solvent content of 45.3%.  When these crystals were soaked with a 
solution of mother liquor containing 10 mM allantoin, the space group changed to C2 
with one molecule per asymmetric unit and the solvent content decreased to 43.6%. 
KpOHCU decarboxylase is an all α-helical protein that belongs to the newly 
discovered OHCU decarboxylase fold (as classified by PFAM).  It consists of nine 
helices in two domains, with the N-terminal domain containing the first four helices 
and the C-terminus of helix nine.  Taken together, helices 2 through 4 and helix 8 are 
consistent with a four-helix bundle.  The core of this domain is lined with hydrophobic 
side chains including two tryptophans, two phenylalanines and several leucine and 
valine residues.   There are no disulfides in this enzyme, and the fold is stabilized 
primarily by hydrophobic interactions within the two all α-helical domains. 
The crystal structures of KpOHCU decarboxylase indicate that this enzyme is a 
monomer in solution, a conclusion supported by size exclusion chromatography (data 
not shown).  In addition, submission of the structure to the EBI-PISA (26) server, 
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which examines protein interfaces, surfaces and assemblies, predicted that higher 
order oligomerization was not likely to be observed.  Further evidence comes from the 
observation that the tetragonal and triclinic/monoclinic crystal forms display 
completely different packing (Fig. 7.1 and Fig. 7.S1).  The monomeric structure of 
KpHpx with the bound product, allantoin, is shown in Fig. 7.1A.  
 
         
 
Figure 7.1.  Structure of KpOHCU decarboxylase monomer (red helices and green 
loops) with allantoin bound (blue).  Also shown are the proposed OHCU 
decarboxylase dimers from A. thaliana (2Q37 - lower left) and zebrafish (2O70 - 
lower right) 
 
 
161 
 
 
Figure 7.S1.  Structure and crystal packing of KpOHCU decarboxylase in tetragonal 
crystal form.  Ribbon representations of two molecules are shown with a semi-
transparent space fill model of allantoin to mark the active site.  One molecule (green) 
packs into the active site of the other (blue) where helix 6 of the enzyme is seen in the 
unliganded (P1) and liganded structures. 
 
A search for structurally similar proteins using the DALI server (27) yielded 
only three homologous structures (Table 7.S1).  Two of these, 2Q37 and 2O70, are the 
OHCU decarboxylase enzymes from A. thaliana and zebrafish respectively (Fig. 7.1).  
The third, 2O8I, is an unpublished structure from Agrobacterium tumefaciens with an 
uncharacterized function (28).  Based upon the degree of similarity to 2Q37, 2O70 and 
KpOHCU decarboxylase, it is likely that this protein is also an OHCU decarboxylase.   
 
Table 7.S1.  Results of DALI search for structural homology 
PDB ID Z-Score RMSD % identity Description 
2O70 19.1 2.4 22 OHCU Decarboxylase 
2Q37 17.1 1.8 29 OHCU Decarboxylase 
2O8I 14.1 2.8 23 Hypothetical Protein ATU2327 
 
KpOHCU Decarboxylase Active Site.  KpOHCU decarboxylase crystals 
soaked in mother liquor supplemented with 10 mM allantoin yielded maps with clear 
difference density in the active site.  While a racemic mixture of both (R)- and (S)-
allantoin enantiomers was used for soaking, the density observed in the active site 
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corresponded to a planar molecule, consistent with the enol form of allantoin.  The 
density allowed us to unambiguously place the allantoin molecule in the active site. 
This placement superimposed well with that of the other OHCU decarboxylase 
structures. 
KpOHCU decarboxylase contains one active site per monomer and all of the 
contacts with the ligand are made by a single monomer.  The active site is formed 
primarily by the loops connecting helices 5 and 6 and helices 7 and 8.  Upon binding, 
KpOHCU decarboxylase forms a significant number of hydrogen bonds to the ligand 
(Fig. 7.2).  At least eight non-covalent interactions can be seen between the protein 
and the ligand, with additional bonding occurring through two active site water 
molecules that are well ordered in the structure.  Most of the polar contacts are with 
backbone atoms of Pro68, Phe117, Ile199, and Ala121 with Ser84 and Glu87 
providing addition bonding through their sidechains.   
Analysis of the B-factors of the crystal structure of both the unliganded and 
liganded form of KpOHCU decarboxylase show a relatively even distribution of low 
B-factors (15 to 20) over the whole protein.  The one exception is the helix that spans 
residues 79 through 88.  Fig. 7.S2 shows a ribbon diagram of the KpOHCU 
decarboxylase structure colored by B-factors.  This helix and the adjoining loop 
regions were examined further both structurally and by CD (see below).   
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FIGURE 7.2.  Active site of KpOHCU decarboxylase and ligand contacts. A, Active 
site with bound product, allantoin, showing FO – FC electron density contoured at 3σ.  
The difference density was calculated before adding the ligand to the model.  B, 
Schematic of ligand binding in KpOHCU decarboxylase active site showing hydrogen 
bonding between the enzyme and the ligand.  C, Stereoview of KpOHCU 
decarboxylase active site with modeled OHCU (yellow).  D, Superposition of the 
energy minimized active site with bound substrate (OHCU, green) and products ((S)-
allantoin and CO2, yellow). 
 
 
 
Figure 7.S2.  Ribbon diagram of unliganded KpOHCU decarboxylase colored by B-
factor.  Allantoin is shown in green for reference.  The colors indicate the magnitude 
of the values from low (blue-cyan-green) to high (yellow-orange-red). 
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 A sequence alignment of KpOHCU decarboxylase with the zebrafish and A. 
thaliana OHCU decarboxylases is shown in Fig. 7.S3.  Despite the relatively low level 
of overall similarity between the sequences, there are several conserved regions.  In 
particular, all but one of the active site residues that make polar contacts with the 
ligand are conserved among the three enzymes (Fig. 7.S3, blue arrows).  The 
exception is Ala74 from the A. thaliana OHCU decarboxylase (Ser84 in KpOHCU 
decarboxylase).  A comparison of the different structures at this residue is impossible 
since Ala74 does not appear in the A. thaliana structure as it is part of a presumably 
disordered loop region. 
 
 
Figure 7.S3.  Sequence alignment of KpOHCU decarboxylase, A. thaliana OHCU 
decarboxylase (2Q37), and the OHCU decarboxylase from zebrafish (2O70).  The 
secondary structure elements shown above the alignment correspond to those observed 
in KpOHCU decarboxylase and the blue arrows indicate residues responsible for 
making hydrogen bonding contacts to the ligand. 
 
An alignment of the unliganded and allantoin-bound KpOHCU decarboxylase 
structures reveals a slight difference in the loop between helices 5 and 6.  While 
several residues change position, the shift of this region most notably alters the 
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position of His67, presumably to accommodate the ligand.  The superposition of these 
two structures, illustrating the motion of His67, is shown in Fig. 7.S4A. 
Modeling of Substrate and Products.  In order to investigate the binding of the 
substrate and products of the KpOHCU decarboxylase catalyzed reaction, molecular 
mechanics simulations of OHCU and allantoin/carboxylate in the active site were 
carried out.  Using the structure of the KpOHCU decarboxylase-allantoin complex as a 
starting point, these molecules were docked into the active site and then energy-
minimized using the AMBER* (21) force field.  Both the molecules themselves and 
the active site side-chains were allowed freedom of movement.  While most of the 
residues remain unmoved, the putative active site base, His67, can adopt several low-
energy states (Fig. 7.S4B,C).    Modelling of OHCU also reveals additional hydrogen 
bonds made between the carboxylate group and Gln 88 as well as between the 
hydroxyl group and His 67.  This structure also shows a shift in the position of the 
allantoin backbone away from Gln 88 and towards His 67.    
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Figure 7.S4.  His67 movement in the active site.  A, Superposition of unliganded 
KpOHCU decarboxylase (gold) and KpOHCU decarboxylase with allantoin bound 
(green).  His67 is shifted to accommodate the ligand in the KpOHCU decarboxylase-
allantoin complex structure.  Modeling of the substrate, OHCU (B), and the reaction 
intermediate (C) showing two of the predicted low energy conformations of His67.  
One of the low energy conformers (blue) is positioned to deprotonate the hydroxyl of 
OHCU, while a second conformer (yellow) is poised to protonate the prochiral carbon 
of the reaction intermediate.  Comparison of the modeled reactant (B) and intermediate 
(C) also reveals that, after release of the carboxy moiety, there is a shift of the 
imidazoline ring towards His67.   
 
Kinetics of KpOHCU Decarboxylase Catalyzed Reaction.  The kinetics of 
conversion of OHCU to allantoin by KpOHCU decarboxylase can be followed 
spectrophotometrically.  Fig. 7.3A shows the spectra of uric acid overlaid with the 
degradation products produced during enzymatic conversion to allantoin.  The large 
difference in absorbance of OHCU and allantoin in the region of 240 - 260 nm allows 
for the facile measurement of this conversion.  By monitoring the change in 
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absorbance at 256 nm, the initial rates of decarboxylation catalyzed by KpOHCU 
decarboxylase at various OHCU concentrations were measured and used to calculate 
the steady state parameters (Fig. 7.3B).  The calculated background rate of non-
enzymatic decay of OHCU (1.5 ± 0.1 × 10-3 s-1), which was in agreement with the 
reported value (2.2 × 10-3 s-1, (4)), was accounted for in all cases.  The enzyme turns 
over at a rate of 122 ± 11 s-1 and has a kcat/KM of 9.7 × 105 M-1s-1.  An attempt to 
measure pre-steady state kinetics of the reaction showed a linear initial rate with no 
apparent burst phase observed at any point up to the highest detection limit of the 
apparatus (0.2 ms).  In addition, the kinetics were unaffected by viscosity, showing no 
difference in rate of reaction in the presence of varying concentrations of sucrose or 
ethylene glycol (data not shown). 
 
 
 
FIGURE 7.3.  Kinetics of KpOHCU decarboxylase reaction.  A, UV traces of the 
intermediates along the uric acid degradation pathway.  Urate (top solid line) is 
converted to 5-HIU (dashed line) by urate oxidase (HpxO in K. pneumoniae); 5-HIU 
is converted to OHCU (dotted line) by an HIU hydrolase (HpxT in K. pneumoniae); 
and OHCU is converted to allantoin (lower solid line) by KpOHCU decarboxylase.  B, 
The steady state kinetics of KpOHCU decarboxylase.  The rate of OHCU 
decarboxylation was measured by monitoring the decrease in absorbance at 256 nm.  
The reactions were followed using a stopped flow apparatus and the rates were 
calculated from the first 10 seconds of the reaction (less than 10% completetion).  C, 
Double reciprocal plot showing the competitive inhibition of KpOHCU decarboxylase 
by allopurinol.  The rate was measured at 600 μM inhibitor (filled circles), 350 μM 
inhibitor (filled triangles) and 150 μM inhibitor (filled squares).  The average value of 
Ki from the three datasets is 31 ± 2 μM. 
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Activity of the Q88E Mutant.  To examine the role played by Gln 88 in 
catalysis, the activity of a glutamine to glutamate mutant was measured.  Using the 
identical protocol and conditions as with the native protein, we measured the rate of 
conversion of OHCU to allantoin by the mutant enzyme.  The Q88E mutant was 
active, but turned over at a slower pace than the native enzyme.  The maximal rate of 
this mutant (2.8 ± 0.2 s-1) was 43 fold slower than that of the native rate.  
Inhibition of KpOHCU decarboxylase by Allopurinol.  As there are currently 
no OHCU decarboxylase inhibitors reported in the literature, we tested several 
substrate analogues for their ability to inhibit KpOHCU decarboxylase activity.  The 
xanthine oxidase inhibitor, allopurinol (29), was found to reduce the rate of KpOHCU 
decarboxylase turnover at micromolar concentrations.  This compound was 
determined to be a competitive inhibitor as demonstrated by a double reciprocal plot 
of inhibition at 150, 350 and 600 μM, (Fig. 7.3C) with a calculated Ki of 30 ± 2 μM. 
Structural Observations and CD Measurements of Domain Movement–In order to 
probe the mechanism of inhibition we attempted to structurally characterize a complex 
of KpOHCU decarboxylase and allopurinol.  Soaks of the tetragonal crystal form with 
allopurinol solutions caused crystal degradation and failed to yield usable data.  
Similar treatment of the monoclinic crystals yielded high quality data with increased 
symmetry (P1 to C2).  Examination of the structure revealed that helix 6 was missing 
from the density and the loop regions connecting this helix to the rest of the structure 
were displaced from the allantoin-bound structure (Fig. 7.4A). 
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FIGURE 7.4.  Conformational change of KpOHCU decarboxylase.  A,  Ribbon 
diagrams showing the structural superposition of KpOHCU decarboxylase-allantoin 
complex (green), unliganded KpOHCU decarboxylase in tetragonal form (yellow) and 
KpOHCU decarboxylase treated with allopurinol (red).  Allantoin is shown in space-
fill representation.  Helix 6 (above allantoin) is visible only in the allantoin bound 
structure.  B, Circular dichroism measurements of unliganded KpOHCU 
decarboxylase (dotted line), KpOHCU decarboxylase treated with allantoin (solid line) 
and KpOHCU decarboxylase treated with allopurinol (dashed line).  The increase in 
signal at 208 nm and 222 nm and the decrease in signal at 193 nm in the presence of 
allopurinol are all consistent with a loss of helical content. 
 
To examine the possibility that the inhibitor was disrupting the tertiary 
structure of the enzyme we examined the CD spectra of KpOHCU decarboxylase in 
the presence and absence of allantoin or allopurinol.  The spectra of the protein alone, 
in the presence of allantoin and in the presence of allopurinol are shown in Fig. 7.4B.  
While the presence of allantoin has only a minor influence on the structure, a marked 
decrease in helical content is apparent in the presence of allopurinol.  The approximate 
helical content drops from 93% in the unliganded structure to 82% in the presence of 
allopurinol (95% in the presence of allantoin).  
7.5 Discussion 
While KpOHCU decarboxylase bears a high degree of structural homology to 
previously reported OHCU decarboxylases, there are marked distinctions between 
these enzymes.  The most striking of these is the disparity in the quaternary structures.  
While both of the eukaryotic OHCU decarboxylases reported dimers as the biological 
unit, the spatial relationship and interactions between the two protomers are 
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significantly different (Fig. 7.1).  The K. pneumoniae enzyme presented herein, 
however, is clearly a monomer in solution.  Considering that all of the protein-ligand 
interactions are made by a single monomer, these results suggest that the minimal 
functional unit of OHCU decarboxylase is a monomer.  The dimeric forms present in 
the eukaryotic structures may be a result of evolutionary pressure.  Further 
biochemical comparison of these enzymes is necessary to determine if the dimers are 
more catalytically efficient or are necessary for some other purpose such as protein-
protein complex formation.  
  The active site residues of OHCU decarboxylases are highly conserved (Fig. 
7.S3).  Despite this similarity, and the observation that this enzyme produces (S)-
allantoin stereospecifically, both the (S)- and (R)- isomers of allantoin have been 
observed bound in the active site (6, 7).  In the KpOHCU decarboxylase structure, 
however, we observed the enol form of allantoin (Fig. 7.2).  Allantoin is known to 
undergo slow non-enzymatic racemization, with one likely mechanism for this 
chemistry being the keto-enol tautomerization (30).  In the presence of KpOHCU 
decarboxylase, this reaction is likely facilitated by His67, which is well positioned to 
abstract a proton from allantoin.  It is not surprising to see that the enol is stabilized by 
the active site, as it is structurally more similar to the substrate than either the (R)- or 
(S)-enantiomers.  Thus, the structure of KpOHCU decarboxylase in complex with this 
isomer of allantoin allows for a clearer picture of how the substrate interacts with this 
enzyme and provides a snapshot of an important intermediate in the reaction 
mechanism. 
Positioning of OHCU in the KpOHCU decarboxylase active site is facilitated 
by the degree of similarity between the substrate and the enol observed in the 
structure.  While the stereochemistry of enzymatically produced OHCU has not been 
well characterized, it can be inferred from structures of urate oxidase with bound 
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ligands.  The addition of the hyroxyl group to urate occurs at the re- face leading to 
the (R)- isomer of OHCU after hydrolysis by HIU hydrolase cleaves the N1-C6 bond 
(31)2.  A stereo diagram showing the positioning of OHCU in the KpOHCU 
decarboxylase active site is provided in Fig. 7.2B.  In addition to the hydrogen 
bonding contacts shown in Fig. 7.2A, the substrate makes additional bonds to Gln88 
through the carboxylate and with His67 through the hydroxyl moiety. 
To further our understanding of the OHCU decarboxylation reaction we 
investigated the kinetics of KpOHCU decarboxylase.  To date, there have been no 
reports on the kinetics of a native OHCU decarboxylase.  This is likely due to the 
difficulty working with the unstable substrate of the reaction.  OHCU can be generated 
in situ by the consecutive reactions of urate oxidase and HIU hydrolase on uric acid 
and 5-HIU, respectively.  The conversion from uric acid to OHCU through 5-HIU can 
be monitored by UV (Fig. 7.3A).  The clear difference in UV spectra between OHCU 
and allantoin in the 240 - 260 nm range allows for the facile measurement of reaction 
rates.  The confounding factor of non-enzymatic decay of 5-HIU and OHCU is 
negligible if reaction times are kept short.  Fig. 7.3B shows the steady state kinetics of 
the KpOHCU decarboxylase catalyzed decarboxylation reaction and the calculated 
kinetic parameters.  Even though a cofactor is not required, this enzyme is surprisingly 
efficient with a kcat/KM of 9.7 × 105 M-1s-1. 
Despite the commercial availability of purine derivatives, a search of the 
literature reveals a paucity of information for small molecule modulators of OHCU 
decarboxylase activity.  There is, however, precedent for binding of such molecules 
apparent in the crystal structure of zebrafish OHCU decarboxylase in complex with 
guanine (6).  Thus, we began our screen for small molecule modulators of KpOHCU 
decarboxylase activity with purine analogues.  Comparison of wild type KpOHCU 
decarboxylase activity with activity levels in the presence of these molecules 
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identified allopurinol, a known xanthine oxidase inhibitor.  We characterized the 
inhibition and determined that this molecule is a competitive inhibitor of KpOHCU 
decarboxylase activity with a Ki of 30 μM. 
In order to probe the interactions between allopurinol and KpOHCU 
decarboxylase, we first attempted to solve the structure of these two molecules in 
complex.  Our efforts to trap the allopurinol-KpOHCU decarboxylase complex 
revealed some very interesting details about the conformational flexibility of the 
enzyme and the mechanism of inhibition.  Our first evidence that KpOHCU 
decarboxylase could exist in different conformational states in solution came from the 
different structures of the two unliganded crystal forms.  The structure of the 
tetragonal form revealed a non-functional conformation where the crystal packing 
interactions occurred near the active site (Fig. 7.S1).  Additionally, soaks of the 
unliganded or liganded KpOHCU decarboxylase crystals with allopurinol showed a 
similar unfolded state as was observed for the tetragonal form.  A superposition of 
these different conformational states is shown in Fig. 7.4. 
These observations suggested that a region of this enzyme containing helix 6 
and bound by the adjoining loop regions was conformationally flexible and was 
sensitive to active site-ligand interactions.  An examination of the B-factors in the full, 
unliganded, structure suggests that this region of the enzyme has the most dynamic 
mobility (Fig. 7.S2).  For further evidence of the impact of ligand binding on the 
conformational state of the enzyme we measured the circular dichroism spectra of the 
enzyme in the absence and presence of allantoin and allopurinol.  The results, shown 
in Fig. 7.4B, indicate that the enzyme has a lower helical content in the presence of the 
inhibitor.  This data, taken together with the structural findings, indicates that the 
protein-ligand interactions drive conformational change and that binding of the 
inhibitor prevents the correct organization of the active site. 
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The structural, biochemical and modelling studies presented herein provide 
several much needed insights into the mechanism of decarboxylation catalyzed by 
OHCU decarboxylase enzymes.  The proposed mechanism is shown in Scheme 7.2.  
KpOHCU decarboxylase is a highly efficient enzyme that operates in a cofactor 
independent manner.  It has been proposed that OHCU decarboxylase may use a 
catalytic strategy similar to OMPDC, a widely studied cofactor-independent 
decarboxylase (6).  While several mechanisms for the decarboxylation reaction 
catalyzed by OMPDC have been put forth, the mechanism that is most consistent with 
structural data and quantum mechanical calculations involves ground-state 
destabilization of the carboxylate group by a proximal aspartate in the active site (11, 
12, 32).  
 
Scheme 7.2.  Mechanism of OHCU decarboxylation catalyzed by KpOHCU 
decarboxylase. 
 
While the active site of KpOHCU decarboxylase contains a large number of 
hydrogen bonding contacts, locking the substrate into place (as is the case for 
OMPDC), our data suggests a different mechanism.  In the OMPDC decarboxylation 
reaction, the leaving carboxylate group is destabilized by an unfavourable interaction 
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with an active site aspartate.  Based upon our structure, which allows for an accurate 
placement of the substrate in the active site, the carboxylate group of OHCU will be in 
close proximity to Gln88 (Fig. 7.2C,D).  To examine if this residue provides a 
destabilizing driving force for decarboxylation, we constructed and measured the rate 
of reaction of the Q88E mutant.  If the KpOHCU decarboxylase catalyzed reaction 
proceeded in an analogous fashion to that of OMPDC, we would expect a rate increase 
for the mutant enzyme.  What we observed, however, was a decrease in enzyme 
activity by over 40 fold.   
Based on this observation we propose that Gln88 instead acts to inductively 
destabilize the carbon-carbon bond between the carboxylate and C5 of the hydantoin 
ring in a manner analogous to purine nucleoside phosphorylase (PNP) (33) and related 
enzymes (34).  In the PNP catalyzed reaction, an active site asparagine withdraws 
electrons from the purine ring through hydrogen bond formation causing a weakening 
and concomitant heterolysis of the C1´-N9 bond.  This type of mechanism is 
consistent with the positioning of Gln88 in the KpOHCU decarboxylase structure and 
with the Q88E mutant activity measurements. 
Upon decarboxylation, an enol intermediate is formed that resembles the 
isomer seen in our crystal structure (Fig. 7.2).  Modeling of the reaction intermediates 
suggest that unfavourable interactions between the liberated CO2 and both the enzyme 
and intermediate force the hydantoin ring towards His67 (Fig. 7.S4C).  This histidine 
is ideally positioned to facilitate proton transfer between the hydroxy and C5 of the 
hydantoin ring.  The structures of liganded and unliganded KpOHCU decarboxylase 
illustrate the conformational flexibility of this residue (Fig. 7.S4A) while our 
modelling studies support the role of His67 in proton transfer (Fig. 7.S4B,C).  In 
addition, examination of the H67N mutant in the zebrafish OHCU decarboxylase 
showed complete loss of activity (6), consistent with its significance for proton 
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transfer.   The enzyme mediated tautomerization, facilitated by His67, yields the 
product, allantoin, exclusively as the (S)-enantiomer.  Pre-steady state kinetic analysis 
and examination of the effect of viscosity on reaction rate suggest that this latter 
reaction occurs very rapidly.  In addition, as there is no apparent alternative for CO2 
escape from the active site, it is likely that the unfavourable interactions caused by the 
presence of this molecule drive product release. 
In summary, we have presented a structural and biochemical characterization 
of KpOHCU decarboxylase, identified a novel inhibitor and proposed a mechanism of 
action for this inhibitor.  CD measurements were used to support the structural 
evidence for dynamic instability of helix 6 and the ability for ligands to modulate this 
conformational change.  The structure of KpOHCU decarboxylase in complex with 
the enol form of allantoin provides a view of the proposed reaction intermediate and, 
together with the biochemical data and modeling studies, allows us to provide a 
mechanistic analysis of the decarboxylation reaction.   
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CHAPTER 8 
STRUCTURES OF KLEBSIELLA PNEUMONIAE ALLANTOIN RACEMASE IN 
COMPLEX WITH ALLANTOIN AND WITH 5-ACETYL HYDANTION AND 
THEIR MECHANISTIC IMPLICATIONS  
8.1 Abstract 
The oxidative catabolism of uric acid produces 5-hydroxy isourate (5HIU) which is 
further degraded to (S)-allantoin by the actions of two enzymes, 5HIU hydorlase and 
2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) decarboxylase.  Both of the 
latter two intermediates, HIU and OHCU, are unstable in solution and breakdown 
nonstereospecifically to allantoin.  In addition, slow non-enzymatic racemization of 
allantoin has been shown to occur at physiological pH.  Since the further breakdown 
of allantoin is catalyzed by an enzyme that is specific for (S)-allantoin, allantoinase, an 
allantoin racemase is necessary for complete and efficient catabolism of uric acid.  In 
this work we present several crystal structures of allantoin racemase from Klebsiella 
pneumoniae (HpxA).  In addition to an unliganded structure solved using SeMet-SAD, 
structures of HpxA in complex with allantoin and in complex with 5-acetyl hydantoin 
are presented.  These structures reveal several important features of the active site 
including an oxyanion hole and a polar binding pocket that interacts with the C5 
substituent of the ligand and serves to control the orientation of the hydantoin ring.  In 
addition, a highly ordered water molecule is situated near one of the catalytic residues 
and is ideally situated to participate in catalysis.  The data presented provides new 
insights into the activity and substrate specificity of this enzyme and enables us to 
propose a mechanism for catalysis that is consistent with the 'two base' mechanism put 
forth for other members of this family. 
8.2 Introduction  
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The enzymatic degradation of uric acid is the final stage of purine catabolism 
and serves in plants and some bacteria to provide a source of nitrogen, particularly 
when other nitrogen sources are depleted (1, 2).  The first stage of this pathway 
involves three enzymes and facilitates the stereospecific oxidative decomposition of 
uric acid to (S)-allantoin.  Upon oxidation by urate oxidase, two additional enzymes, 
5-hydroxy isourate (HIU1) hydrolase and 2-oxo-4-hydroxy-5-ureidoimadozoline 
(OHCU) decarboxylase, complete the conversion from urate to (S)-allantoin (3-5).  
While the product of these enzymatic conversions is solely the (S)- enantiomer, non-
enzymatic decomposition of both HIU and OHCU can occur and does so non-
stereospecifically.  In addition, slow, non-enzymatic racemization of allantoin has 
been observed to occur (6).    
The conversion of allantoin to allantoate by an allantoinase enzyme is a point of 
convergence in the metabolism of ureides (1, 2, 7).  This step is present in all 
organisms that catabolize allantoin.  To date two types of allantoinase have been 
identified, a metal-dependent and a metal-independent form (8-10).  While these two 
enzymes may differ in mechanism, what is common is that they both preferentially 
bind the (S)- enantiomer of allantoin.  Considering the selectivity of the allantoinase 
enzymes and the various mechanisms operating to produce racemic mixtures of 
allantoin, efficient use of this molecule would require the presence of a racemase 
enzyme.  Recent genetic studies on Klebsiella pneumoniae and Klebsiella oxytoca 
M5al have identified a gene cluster for purine utilization that encodes several enzymes 
that catalyze novel chemical transformations, including an enzyme that was putatively 
identified as an allantoin racemase (11, 12).  This enzyme shares 45% identity over 
96% of its length with the hydantoin racemase from Pseudomonas sp.  The proposed 
purine degradative pathway in Klebsiella sp. is shown in Scheme 8.1.   
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Scheme 8.1 Proposed purine catabolic pathway in K. pneumoniae (11, 12) 
 
Despite the observation of allantoin racemase activity in the early 1970's (13-
15), very little is known about this enzyme.  In fact, a search of the literature does not 
yield a single report published on the biochemical or structural characterization of this 
enzyme since the original work carried out over thirty years ago.  Despite this paucity 
of data for allantoin racemase, some progress has been made on the characterization of 
a homologous enzyme, hydantoin racemase (16).  This enzyme belongs to the 
aspartate/glutamate racemase superfamily and is known to catalyze racemization of 5-
substituted hydantoins in a cofactor- and metal-independent fashion.  Hydantoin 
racemase, which catalyzes the racemization of various 5-substituted hydantoins, is a 
commercially important biocatalyst used in the production of optically pure amino 
acids (17).        
Hydantoin racemase and other members of the aspartate/glutamate racemase 
superfamily are believed to operate using a two base mechanism that involves a pair of 
highly conserved cysteine residues (18, 19).  Binding and kinetic studies combined 
with site-directed mutagenesis have demonstrated the importance of these two 
cysteines for both substrate recognition and catalysis.  While this enzyme can bind and 
catalyze the conversion of both isomers, it has been reported that it does so with 
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differing specificity.  Much of the binding and catalytic selectivity for the different 
isomers has been attributed to these two active site cysteines (19, 20). 
In this work we present the first reported x-ray crystal structures of allantoin 
racemase in both unliganded and ligand-bound forms.  These structures, from the 
opportunistic human pathogen, Klebsiella pneumoniae, provide valuable insights into 
substrate binding and selectivity.  In addition, the structural information allows for a 
clearer picture of how this enzyme utilizes the conserved 'two base' mechanism to 
catalyze the racemization of allantoin.   
8.3 Results 
Structure of Unliganded HpxA.  The structure of HpxA was solved using 
SeMet SAD phasing to 2.2 Å.  Other than the polyhistidine tag and the two N-terminal 
residues, the entire protein was modeled.  HpxA is an α/β protein with two domains 
that form a V shape in the protomer.  The two domains share a high degree of 
similarity (RMSD 3.1 Å), with each containing a 4-stranded parallel β-sheet 
sandwiched between two pairs of α-helices (Figure 8.1B).  When symmetry related 
molecules were considered, the crystallographic data suggested that HpxA formed a 
stable hexamer in the crystal (Figure 8.1A).  The quaternary structure was verified by 
size exclusion chromatography (data not shown).  The hexamer is made up by a trimer 
of dimers, with the three identical dimer interfaces occurring at the groove between 
domains.  This interface has an approximate buried surface area of 3 400 Å2 and is 
dominated by polar contacts between amphipathic helices 4 and 9 of the two 
protomers.     The interface between the dimers is predominantly along helices 2 and 3 
and has only slightly less buried surface area (approximately 3 340 Å2) than the dimer 
interface itself.  In addition, the C-terminal 20 residues form a loop that packs along 
the length of helix 2 of the neighboring molecule providing additional polar contacts.  
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Overall, this leads to a tightly packed hexamer with a total buried surface area of 
approximately 22 000 Å2. 
 
 
Figure 8.1 Structure of HpxA.  A)  Hexameric structure of HpxA seen in the crystals 
and confirmed by size exclusion chromatography.  B)  HpxA protomer.  C)  Topology 
diagram of HpxA.  Helixes are shown as blue cylinders and strands as green arrows.  
The numbers correspond to the residue numbers of the first and last amino acid of 
each secondary structure element.  The N and C termini are marked with an N and C, 
respectively. 
 
 C79S/C184S HpxA - Allantoin Structure.  In order to examine active site 
interactions in HpxA, we constructed the C79S/C184S double mutant and solved the 
structure in complex with allantoin.  The observed difference density in the active site 
allowed for the unambiguous placement of the ligand (Figure 8.2A).  While the 
solution used for the soaks of the crystals was a mixture of the (R)- and (S)- isomers, 
the observed density best fit the enol form of allantoin (Figure 8.2B).  Most of the 
interactions between the enzyme and the ligand are made through the backbone of 
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HpxA.  A notable exception to this is a region surrounding the amide tail of the ligand 
where several hydrogen bonds are made to the sidechains of Thr118, Thr119, the 
backbone of Gly183 and to a water molecule positioned by Thr123.  
 
 
 
Figure 8.2 Active site of HpxA.  A) Stereo diagram of the active site of HpxA in 
complex with allantoin.  The structure shown (C in green, N in blue, O in red) is that 
of the wild type with allantoin (C in black, N in blue, O in red) placed in the active site 
as seen in the C79S/C184S structure.  Waters are represented as red spheres and are 
labeled with 'w'.  Putative hydrogen bonds are illustrated with dashed lines.  B)  
Schematic drawing of the active site contacts between HpxA and allantoin.  Dashed 
lines indicate putative hydrogen bonds.  Cys79 and Cys184 are not shown.   
 
The hydantoin ring of allantoin is positioned in the active site through three 
major sets of interactions.  In addition to the above-mentioned binding pocket that 
tightly holds the allantoin tail in place, additional interactions are made through the 
two oxygen atoms of the hydantoin ring.  These are each held in place by a pair of 
residues, the backbone amide nitrogens of Phe80 and Gly185 for the C4 oxygen and 
the backbone amide nitrogen of Ile47 and the sidechain of Asn12 for the C2 oxygen 
respectively (Figure 8.2B).  Both of these pairs of hydrogen bonding interactions 
could also provide the necessary stabilizing interactions required for an oxyanion hole.  
Considering the geometry of the ligand in the active site, however, it is likely that only 
the former pair of residues would function in this capacity during catalysis.  
The two conserved cysteine residues, Cys79 and Cys184, which are substituted 
by serines in the mutant structure, are situated on opposite sides of allantoin in the 
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asymmetric active site of HpxA (Figure 8.3A).  In the structure of the C79S/C184S 
HpxA double mutant with allantoin bound the electron density for the Ser79 sidechain 
was diffuse and was best fit by two rotamers set to have 50% occupancy each (Figure 
8.3A).  The distances between the two serines and C5 of allantoin in the structure are 
3.2 and 4.2 Å for Ser79 (rotamer closest to allantoin) and Ser184, respectively.  Also 
present in the active site is a water molecule situated near Ser79 (Figure 8.3A).  This 
molecule is 2.6 Å from Ser79 and 4.3 Å from C5 of allantoin.  The water molecule 
also makes hydrogen bonds with the backbone nitrogen of Gly81 and the sidechain of 
Glu53.          
 
 
 
Figure 8.3 Ligands bound to HpxA.  A)  Stereo diagram of allantoin bound to the 
C79S/C184S HpxA double mutant.  B)  Stereo diagram of 5-acetyl hydantoin bound 
to the C79S/C184S HpxA double mutant.  In both cases carbon atoms are green, 
oxygen atoms are red and nitrogen atoms are blue.  The red sphere labeled with 'w' is a 
water molecule.  The sidechain of Phe80 has been omitted for clarity.  The electron 
density in both cases is from difference maps generated before the addition of the 
ligand molecule into the model and are contoured at 3σ. 
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Structural Similarity to Other Proteins.  A search for structurally homologous 
proteins using the DALI (21) server yielded several related structures (Table 8.1).  As 
expected, all of these structures belonged to the Aspartate/Glutamate racemase 
superfamily of proteins.  The protein of known structure that is most similar to HpxA 
is the hydantoin racemase from Pyrococcus horikoshii (PDB identifier 2EQ5 (22)).   
 
Table 8.1  Results of DALI search for structurally similar proteins using PDB90a 
PDB ID Z-Score RMSD % Identity Annotated Function 
2EQ5 23.4 2.3 20 Hypothetical hydantoin racemase 
3EIS 16.6 3.0 18 Arylmalonate decarboxylase 
severalb 12.5 - 16.2 2.9 - 4.1 12 - 20 Glutamate racemase 
1JFL 15.1 2.9 12 Aspartate racemase  
aPDB90 is a representative subset of the PDB structures at 90% sequence identity  
b2GZM, 2VVT, 1ZUW, 2DWU, 2JFG, 3IST, 2JFU, 2OHO, 2JFY and 1B73 
 
While this protein was also crystallized in a hexagonal space group (P65), the 
observed quaternary structure was a dimer.  The orientation of the two protamers in 
the dimeric 2EQ5 is similar to that of hpxA, but the interface is populated primarily by 
smaller, hydrophobic residues leading to a slightly shorter distance between the two 
molecules.  A structural superposition of HpxA and 2EQ5 shows that the two proteins 
contain very similar secondary structure elements although some of the helical regions 
do not align well (Figure 8.4A).  In spite of the overal similarity of the two proteins, 
the active sites display some distinct differences (Figure 8.4B).  Superposition of the 
acitve site residues of HpxA and 2EQ5 show expected similarities in the conserved 
cysteines and in the putative oxyanion hole.  Beyond these features, little similarity 
exists.  Not surprisingly, the tail-binding region of the HpxA active site that is 
populated by several threonine residues is not present in the hydantoin racemase 
structure.  In 2EQ5, this region is composed of predominantly non-polar residues, 
presumably to accommodate the typically aliphatic chains present in the 5-substituted 
hydantoin substrates.  Additional interactions observed between allantoin and HpxA, 
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particularly at the C2 oxygen, are also not present in 2EQ5.  Overall the active site of 
the hydantoin racemase is larger and more open than that observed in the allantoin 
racemase structure of HpxA. 
 
 
 
Figure 8.4 Superposition of HpxA and the hydantoin racemase from P. horikoshii 
(2EQ5).  A)  Secondary structural superposition of the protomers from HpxA (white) 
and 2EQ5 (green).  B)  Stereo diagram of the superposition of the active sites of HpxA 
(white carbon atoms, blue nitrogen atoms, and red oxygen atoms) and 2EQ5 (green 
carbon atoms) with allantoin shown (yellow carbon atoms).  The two active site 
cysteines (serines in HpxA-allantoin structure) are labeled with C/S, the putative 
oxyanion hole is designated with an O, and each of the threonine residues that interact 
with the 'tail' region of allantoin in HpxA are labeled with T. 
 
 C79S/C184S HpxA - 5-acetyl Hydantion Structure.   To further probe the active 
site of HpxA and examine how the residues contained within it determine specificity 
and carry out the racemization reaction, we solved the structure of HpxA in complex 
with the allantoin analogue, 5-acetyl hydantoin.  Unlike allantoin, which is observed 
as an enol in the active site, the (R)- enantiomer (equivalent to the (S)- enantiomer of 
allantoin) is clearly bound to HpxA in this structure (Figure 8.3B).  While the 
orientation of the hydantoin ring is similar for the two ligands, the tail region makes 
distinctly different binding interactions.  The substitution of a carbon for N6 of 
allantoin leads to a different geometry and moves the acetyl group away from the 
'threonine pocket' of the active site.  This causes a slight shift in the ring and leads to 
additional hydrogen bonding between the acetyl group of 5-acetyl hydantoin and 
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Ser184 of the enzyme.  What is similar in both structures however, is the electron 
density for the Ser79 sidechain, which is consistent with the presence of two rotamers, 
each having approximately 50% occupancy.      
8.4 Discussion 
Overall Structure of HpxA.  Klebsiella pneumoniae HpxA is a two domain, α/β 
protein that is structurally homologous to members of the Glu/Asp racemase 
superfamily.  The two domains of this enzyme share the same secondary structural 
elements suggesting that a gene duplication event occurred at some point in this 
protein's evolutionary history (Figures 8.1B and C).  A clear hexameric quaternary 
structure was observed in the crystal structures of this enzyme and was confirmed by 
size exclusion chromatography (data not shown).  Despite having a similar hexagonal 
space group, the most structurally similar enzyme, hydantoin racemase from the 
archaea Pyrococcus horikoshii (22), was observed as a dimer in the crystal structure.  
While all of the necessary active site contacts to the ligands are made by a single 
protomer in HpxA, a very tight dimer, similar to what is observed in the hydantion 
racemase structure, is formed between neighboring protomers in the hexameric 
molecule (Figure 8.1A).  Size exclusion chromatography on hydantoin racemases 
from other organisms give results consistent with a hexamer (23) or a tetramer (24, 
25).   It is possible that the hexamer observed in the K. pneumoniae structure provides 
some evolutionary advantage over the dimer observed in the archael hydantoin 
racemase, although further research is needed to clarify this point. 
Comparison of HpxA to Other Structures.  A DALI search for structural 
homologues of HpxA yielded several proteins of the Glu/Asp racemase superfamily.  
The proteins of this family also share the two domain, α/β fold that is observed in 
HpxA.  While these proteins have some degree of structural similarity, there is little 
sequence conservation amongst the members of this group (Figure 8.5).  Highly 
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conserved residues include the two cysteines implicated in catalysis (Figure 8.5, blue 
triangles) and several other residues that serve predominantly structural roles.  Aside 
from the catalytic cysteines, none of the completely conserved residues appear in the 
active site of HpxA.  Note that the cysteine equivalent to Cys79 in HpxA is not 
conserved in 3EIS, an arylmalonate decarboxylase, as these enzymes are reported to 
proceed via a slightly different mechanism than other members of the superfamily. 
 
 
 
Figure 8.5 Sequence alignment of several Asp/Glu racemase superfamily members.  
The sequences were aligned using ClustalW (26) and the figure was produced using 
the  ESPript server (27).  The four sequences are the Klebsiella pneumoniae allantoin 
racemase (HpxA), Pyrococcus horikoshii hydantoin racemase (2EQ5 (22)), Bordetella 
bronchiseptica Arylmalonate decarboxylase (3EIS (22)), and Bacillus anthracis 
glutamate racemase (2GZM (28)).  Red boxes with white lettering are completely 
conserved residues while boxes with red letters on a white background are regions of 
sequence similarity.  The blue triangles indicate the two conserved cysteines, and the 
numbering and secondary structural elements shown correspond to the HpxA structure 
presented herein. 
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HpxA Active Site and Ligand Binding.  A comparison of unliganded and the 
allantoin-bound complex of HpxA showed that the enzyme does not undergo any 
structural changes upon ligand binding.  Other than a slight difference in the side chain 
conformation of Glu53, and the fitting of two rotamers to the density for Ser79 in the 
C79S/C184S HpxA-allantoin structure, all of the residues of the liganded structure 
align well with those of the unliganded structure.  Alternate conformations of 
Ser79/Cys79 are likely important for catalysis, while the observed flexibility of the 
Glu53 sidechain suggests that it may act as a gate for the relatively inaccessible active 
site (Figure 8.6).  Glu53 also interacts with an active site water molecule and may 
participate in catalysis (see discussion of mechanism below).  
 
 
 
Figure 8.6 Access to the HpxA active site.  The structure of HpxA is shown (pale 
green, ribbon and ball and stick) with allantoin bound (blue, ball and stick).  Glu53, 
which may serve as a gate for the active site, is shown in ball and stick with green 
carbon atoms and red oxygen atoms. 
 
The electron density observed for the difference maps observed in the active 
site for the C79S/C184S HpxA-allantoin structure clearly indicates that allantoin is 
present in its enol form (Figure 8.3A).  This is not a surprising result considering that 
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allantoin is known to undergo slow racemization in solution via keto-enol 
tautomerization (6) and that the putative reaction intermediate for the racemization of 
allantoin is the enolate.  This form of the ligand is not without precedent, and has been 
observed in the related structures of Klebsiella pneumoniae OHCU decarboxylase (29) 
and Alcaligenes bronchisepticus arlymalonate decarboxylase (30). 
The two active site cysteines, which are substituted by serines in the HpxA 
double mutant, have been reported to play the major roles in a two base mechanism 
proposed for members of the Asp/Glu racemase superfamily (19, 31).  In the 
C79S/C184S HpxA-allantoin structure, these residues are situated on either side of the 
ligand (Figures 8.2A and 8.3A).  The distance between the oxygen atoms of Ser79 and 
Ser184 in this structure is 6.6 Å (using the rotamer of Ser79 that is closer to Ser184) 
and would be approximately 6.3 Å between thiols if cysteines were used in place of 
serine residues.  The distance to C5 of allantoin in the structure from Ser79 and 
Ser184 are 3.2 and 4.2 Å respectively.  These distances reflect the asymmetry in the 
active site and the form of allantoin that is bound. 
In the presence of allantoin, a well ordered water molecule is observed in 
proximity to Ser79 and C5 of the ligand (Figure 8.3A).  This water molecule is held in 
place by interactions with the amide nitrogen of Gly81, and the sidechains of Glu53 
and Ser79.  The geometry of the water molecule can be determined from the 
orientation of the three hydrogen bond donating and accepting groups.  In the 
C79S/C184S HpxA-allantoin structure, the Gly81 amide nitrogen acts as a hydrogen 
bond donor while the polar sidechain of Glu53 accepts a hydrogen bond from the 
water molecule.  This places the second hydrogen of this water molecule in the ideal 
position to be abstracted by the thiolate of Cys79 (the Ser79 to water distance in the 
liganded structure is 2.6 Å).  Alternatively, when the cysteine sidechain is in the thiol 
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form, hydrogen bonding between the sulfur and the water will orient the thiol 
hydrogen ideally for attack by C5 of the hydantoin ring.  
An important structural element observed in the liganded HpxA structures is 
the presence of a putative oxyanion hole.  This pocket, created by the backbone amide 
nitrogens of Phe80 and Gly185 (Figure 8.3), which also serves to orient the hydantoin 
ring by interacting with the C4 oxygen, could stabilize negative charge that builds up 
at this oxygen atom along the reaction coordinate.  This interaction is observed in both 
the structures of C79S/C184S HpxA in complex with allantoin (Figure 8.3A) and 5-
acetyl hydantoin (Figure 8.3B), indicating its significance for ligand binding.  In 
addition, the enol form of allantoin bound in the active site provides evidence that this 
pocket may serve to stabilize an oxyanion, as this ligand is structurally similar to the 
proposed enolate intermediate (see discussion of mechanism below).    
One of the observed differences between the HpxA structure and that of 
hydantoin racemase is the presence of a polar region in the binding pocket of HpxA 
populated by several threonine side chains.  This difference presumably stems from 
the difference in the substituent at the 5- position of the hydantoin ring.  While 
hydantoin racemase accommodates non-polar, alipatic and aromatic groups such as 
ethyl, isobutyl and benzyl, the urea group at the 5- position of allantoin would require 
a more hydrophilic environment.  This 'threonine pocket' is also likely to be very 
important for the selectivity of this enzyme.  An examination of the two liganded 
structures of HpxA (Figure 8.3) indicates that this region provides an anchoring point 
for the tail region of the ligand and aids in the orientation of the hydantoin ring by 
securing the 5- substituent in this pocket.  The observation of selectivity for the (R)- 
enantiomer of 5-acetyl hydantoin is likely a result of the interactions at this 'threonine 
pocket.'  Binding of the (S)-5-acetyl hydantoin acetyl group into this pocket would 
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drive the hydantoin ring to a position almost perpendicular to that observed in the 
structure and would result in several unfavorable protein-ligand interactions. 
Mechanistic Implications.  While there are no mechanistic studies reported on 
allantoin racemase, insights can be gleaned from the structures reported herein with 
consideration of studies of the other members of the Asp/Glu racemase superfamily 
(18-20, 31-33).  Hydantoin racemase is reported to be slightly more active towards the 
(R)- enantiomers of various 5- substituted hydantoins, although the size of the 
substituent has an effect upon the degree of selectivity (32).  The structures of 
liganded HpxA reveal a polar 'threonine pocket' that interacts with the urea tail group 
of allantoin and serves to orient the hydantion ring.  The other two major interactions 
with allantoin occur through the oxygen atoms and, while mediating the lateral motion 
(in reference to the plane of the ring), they do not preclude rotation of the molecule.  
These three 'anchor points,' therefore, allow for optimal positioning of the two isomers 
with respect to the two active site cysteines (Figure 8.7).   
 
 
 
Figure 8.7 Allantoin isomers in HpxA active site.  Stereo drawing of the (R)- (white 
carbon atoms) and the (S)- (yellow carbon atoms) isomers of allantoin docked in the 
active site of HpxA.  The three main interactions in the HpxA active site, the 
'threonine pocket,' the oxyanion hole contacts with the C4 oxygen atom and the 
interactions with the C2 oxygen atom, were used to orient the ligands.  The observed 
enol form of allantoin is shown in black. 
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Based upon the solved structures of HpxA and the known chemistry of 
Glu/Asp/Hydantoin racemases, a mechanism for the allantoin racemase reaction is 
proposed (Scheme 8.2).  Upon binding of (R)-allantoin, C5 of the ring is deprotonated 
by Cys184.  This produces the enolate intermediate, with stabilization for the negative 
charge provided by the oxyanion hole.  Abstraction of a proton from the proximal 
water by Cys79 is facilitated by weakening of the O-H bond as a result of the 
inductive force of Glu53.  Collapse of the reactive oxyanion species drives attack of 
the thiol of Cys79 and abstraction of this proton.  Product release is likely driven by 
two separate forces, the unfavorable interaction between the hydantoin ring and the 
protonated Cys184, and the repulsion of both the Cys79 thiolate and Glu53 sidechains 
by the hydroxide.  The latter interaction could drive conformational change of the 
Glu53 sidechain, which may act as a 'gate' for entry into the active site.  This would 
allow for product release and replacement or reprotonation of the active site water. 
  
       
 
Scheme 8.2 Proposed mechanism of catalysis for racemization of allantoin by HpxA 
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The asymmetry in the active site suggests that the mechanism for conversion 
of the (S)- to (R)- enantiomer would likely proceed in a slightly different fashion.   
While the participation of a nearby water molecule is likely to occur for (R)- to (S)- 
chemistry, there is no such water molecule in the vicinity of Cys184.  Thus, while the 
mechanisms for the two reactions would be analogous, Cys184 would act as both base 
and acid for racemization of (S)-allantoin.   
In this paper, we have reported the first structural characterization of an 
allantoin racemase.  The structures presented reveal several important features of the 
active site of this enzyme, including an oxyanion hole and a polar binding region that 
strongly interacts with the urea tail of allantoin.  Analysis of these structures provides 
insight into the reactivity of this enzyme and allows us to propose a mechanism for the 
allantoin racemase reaction.  Biochemical studies of several active site mutants are 
currently underway in order to better understand the mechanism and selectivity of the 
reaction catalyzed by this enzyme. 
8.5 Materials and Methods 
Protein Purification and Crystallization.  The gene encoding Klebsiella 
pneumoniae HpxA was cloned from genomic DNA from K. pneumoniae subsp. 
pneumoniae (Schroeter) Trevisan MGH78578 (ATCC 700721) and placed in a 
modified Pet28 (Novagen) vector encoding an N-terminal 6-His tag by standard 
molecular biology techniques.  The C79S, C184S and C79S/C184S mutant plasmids 
were made at the Cornell Protein Characterization and Production Facility by using 
site-directed mutagenesis of the native gene.  Briefly, mutagenesis was performed on 
HpxA by a standard PCR protocol using PfuTurbo DNA polymerase (Invitrogen) and 
DpnI (New England Biolabs) to digest the methylated parental DNA prior to 
transformation.  The presence of the mutated residue was verified by sequencing.   
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For protein expression in all cases, the plasmid was transformed into 
B834(DE3) (methionine auxotrophic) cells and the protein was expressed and purified 
as follows.  For SeMet protein, the cells were grown in M9 minimal media 
supplemented with 0.4% glucose, MEM vitamin solution, 2 mM MgSO4, 90 mM of 
FeSO4 (25 mg/L), 100 μM CaCl2, 40 mg/L each of 19 amino acids (methionine 
excluded), 50 mg/L of seleno-L-methionine and 50 mg/L kanamycin.  The cells were 
grown at 37°C to an O.D.600 of 0.5 before reducing the temperature to 15°C.  After 30 
minutes at this temperature the cells were induced with 0.5 mM IPTG and grown for 
an additional 16 hours.  The cells were harvested by centrifugation and the pellet 
stored at -20°C prior to purification.  For native protein, the procedure followed was 
the same with the exception that LB was used as a growth medium. 
For protein purification, the pellets were thawed in buffer containing 300 mM 
NaCl, 10 mM imidazole, 2 mM DTT and 50 mM sodium phosphate, pH 7.6.  The 
cells were lysed by sonication and centrifuged to remove cellular debris.  The cleared 
lysate was passed through a column containing pre-equilibrated Ni-NTA resin and 
then washed with a similar buffer containing 20 mM imidazole and 10% glycerol.  
The protein was eluted with buffer containing 300 mM NaCl, 2 mM DTT and 250 
mM imidazole, pH 7.6 and immediately buffer exchanged into 30 mM NaCl, 2 mM 
DTT and 10 mM sodium acetate, pH 5.6.  The protein was concentrated to 15 mg/ml 
using a centricon centrifugal concentrator (Amicon) and determined to be greater than 
95% pure by SDS-PAGE.  Aliquots of the protein were flash frozen immediately after 
buffer exchange and stored at -80°C for crystallization trials.  Crystallization was 
performed by the hanging-drop vapor diffusion method at 18°C.  For both the native 
and SeMet protein, crystals formed after 3 - 5 days in 24 - 34% Peg 400 with 0.1 M 
sodium acetate, pH 3.7 - 4.1.  Crystals were harvested and frozen without additional 
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cryoprotectant.  For allantoin and 5-acetyl-hydantoin complexes, crystals were soaked 
for 2 hours in solutions of mother liquor supplemented with 5 mM ligand.      
Data Collection, Processing, Structure Determination and Refinement.  The 
SeMet data were collected at 100°C at the Northeast Collaborative Access Team (NE-
CAT) beam line 24-ID-C of the Advanced Photon Source at Argonne National Labs at 
the maximum f´´ for selenium as determined by a fluorescence scan of the crystal.  
The SeMet dataset was collected over 360° using a 1° oscillation range.  The space 
group was determined to be P6322 with 2 molecules per asymmetric unit for a solvent 
content of 51%.  Data was indexed and scaled using HKL2000 (34) and heavy atom 
sites were located using the SHELX suite (35).  The program autoSHARP (36) was 
used for refinement of heavy atom positions, phasing, calculation of residual maps, 
density modification and automated model building.  The program was able to 
correctly place 469 of 494 residues in two chains with the correct side chains.  
Additional residues and water molecules were placed during iterative rounds of 
manual model building followed by refinement using Refmac5 (37).   
The data for ligand bound complexes were collected at NE-CAT beam line 24-
ID-C and 24-ID-E at a wavelength of 0.979 Å.  These data also indexed in space 
group P6322 and had similar unit cell dimensions and percent solvent content.  
Refinement was carried out as detailed above using the SeMet structure as a starting 
point.  The ligand was built into difference density only after the refinement had 
converged.  Data collection and refinement statistics for all structures are provided in 
Tables 8.2 and 8.3, respectively.   
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Table 8.2.  Data Collection Statistics. 
 HpxA - SeMet HpxA - 
C79S/C184S - 
allantoin  
HpxA - 
C79S/C184S - 5-
acetyl-hydantion 
resolution (Å) 50.0 - 2.1  50.0 - 2.0 50.0 - 1.82 
wavelength (Å) 0.9792 0.9791 0.9791 
beam line NE-CAT ID-C NE-CAT ID-E NE-CAT ID-E 
space group P6322 P6322 P6322 
a, b (Å) 124.8 124.9 125.0 
c (Å) 126.8 127.0 127.0 
no. of reflections 106 706 197 739 805 670 
unique reflections 28 561 39 452 52 509 
average I/σ 15.0 (2.1) 25.4 (4.3) 47.0 (7.9) 
redundancy 3.7 (3.5) 5.0 (4.5) 15.3 (11.3) 
completeness (%) 94.6 (99.6) 98.3 (98.2) 99.9 (100.0) 
Rsyma (%) 9.7 (40.1) 9.6 (38.1) 7.0 (30.1) 
Numbers in parentheses correspond to the highest resolution shell 
a IIIR i Σ−ΣΣ= /isym , where I  is the mean intensity of the N reflections with 
intensities Ii and common indices h, k, l  
 
Table 8.3.  Data Refinement Statistics. 
 HpxA - SeMet HpxA - 
C79S/C184S - 
allantoin  
HpxA - 
C79S/C184S - 
5-acetyl-
hydantion 
resolution (Å) 50.0 - 2.1 50.0 - 2.0 50.0 - 1.82 
no. of protein atoms 3542 3573 3518 
no. of ligand atoms 0 14 22 
no. of water atoms 190 302 446 
no. of reflections in 
working set 
32 766 37 463 49 799 
no. of reflections in test set 1 740 (5 %) 1 974 (5 %) 2675 (5%) 
R factora (%) 20.5 22.2  20.8 
Rfreeb (%) 23.9 24.6 22.2 
rmsd bonds (Å) 0.007 0.005 0.005 
rmsd angles (o) 1.013 0.927 0.927 
mean B factor (Å2) 32.9 31.6 19.9 
Ramachandran plot    
   most favored (%) 94.3 95.2 95.2 
   additionally allowed (%) 5.7 4.8 4.8 
   generously allowed (%) 0.0 0.0 0.0 
   disallowed (%) 0.0 0.0 0.0 
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a R factor ∑−Σ= hkl obscalcobshkl FFkF / , where Fobs and Fcalc are observed and 
calculated structure factors respectively.  
b For Rfree, the sum is extended over a subset of reflections (5%) excluded from all 
stages of refinement 
 
The topology diagram was based upon the results from the PDBsum server 
(38).  The sequence alignment was carried out using ClusalW (26) and the 
corresponding figure was made using the ESPript server (27).  For the superposition of 
allantoin enantiomers for Figure 8.7, the (R)- and (S)- enantiomers were positioned by 
aligning the C2 and C4 oxygen atoms and the urea nitrogen atom with the respective 
atoms from the observed enol form.  All other figures were made using PyMol (39) 
and ChemBioDraw (Cambridgesoft). 
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APPENDIX I 
STRUCTURE OF KLEBSIELLA PNEUMONIAE 5-HYDROXY ISOURATE 
HYDROLASE  
Summary 
5-Hydroxy isourate (HIU) is the product of oxidation of uric acid by uricase.  This 
molecule is converted to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) by 
HIU-hydrolase.  Presented below is the structure of the HIU-hydrolase from Klebsiella 
pneumoniae, called HpxT.  The details of the crystallization and structure solution are 
provided in addition to the structural results. 
Experimental 
The HpxT plasmid was provided by the protein production facility and 
transformed into BL21(DE3) cells using standard techniques.  The protein was 
expressed and purified as detailed previously (see Chapter 6 or 7, Materials and 
Methods).  The crystals were grown using the hanging-drop method, grew in many 
different conditions and were predominantly rod-shaped.  The conditions used for 
diffraction included: 0.7 - 0.9 ammonia phosphate in 0.1 M imidazole; pH 7.9, 6 - 10 
% PEG 3000, 0.2 M MgCl2, in 0.1 M cacodylate, pH 6.5; and 8 - 14% PEG 8000, 0.2 
M calcium acetate in 0.1 M imidazole, pH 7.0 - 7.5.  Crystals grew in one to two 
weeks and were cryoprotected with the above solutions supplemented with either 15% 
PEG 3000, 15% ethylene glycol, or 15% glycerol (little difference noticed in 
diffraction between cryos).  The crystals tested from the above conditions diffracted 
beyond 2 Å at APS or CHESS and generally yielded high quality data.  The structure 
was solved by molecular replacement with MOLREP using 2IGL as a search model.  
Refmac5 was used for refinement while manual model building and the addition of 
water molecules was accomplished using COOT.  Data collection and refinement 
statistics are given in tables A1.1 and A1.2 below. 
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 In attempts to examine ligand binding in HpxT several known ligands have 
been soaked into crystals or co-crystallized with this enzyme.  Uric acid, 8-
azaxanthine, 2,6-diaminouracil, allantoin as well as several other purines and 
analogues have been employed in this manner.  To date, all soaks or co-crystallization 
of these ligands into the enzyme have been unsuccessful.  These were attempted under 
various growth conditions and using crystals grown from different solutions.  This 
work led to the cloning, purification and crystallization of several mutants in order to 
increase the chance of solving a structure in complex with a ligand. 
 Several mutants of this protein were provided by the protein production 
facility.  These included the H7N, R41K, H91N, and S105A mutants.  All of these 
were transformed, expressed and purified as mentioned above.  While these mutants 
yielded crystals of similar morphology under the same conditions as native, they 
diffracted to no better than 3 Å and were highly mosaic.  Screens for additional 
diffraction conditions are under way and, to date, only a single condition (Hampton 
Screen II, condition 30) has yielded usable data to approximately 2.7 Å.   
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 Table A1.1 Data Collection Statistics 
 HpxT-1 HpxT-2 
resolution (Å) 2.04 1.76 
Wavelength (Å) 0.987 0.987 
beam line 24-ID-C 24-ID-C 
space group P212121 P212121 
a (Å) 42.3 42.3 
b (Å) 100.6 100.7 
c (Å) 105.6 105.7 
no. of reflections 136785 170844 
unique reflections 29399 42995 
average I/σ 17.8 (4.5) 19.9 (5.9) 
Redundancy 4.1 (4.5) 4.1 (3.7) 
completeness (%) 99.7 (98.4) 94.2 (89) 
Rsyma (%) 9.2 (34.8) 5.8 (18.6) 
*these are the statistics from two of the first data sets collected.  They are only two 
examples of many dozens of datasets with resolutions ranging from 1.6 to 2.3 Å 
Numbers in parentheses correspond to the highest resolution shell 
a IIIR i Σ−ΣΣ= /isym , where I  is the mean intensity of the N reflections with 
intensities Ii and common indices h, k, l  
 
Table A1. 2 Data Refinement Statistics* 
 KpHpxT 
resolution (Å) 2.04 
protein atoms 3110 
ligand atoms 0 
water atoms 155 
reflections in working set 27 847 
reflections in test set 1492 
R factora 24.4 
Rfreeb 28.0 
rmsd bonds (Å) 0.008 
rmsd angles (o) 1.21 
mean B factor (Å2) 21.1 
*these are the statistics from one of the first data sets collected.  It is only one example 
of many dozens of datasets with resolutions ranging from 1.6 to 2.3 Å 
a R factor ∑−Σ= hkl obscalcobshkl FFkF / , where Fobs and Fcalc are observed and 
calculated structure factors respectively.  
b For Rfree, the sum is extended over a subset of reflections (5%) excluded from all 
stages of refinement 
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 Structure of HpxT 
 
Figure A1.1.  Structure of HpxT.  HpxT is a tetramer (left) in solution (verified by size 
exclusion chromatography).  The HpxT protomer (right) is also shown. 
 
 
 
         
 
Figure A1.2  Active site of HpxT.  The active site occurs at the interface of two 
protomers and is, consequently, symmetric in structure.  The structure of the active 
site is shown (left) with the residues from one protomer colored blue.  The schematic 
of the active site residues is also shown (right). 
 
Ongoing Work 
 The goal of this work is to better understand ligand binding for this enzyme, 
particularly how the symmetric active site can catalyze an asymmetric conversion, and 
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 to examine the mechanism for this conversion.  With this in mind, the priority is to 
solve structures of this enzyme in complex with different ligands.  As mentioned 
above, several mutants have been purified and a new crystallization condition 
identified that may yield the desired results.  Additional optimization of this condition 
will hopefully yield crystals that will enable us to soak in ligands or provide a new 
strategy for co-crystallization.   
 In addition, a UV-based assay has been developed to examine the activity of 
this enzyme.  In situ production of the substrate, HIU, and the difference between the 
spectra of HIU and the product, OHCU, enable us to measure the rate of turnover of 
this enzyme.   Measurements of the relative rates of reaction for the native enzyme and 
the mutants will provide additional insights into the mechanism of reaction. 
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APPENDIX II 
STRUCTURE OF LEISHMANIA DONOVANI OROTODINE MONOPHOSPHATE 
DECARBOXYLASE-OROTATE PHOSPHORIBOSYLTRANSFERASE 
Summary 
The de novo biosynthesis of pyrimidine nucleotides is a highly conserved pathway that 
acts, along with the recycling pathway, to maintain cellular pyrimidine levels.  While a 
small number of micro-organisms lack the de novo pathway some, such as 
Plasmodium falciparum (the causative agent of malaria), depend solely on the de novo 
biosynthesis pathway for pyrimidines.  The biosynthesis of uridine 5'-monophosphate 
(UMP) from glutamate requires six enzymatic reactions.  The pathway and the 
enzymes that catalyze the six reactions are shown in Figure A2.1.   
 
 
 
Figure A2.1.  Biosynthesis of UMP. 
 
     The final two steps of UMP biosynthesis require a transfer of ribose-5-phosphate to 
orotate and then a subsequent decarboxylation reaction.  These reactions are catalyzed 
by orotate phosphoribosyl transferase (OPRT) and orotidine monophosphate 
decarboxylase (OMPDC) respectively. 
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 In most prokaryotes OPRT and OMPDC are encoded by separate genes, while 
in plants and animals these genes are fused and encode a single enzyme called UMP 
Synthase.  A small subset of organisms, including Trypanosomes and Leishmania, 
also express only a single gene product but the order of the genes is reversed relative 
to the gene for UMP synthase (Figure A2.2) 
 
 
Figure A2.2.  Organization of OPRT and OMPDC genes in various organisms. 
 
 In order to examine the structural organization of the OMPDC-OPRT enzymes 
and how this relationship influences function, we solved the structure of the L. 
donovani OMPDC-OPRT bifunctional enzyme in complex with UMP and also that of 
the truncated protein containing only OMPDC from the same organism. 
Experimental 
 The LdOMPDC-OPRT plasmid was provided by the Ullman lab from Oregon 
Health and Science University.  The plasmid was transformed into BL21 cells and 
expressed as reported previously (see Chapter 6 or 7, Materials and Methods section).  
Unfortunately, while the protein expressed well, it was not stable upon buffer 
exchange into the typical crystallization buffer (10 mM Tris, pH 7.6 and 30 mM 
NaCl).  In order to assure that the protein remained in solution, the purification was 
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 performed under standard conditions with 2 mM DTT and 5 mM UMP added to all 
buffers.  The protein was then either put into trays in the elution buffer (300 mM 
NaCl, 250 mM imidazole, 5 mM UMP, 2 mM DTT, pH 8.0) or buffer exchanged into 
a high salt buffer such as 0.1 M Tris, pH 8.0, with 300 mM NaCl, 5 mM UMP and 2 
mM DTT.   
 The protein was crystallized using the hanging drop method and was used at 
concentrations of 15 - 25 mg/ml.  While several conditions gave microcrystals, the 
only crystals observed with a 3D morphology were under 24 - 38 % PEG-400, 0.2 - 
0.4 M NaCl and 0.1 M Hepes, pH 6.8.  The crystals were approximately 25 - 100 μm 
in size and were rectangular or cubic in shape.  The crystals were frozen in a solution 
containing the well solution mentioned above supplemented with 5 mM UMP.  Data 
collection was difficult as the crystals varied in quality and often yielded mosaic data.  
In addition, the long unit cell access meant that spots were very close together during 
data collection.  By optimizing the detector distance and collecting 0.5° wedges, we 
were able to collect a complete data set for these crystals that diffracted to 
approximately 2.9 Å. 
 All initial attempts to phase using molecular replacement with several 
homologous structures failed.  As a result, SeMet protein was expressed and purified 
for crystallization trials.  Unfortunately, the SeMet crystals did not grow as well as the 
native and we were unable to collect any usable data from these.  In order to facilitate 
phasing, we then attempted to solve the structure of the two monofunctional proteins, 
LdOMPDC and LdOPRT.  Screens of crystallization conditions for LdOMPDC 
yielded a large crystal that diffracted well.  This crystal grew in 1.6 M ammonium 
sulfate, 10% 1,4-dioxane and 0.1 M MES monohydrate, pH 6.5.  Using this high 
resolution data from the LdOMPDC crystal and the human OMPDC structure as a 
model we were able to use molecular replacement to solve the structure.  CNS and 
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 Refmac5 were used for refinement, with iterative cycles of manual model building 
using COOT.   
 The LdOMPDC structure was used to provide phases for the LdOMPDC-
OPRT data by molecular replacement.  This enabled the placement of the OPRT 
domains using yeast OPRT as a model.  Using Refmac5 and phenix for refinement, 
and coot for manual model building, the structure was refined to its current state.  
 
Table A2.1 Data Collection Statistics 
 LdOMPDC LdOMPDC-OPRT 
resolution (Å) 1.7 2.99 
Wavelength (Å) 0.987 0.987 
beam line 24-ID-C 24-ID-C 
space group C2 P43212 
a (Å) 101.38 64.72 
b (Å) 98.14 64.72 
c (Å) 62.14 477.60 
b (°) 106.54 90 
no. of reflections 262 430 119 046 
unique reflections 62 080 34 461 
average I/σ 24.9 (4.4) 11.3 (2.3) 
redundancy 4.2 (3.6) 3.5 (1.7) 
completeness (%) 98.5 (93.5) 87.7 (39.7) 
Rsyma (%) 6.4 (27.7) 13.1 (37.4) 
*these are the statistics from two of the first data sets collected.  They are only two 
examples of many dozens of datasets with resolutions ranging from 1.6 to 2.3 Å 
Numbers in parentheses correspond to the highest resolution shell 
a IIIR i Σ−ΣΣ= /isym , where I  is the mean intensity of the N reflections with 
intensities Ii and common indices h, k, l  
Results 
 The structure of LdOMPDC-OPRT was solved by MR using the 
monofunctional LdOMPDC and the yeast OPRT as search models.  The data reveals 
an unusual tetrameric structure shown in Figure A2.3.  The presence of this tetramer in 
solution was verified by size exclusion chromatography (Figure A2.5).  
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Figure A2.3.  L. donovanii OMPDC-OPRT overall structure.  Individual chains shown 
in yellow, green, blue and violet, while background surface highlights the two 
OMPDC dimers in blue and the two OPRT dimers in green 
 
 
 
 
Figure A2.4.  L. donovanii OMPDC and OPRT dimers compared to homologous 
enzymes.  The OMPDC dimer from L. donovanii (top left) is shown above the human 
homologue (bottom left).  Also shown is the L. donovanii OPRT dimer (top right) 
above the homologous enzyme from S. cerevisiae (bottom right).  
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Figure A2.5.  Size exclusion chromatography of LdOMPDC-OPRT.  Size exclusion 
chromatography was used to verify the oligomeric state of the protein.  The L. 
donovani OMPDC-OPRT fusion monomer has a molecular weight of 53.8 kDa.  A 
peak was observed (210 kDa) that corresponds to a tetrameric species (215.2 kDa 
expected) as well as a smaller peak (85 kDa) that could be a dimeric state. 
 
 
 
   
 
Figure A2.6.  Structure of LdOMPDC.  In order to use molecular replacement to solve 
the structure of LdOMPDC-OPRT, a structure of the monofunctional LdOMPDC was 
solved.  The LdOMPDC crystal (left) diffracted to better than 2 Å and allowed for the 
facile determination of the LdOMPDC structure (right; while the structure was a 
dimer, only the protomer is shown) 
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 Ongoing Work 
The refinement of the structure of LdOMPDC-OPRT is continuing and has nearly 
converged.  In addition, the Human equivalent, HsUMPS, has been purified and will 
be used to compare the quaternary structures of the two bifunctional enzymes by gel 
filtration and other means.   
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APPENDIX III 
STRUCTURE OF SACCHAROMYCES CEREVISIAE THI20  
Summary 
Yeast Thi20 is a fusion protein with homology to the bacterial thiaminase, TenA, and 
to the HMP(P) kinase, ThiD.  Although little is know about Thi20, our hypothesis is 
that it participates in thiamin salvage by catalyzing hydrolysis of HMP precursors.  To 
further understand this protein and its function, we have solved the x-ray crystal 
structure of the Saccharomyces cerevisiae Thi20. 
Experimental 
Several fungal Thi20 genes were cloned into plasmids, expressed and purified 
as previously described (see Chapter 6 and 7, Materials and Methods).  These 
constructs, which included Saccharomyces cerevisiae Thi20 (ScThi20), Pichia stipitis 
Thi20 (PsThi20) and Candida glabrata Thi20 (CgThi20), were expressed with an N-
terminal 6-His tag.  Of these, only ScThi20 yielded crystals upon screening.  The data 
from these crystals, however, was highly anisotropic and also displayed a high degree 
of mosaicity.  All attempts to optimize the crystallization conditions, cryoprotectants 
and to find alternative crystallization conditions for these constructs failed.  To expand 
the search, ScThi20 was recloned into a vector with a C-terminal 6-His tag.  While 
screens using this protein were not initially successful, seeding with the crystals 
formed from the N-terminally tagged ScThi20 yielded diffraction quality crystals.  
These crystals, formed in 12% PEG 8000, 0.2 M calcium acetate and 0.1 M imidazole, 
pH 7.5, were diamond shaped and diffracted to approximately 2.7 Å at beamline 
24ID-C (data collection statistics provided in Table A3.1). 
 The ScThi20 structure was solved by molecular replacement using 2GM7 and 
1JXH as search models.  Molecular replacement in the original space group (P212121) 
initially failed, but solutions were found using the subgroup P21.  After a solution was 
 
218 
 found in P21, one fourth of the unit cell (one dimer) was transformed into the higher 
space group and used without further difficulty.  CNS and Refmac5 were used for 
refinement with manual model building performed using COOT (the refinement 
statistics are provided in Table A2.2). 
 
Table A3.1 Data Collection Statistics 
 ScThi20c 
resolution (Å) 2.68 
Wavelength (Å) 0.987 
beam line 24-ID-C 
space group P212121 
a (Å) 59.70 
b (Å) 140.10 
c (Å) 143.27 
no. of reflections 87 487 
unique reflections 31 670 
average I/σ 12.2 (1.5) 
redundancy 2.8 (1.5) 
completeness (%) 92.8 (70.0) 
Rsyma (%) 9.4 (32.9) 
a IIIR i Σ−ΣΣ= /isym , where I  is the mean intensity of the N reflections with 
intensities Ii and common indices h, k, l  
 
Table A3. 2 Data Refinement Statistics 
 ScThi20c 
resolution (Å) 2.68 
protein atoms 7902 
ligand atoms 0 
water atoms 44 
reflections in working set 30019 
reflections in test set 1606 
R factora 24.4 
Rfreeb 28.9 
rmsd bonds (Å) 0.006 
rmsd angles (o) 0.974 
mean B factor (Å2) 38.6 
a R factor ∑−Σ hkl obscalcobshkl FFkF /= , where Fobs and Fcalc are observed and 
calculated structure factors respectively.  
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 b For Rfree, the sum is extended over a subset of reflections (5%) excluded from all 
stages of refinement 
 
 Results 
The structure of ScThi20 reveals a dimer (Figure A3.1), a structure which is supported 
by gel filtration (data not shown).  The ThiD portion of ScThi20 dimerizes in a fashion 
that is similar to known ThiD enzymes (Figure A3.2).  The dimer interface between 
the TenA domains of Thi20, however, is unlike that observed in previously solved 
TenA structures. 
 
 
Figure A3.1.  Structure of ScThi20.  The dimer is shown with helices colored blue and 
strands colored in green.  The ThiD domain is on the left, while the all α-helical 
domain of TenA is on the right. 
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Figure A3.2.  Structure of ThiD dimer.  The ThiD domain dimer from ScThi20 (left) 
has a similar interface as that of S. typhimurium ThiD (1JXI, right). 
 
Ongoing work 
 The refinement of ScThi20 is ongoing and is nearly complete.  Additional 
analysis of the structure and comparison to known structures is required in order to 
learn more about the function of this enzyme.  Attempts are underway to improve the 
quality and diffraction of the ScThi20 crystals and to soak in or co-crystallize ligands. 
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